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ABBREVIATIONS AND NOTES 
AD: autosomal dominant 
AR: autosomal recessive 
ceRNAs: competing endogenous RNAs 
CLEAR: coordinated lysosomal expression and regulation 
CNS: central nervous system  
ER: endoplasmic reticulum 
FL: full length 
GCase: beta-glucocerebrosidase 
GD: Gaucher disease 
GlcCer: glucosylceramide 
GWAS: genome-wide association study 
HGMD: human gene mutation database 
HS: heparan sulfate 
LNA: locked nucleic acid 
lncRNAs: long non-coding RNAs 
LOVD: leiden open variation database 
miRNA: microRNA 
MPS: mucopolysaccharidosis 
MRE: miRNA recognition element  
NGS: next-generation sequencing 
NMD: nonsense-mediated mRNA decay 
OR: odds ratio 
PD: Parkinson's disease  
PTC: premature stop codon  
SNPs: single nucleotide polymorphisms 
TFEB: transcription factor EB 
UPR: unfolded protein response 
WES: whole-exome sequencing 
WGS: whole-genome sequencing 
 
Note. In this thesis, materials and methods are reported in the result section, below each figure.
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ABSTRACT 
3 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive death of 
dopaminergic neurons in the substantia nigra. PD is a complex disease caused by the combination of 
environmental factors and genetic components. In recent years, considerable progresses have been made in 
the identification of the genetic determinants of PD: several genes were shown to cause rare monogenic 
forms of the disease. Moreover, a larger number of predisposing genetic variants have been associated with 
sporadic PD by genome-wide association studies. Among them, GBA seems to be the main genetic risk 
factor for PD. However, despite these advancements, a large fraction of the expected PD heritability is still 
missing. 
In this frame, the main aims of my PhD project were, on one hand, the study of the possible mechanisms 
of regulation of GBA, in particular the assessment of the role of GBAP1, its pseudogene, with the view to 
identify novel strategies to augment glucocerebrosidase activity and, on the other hand, the identification of 
novel genetic determinants for the disease by whole-exome sequencing (WES) of selected PD families. 
Concerning GBA we demonstrated that mir-22-3p can modulate the levels of GBA transcripts down-
regulating GCase expression and that GBAP1 might work as competing endogenous RNA acting as sponge 
and decreasing the miRNA mediated control on GBA. We then characterized the splicing pattern of the 
pseudogene and we showed that GBAP1 transcripts are down-regulated by the nonsense-mediated mRNA 
decay mechanism. On the basis of these results, we propose the existence of an RNA-based complex 
regulatory network involving GBA, GBAP1 and miR-22-3p.  
Regarding the identification of novel PD genes, 24 PD families with a dominant or a recessive inheritance 
pattern were selected and whole-exome sequencing was performed on the proband of each family and on 
affected cousins or uncles, when available.  
Six of these families resulted carriers of mutations in genes already associated with parkinsonism (4 GBA, 1 
LRRK2, and 1 ATP7B). Moreover, we found 2 homozygous mutations in novel candidate genes in 2 
consanguineous families: a splicing mutation in a gene involved in the unfolded protein response 
(DNAJC12) and a missense variant in a gene coding for a lysosomal enzyme (HGSNAT).  
We characterized the splicing mutation and we demonstrated that this variation causes the skipping of the 
downstream exon and the introduction of the premature stop codon. Interestingly, we demonstrated that 
the silencing of the DNAJC12 gene increases the α-synuclein protein levels in SH-SY5Y neuroblastoma 
cells. Concerning the missense mutation, we measured the activity of the HGSNAT enzyme in the patient’s 
fibroblasts, which resulted below the lower limit of the normal range. We hypothesize that the HGSNAT 
activity is not reduced enough to cause a lysosomal disorder, but may predispose to PD. Moreover, the 
pathogenic role of the two novel PD genes identified in my PhD project is strongly supported by the 
identification, by us and by our collaborators in Vancouver, of one additional unrelated PD family with 
mutations in the same gene for both HGSNAT and DNAJC12. Ongoing analyses will characterize the 
functional role of the novel candidate genes in PD pathogenesis. 
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1.1 Parkinson's Disease 
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disease with a multifactorial 
etiology, resulting from the combination of different genetic determinants and multiple environmental 
factors. 
The disease affects more than 1% of the population over 55 years of age and the percentage rises to 3% 
over the age of 75. The annual incidence (adjusted for age and gender) is 13.4 new cases per 100,000 
individuals; in particular, the number of cases is higher in males (19:100,000) than in females 
(9.9:100,000) [Farlow et al., 2014]. The lifetime risk to develop the disease is close to 1.5% and the 
median age of onset is around age 60, with a life expectancy of 15 years after diagnosis [Lees et al., 
2009]. In general, an onset before age 20 is very rare and is considered juvenile Parkinson’s, before age 
50 is called early-onset Parkinson's, while after age 60 is classified as late-onset and it is the most 
common form [Farlow et al., 2014]. It is estimated that 5% of patients manifest symptoms before age 
40 [Schrag et al., 2006]. The symptoms characterizing the disease and on which the diagnosis is based, 
consist of: resting tremor, bradykinesia, rigidity and postural instability. Generally, in the early stages of 
the disease the symptoms appear asymmetrically and then affect the rest of the body. In late stages, the 
worsening of symptoms is associated with cognitive and psychiatric disorders, such as hallucinations, 
depression, sleep and speech disorders, memory loss and dementia. 
1.1.1 Pathogenesis 
PD is a disorder of the central nervous system (CNS) characterized by the progressive degeneration, 
and the consequent death by apoptosis, of the dopaminergic neurons localized in the substantia nigra, a 
region of the brain located between the midbrain and the diencephalon [Lees et al., 2009]. The first 
symptoms of the disease appear when the loss of dopaminergic neurons exceeds the 50%, a level 
beyond which compensation systems, which usually contribute to maintain normal mobility, are not 
enough to overcome the lack of dopamine (a neurotransmitter typically secreted by dopaminergic 
neurons). During disease progression, the neuronal degeneration does not remain confined to the 
substantia nigra, but also extends to other areas of the brain and other neuronal types, resulting in the 
appearance of secondary symptoms typical of the late stages of the disease. 
It is widely accepted that the neurodegeneration occurs in response to a series of pathogenic events that 
could take place inside neurons themselves - such as mitochondria dysfunction, dysregulation of 
calcium and ROS (Reactive Oxygen Species) homeostasis, alterations in the protein quality control and 
degradation systems, lysosomal impairment, and alterations in the process of autophagy and apoptosis - 
or come from outside, with the transfer of the α-synuclein protein from an abnormal cell to a normal 
one, with a mechanism of action similar to the one described in prion diseases [Hirsch et al., 2013; 
Heman-Ackah et al., 2013; Antony et al., 2013]. 
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In addition to the neuronal degeneration, another hallmark of PD is the presence of eosinophilic 
cytoplasmic aggregates of proteins, mainly consisting of α-synuclein, called Lewy bodies [Spillantini et 
al., 1999; Cooper et al., 2006; Credle et al., 2015; Hunn et al., 2015]. Lewy bodies are also found in 
other conditions generically defined as “synucleinopathies”, and sometimes in Alzheimer's disease. 
Their role in PD pathogenesis has still to be defined: it is not clear whether they interfere with cell 
function or if they represent a protective response by which the neuron tries to confine and eliminate 
cytotoxic proteins [Minami et al., 2015]. 
1.1.2 Etiology 
The etiology of PD is still unclear, although it is now widely accepted as a multifactorial disease, 
resulting from the interaction of environmental components and genetic factors. The role of genetic 
factors seems to be predominant in the early-onset forms, while the etiology of idiopathic late-onset 
PD still remains difficult to explain [Goldman, 2014]. In most cases the onset is sporadic and only in 5-
10% of patients it is possible to trace a family history of the disease [Spatola and Wider, 2014]. The 
major risk factor is age, although it is not fully understood how the aging process is involved in the 
onset of the disease. 
Epidemiological data indicate that some environmental and occupational factors such as lifestyle, 
exposure to chemicals, industrials, pesticides and metals (Al, Cu, Fe, Hg, Mn, Pb), the rural 
environment and professional activity (agricultural or mining work) may increase the risk to develop the 
disease. However, other studies are necessary to define in detail doses, exposure mode, and susceptible 
populations [Goldman, 2014]. Smoking and caffeine seem to be associated with a protective effect 
[Goldman, 2014], but there isn’t a unanimous agreement on this subject and the debate is still open, 
with some authors suggesting the possibility that the apparent “neuroprotective” effect of smoking and 
caffeine observed in epidemiologic studies may be due to reverse causation [Ritz et al., 2014]. 
1.2 Genetics of PD 
Until few years ago the role of environmental factors in the development of PD was considered as 
predominant, but accumulating evidence suggests that the genetic component may play a more 
important role than previously thought. Over the last twenty years, linkage analysis and positional 
cloning in large families with Mendelian forms of PD led to the identification of new genes involved in 
the pathogenesis of the disease, whereas association studies have identified an increasing number of loci 
and susceptibility genes responsible for sporadic forms of PD. 
1.2.1 Linkage analyses 
Various linkage studies have been performed on families with Mendelian or quasi-Mendelian 
transmission of PD to identify chromosomal regions associated with monogenic forms of the disease. 
Thanks to this approach, 14 loci have been identified, involved in both autosomal dominant (PARK 
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1/4, 3, 5, 8 and 17) and autosomal recessive forms of the disease (PARK 2, 6, 7, 9, 14 and 15). For 12 
of these loci the causative gene was also identified [Lesage and Brice, 2009; Lin and Farrer 2014], as 
reported in Table 1.1. The number of genes involved in PD is recently increased considering the latest 
discoveries using the whole-exome sequencing approach [Zimprich A et al., 2011; Vilariño-Güell C et 
al., 2011; Edvardson et al., 2012; Krebs et al., 2013; Quadri et al., 2013; Vilariño-Güell C et al., 2014; 
Funayama et al., 2015; Lesage et al., 2016].  
Concerning the autosomal dominant (AD) forms, the most important genes are SNCA and LRKK2. 
SNCA codes for α-synuclein, a protein predominantly expressed at the pre-synaptic membrane of CNS 
neurons that is considered the main component of Lewy bodies. Although the exact function of this 
protein is not yet entirely clear, it seems to have a role in synaptic plasticity, in vesicular trafficking, and 
in the inhibition of dopamine release. To date duplications/triplications of the SNCA locus and three 
missense mutations have been described (NM_000345.3 c.88G>C p.A30P; c.136G>A p.E46K; 
c.157G>A p.A53T); changes in α-synuclein expression or the presence of mutations that increase its 
tendency to form aggregates have a toxic effect on dopaminergic neurons [Hunn et al., 2015]. 
LRRK2 (leucine-rich repeat kinase 2) codes for a kinase expressed in different areas of the brain, 
including the substantia nigra. About 80 mutations in this gene have been reported, however, only 
seven can be considered pathogenic. Among these, the most important in terms of frequency are the 
NM_198578 c.4321C>T (p.R1441C) and the c.6055G>A (p.G2019S). It is thought that the protein is 
involved in intracellular signaling and vesicular trafficking, although its precise biological function has 
not been clarified yet [Martin et al., 2014; Spatola and Wider et al., 2014]. 
Concerning the autosomal recessive forms (AR), the main genes are: PRKN, PINK1, and DJ-1. 
PRKN encode the parkin protein, an E3 ubiquitin ligase that conjugates ubiquitin to proteins targeted 
to be degraded by the proteasome. Parkin is recruited by mitochondria depolarization, where it induces 
the ubiquitination of the mitochondrial outer membrane proteins and promotes the removal of 
defective mitochondria by a specialized form of autophagy called mitophagy [Yin et al., 2013]. More 
than 100 mutations have been identified in the PRKN gene, most of which are large deletions or 
duplications of one or more exons; small deletions/insertions, nonsense and missense mutations were 
also described. Mutations in this gene are responsible for 50% of the recessive forms of early-onset PD 
[Lesage and Brice, 2012]. 
PINK1 (PTEN induced kinase 1) encodes a mitochondrial serine-threonine kinase that seems to 
protect neurons from mitochondrial dysfunction and oxidative stress-induced apoptosis. More than 50 
mutations were discovered in this gene, most of which are point mutations, but deletions of the entire 
gene were also reported [Lesage and Brice, 2012]. 
Finally, the DJ-1 gene codes for a very abundant protein in the brain, and in particular in astrocytes. 
DJ-1, forming a complex with PINK1 and parkin, acts as sensor for oxidative stress, and it has a role in 
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the regulation of mitochondria morphology, as well as in the degradation of unfolded proteins 
[Wilhelmus et al., 2012]. Defects in this gene are quite rare, only 15 mutations were described [Lesage 
and Brice, 2012]. 
Table 1.1| Loci and genes associated with monogenic forms of PD 
Locus Chromosome Gene Inheritance Possible pathways 
PARK1/PARK4 4q21-q22 SNCA AD Synaptic function 
PARK2 6q25.2-q27 PRKN AR/sporadic 
Mitochondrial function/mitophagy;  
ubiquitination 
PARK3 2p13 uk AD - 
PARK5 4p13 UCHL1 AD/sporadic Ubiquitination 
PARK6 1p35-p36 PINK1 AR/sporadic Mitochondrial function/mitophagy 
PARK7 1p36 DJ-1 AR Mitochondrial function 
PARK8 12q12 LRRK2 AD/sporadic 
Synaptic function; 
autophagy/lysosomal degradation 
PARK9 1p36 ATP13A2 AR autophagy/lysosomal degradation 
PARK11 2q36-37 uk AD - 
PARK13 2p12 HTRA2 AD/sporadic autophagy/lysosomal degradation 
PARK14 22q13.1 PLA2G6 AR Mitochondrial function 
PARK15 22q12-q13 FBXO7 AR Ubiquitination 
PARK17 16q11.2 VPS35 AD Autophagy/lysosomal degradation; endocytosis 
PARK18 3q27.1 EIF4G1 AD Translation 
PARK19 1p31.3 DNAJC6 AR Synaptic function; endocytosis 
PARK20 21q22.11 SYNJ1 AR Synaptic function; endocytosis 
PARK21 3q22.1 DNAJC13 AD/sporadic Synaptic function; endocytosis 
PARK22 7p11.2 CHCHD2 AD Mitochondrial function 
PARK23 15q22.2 VPS13C AR Mitochondrial function 
uk, unknown. Modified from Klein et al., 2012. 
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1.2.2 Association studies 
Numerous case-control association studies, both on candidate genes and on the entire genome 
(Genome-Wide Association Study, GWAS), allowed the identification of genetic variants predisposing 
to PD in different populations. 
Association studies were also instrumental to confirm the involvement of genes responsible for 
Mendelian forms of PD, like SNCA and LRRK2, in sporadic PD. In particular, regarding the SNCA 
gene, the association with sporadic PD of the dinucleotide microsatellite Rep1, located upstream of the 
transcription start site, has been repeatedly reported; moreover, haplotype analysis confirmed the 
association between different SNPs (Single Nucleotide Polymorphisms, SNPs) in the gene and the 
disease. Even meta-analysis studies support the association of SNCA with PD; in particular, the 
association signals are located in the promoter region and at the 3’ end of the gene [Lesage and Brice, 
2012]. These data were also confirmed in a large Italian cohort of 891 healthy subjects and 904 PD 
patients [Trotta et al., 2012]. The same study also verified the association between PD and MAPT 
(Microtubule-Associated Protein Tau), a gene encoding for tau, the microtubule-associated protein 
expressed in the adult CNS. SNPs in this gene have been recently associated with PD; in particular, the 
H1 haplotype, one of two common haplotypes for this locus in the Caucasian population, is a risk 
factor with an estimated odd ratio (OR) of 1.5 [Lesage and Brice, 2012]. Interestingly, mutations 
described in the MAPT gene, which usually cause tau hyperphosphorylation resulting in tau protein 
accumulation in neurons, are associated with various forms of dementia known as tauopathies [Kimura 
et al., 2014]. 
In addition, the most common and important risk factor for PD seems to be the GBA gene, whose 
association with PD was repeatedly validated [Sidransky et al., 2009; Do et al., 2011; IPDCG et al., 
2011; Liu et al., 2011]. This gene codes for a lysosomal enzyme, the beta-glucocerebrosidase (GCase), 
whose severe deficiency causes the Gaucher disease (GD), one of the most frequent lysosomal storage 
disorders. Heterozygosity for mutations in this gene have been associated with a 5 times higher risk to 
develop PD [Lesage and Brice, 2012]. 
Besides SNCA, LRRK2, MAPT and GBA, now commonly considered the major susceptibility genes 
for PD, a large number of GWAS on different populations, followed by several meta-analyses, lead to 
the identification of new genetic determinants of PD listed in Table 1.2. 
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Table 1.2| Main GWAS results 
Chromosome Gene OR p value 
1q21 GBA 5.43 1.44∙10-14 
1q21.1 SYT11 1.44 1.18∙10-6 
1q32 RAB7L1/PARK16 0.86 1.52∙10-12 
2q21.3 ACMSD 1.07 3.16∙10-3 
2q24.3 STK39 1.12 1.64∙10-3 
3q27 MCCC1/LAMP3 0.87 6.92∙10-5 
4p15 BST1 0.87 3.94∙10-9 
4p16 GAK 1.14 7.46∙10-8 
4q21.1 SCARB2 0.90 7.60∙10-10 
4q21.1 STBD1 0.91 5.29∙10-5 
6p21.3 HLA-DRB5 0.80 5.50∙10-10 
7p15 GPNMB 0.89 3.86∙10-8 
8p22 FGF20 0.88 8.49∙10-7 
12q24 CCDC62/HIP1R 1.13 9.06∙10-7 
16p11.2 STX1B 1.15 8.21∙10-9 
17p11.2 SREBF1 0.95 5.60∙10-8 
17q21.1 MAPT 0.80 1.95∙10-16 
Modified from Singleton et al., 2013. 
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1.3 GBA 
The GBA gene encode the beta-glucocerebrosidase, a lysosomal enzyme involved in the metabolism of 
sphingolipids. There are two other isoforms of this enzyme: GBA2, which is localized at the plasma 
membrane, and GBA3, which is the cytosolic isoform [de Graaf et al., 2001; Boot et al., 2007]. 
The GBA gene is located on chromosome 1q22, it comprises 11 exons and spans 7.6kb (Figure 1.1). 
The gene is characterized by a proximal (P1) and a distal (P2) promoter: P1 contains a TATA box and 
different binding sites for transcription factors, while P2, located 2.6kb upstream of the translation start 
site, shows the typical features of an housekeeping gene promoter [Svobodová et al., 2011]. 
In the same genomic region, there is also a highly homologous pseudogene (GBAP1), located 
approximately 16kb downstream of the GBA gene, which shares the same exon-intron organization of 
the functional gene (Figure 1.1).  
 
Figure 1.1 |Localization and structure of the GBA gene locus. 
A schematic representation of chromosome 1 with the localization of the GBA and GBAP1 genes; introns are represented 
by black lines and exons by rectangles. 
 
The glucocerebrosidase, belonging to the glycoside hydrolase family, is a protein mainly associated to 
the internal lysosomal membrane, even if small quantities of the enzyme are present on the extracellular 
membrane. GCase catalyzes the hydrolysis of glucosylceramide (GlcCer), a membrane 
glycosphingolipid, to ceramide and glucose. 
The GCase is characterized by three structural domains. The domain I (residues 1-27 and 383-414) 
contains two disulfide bridges important for the correct protein folding and some specific glycosylated 
residues essential for catalytic activity. The domain II (residues 30-75 and 431-497) has a regulatory and 
structural function, and it is also important for the interaction with the saposin C, an enzyme activator 
also mediating the interaction with the lysosomal membrane. Finally, the domain III (residues 76-381 
and 416-430) is constituted by a TIM barrel domain with catalytic function [Dvir et al., 2003]. 
Severe deficiencies of the enzyme lead to the accumulation of the substrate and are responsible for the 
multi-organ clinical manifestations of the Gaucher disease (GD), one of the most common genetic 
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lysosomal storage disorders. Although GD encompasses a continuum of clinical presentations from a 
perinatal lethal disorder to an asymptomatic form, traditionally, it has been divided in three major 
clinical types based upon the absence (type 1, non-neuronopathic, OMIM #230800) or presence of 
primary CNS involvement (Type 2, acute neuronopathic, OMIM #230900; and Type 3, subacute 
neuronopathic, OMIM #231000). Over 300 mutations have been identified in GBA and linked to GD 
so far [Hruska et al., 2008], and, interestingly, no strong correlation between the clinical phenotype, the 
genotype, and the residual enzyme activity was observed [Goker-Alpan et al., 2005; Lachmann et al., 
2004]. 
In recent years, GD and PD have been connected on account of the clinical observation of 
parkinsonism and LB pathology in patients with GD [Lwin et al., 2004]. Compared with the general 
population, patients with GD type 1 have a 20-fold increased lifetime risk of developing parkinsonism 
[Westbroek et al., 2011], whereas individuals carrying heterozygous GBA mutations, have a five times 
greater risk of developing PD than non-carrier individuals [Sidransky et al., 2009]. Several studies 
confirmed that GBA mutations, in particular the two most common mutations N370S and L444P, are 
more frequent in PD patients than in healthy controls, demonstrating that genetic lesions in this gene 
are a common risk factor for the disease, especially in the familial form [International Parkinson’s 
Disease Genomics Consortium, 2011]. 
Despite these efforts, to date, the mechanism underlying the relation between GBA mutations and the 
development of PD remains unclear and it is a cause of debate in the scientific community. In fact, 
there are reports in the literature supporting a gain-of-function effect of the mutated protein, as well as 
publications supporting a loss-of-function mechanism [Sidransky et al., 2012]. Moreover, not only a 
widespread deficiency of GCase activity has been demonstrated in the brains of PD patients carrying 
GBA mutations, but also PD patients without GBA mutations were shown to exhibit deficiency of 
GCase in substantia nigra [Gegg et al., 2012]. Importantly, recent data demonstrated that in neurons 
and in brains from this type of PD patients, the lysosomal accumulation of GlcCer directly influences 
the abnormal lysosomal storage of α-synuclein oligomers, thus resulting in a further inhibition of the 
GBA activity. These findings suggest, for the first time, that the bi-directional effect of GBA and α-
synuclein accumulation forms a positive feedback loop that may lead to a self-propagating disease 
[Mazzulli et al., 2011]. 
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1.4 MicroRNAs 
MiRNAs are short (19-25 nucleotides) single-stranded RNAs found in plant and animals. They act as 
post-transcriptional regulators of gene expression by repressing target mRNAs translation and/or by 
inducing the degradation of the mRNA. Hundreds of miRNAs have been cloned and thousands more 
have been predicted bioinformatically, making them a major class of regulators [Berezikov et al., 2006]. 
Assisted by the RNA silencing machinery, each miRNA might inhibit the expression of hundreds of 
target mRNAs [Lim et al., 2005], whose recognition is based on imperfect complementary binding 
between miRNAs and their target sites, usually located within the 3’ untranslated regions. In particular, 
a region of 7-8 nucleotides at the 5’ end of the miRNA, called seed region, seems to be extremely 
important for target recognition [Nielsen et al., 2007]. MiRNAs have been implicated in a variety of 
biological processes, including embryonic development, cell differentiation, cell cycle regulation, and 
apoptosis [Esquela-Kerscher et al., 2006], as well as in pathological processes like cancer [Meltzer et al., 
2005], Alzheimer disease and metabolic disorders [Krützfeldt et al., 2006]. The evidence of a 
dysregulated expression of specific miRNAs in different human diseases makes them both promising 
diagnostic markers and therapeutic agents or targets. In addition, miRNA-based drugs have already 
been developed and they have a great potential for treating cancer, psychiatric disorders and other 
human diseases [Srinivasan et al., 2013]. 
MiRNAs can be encoded as independent transcriptional units, or be part of polycistronic clusters. They 
are mainly transcribed by RNA polymerase II or III as primary transcripts (pri-miRNAs) containing 
domains that allow the folding into a hairpin structure. These pri-miRNAs are subsequently recognized 
and processed in the nucleus by the Drosha complex, which generates precursors of 70-100 nucleotides 
(pre-miRNA), that are subsequently exported in the cytoplasm by the exportin 5 in a Ran-GTP-
dependent manner. In the cytoplasm, the Dicer complex recognizes the pre-miRNA and produces 
mature miRNA through a endonucleolytic cleavage that removes the loop of the hairpin, generating a 
double-strand RNA of 22 nucleotides with 3 'ends protruding, which is eventually recognized and 
assembled into the RISC complex (RNA-induced silencing complex). Usually, the functional miRNA, 
derived from one of the two strands, is selected and loaded on the Argonaut protein (Ago) of the 
complex, while the complementary strand, referred to as miRNA*, is generally degraded [He and 
Hannon, 2004]. However, more recent data have shown that miRNAs* are often present 
physiologically at relevant concentration and can be associated with an Ago protein inhibiting specific 
mRNA targets, as demonstrated both in cell culture and in transgenic animals [Okamura et al., 2008; 
Jazdzewski et al., 2009]. Considering that both strand could act as functional miRNA; the two miRNAs 
are usually called 3p or 5p depending on the strand of the hairpin from which they originate. 
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Figure 1.2|miRNA Biogenesis. 
Modified from He and Hannon, 2004. 
Several studies identified miRNAs that target genes associated with Mendelian or sporadic forms of 
PD. For example, two miRNAs, miR-7 and miR-153, were confirmed to target α-synuclein [Doxakis, 
2010]. In particular, miR-7 is able to suppress α-synuclein-mediated cytotoxicity in neuronal cell models 
[Junn et al., 2009]. Moreover, studies on miRNA expression pattern in brains of PD patients showed a 
decrease in the levels of miR-34b and miR-34c. In PD cellular models, a miR-34b/c reduction was 
associated to a decrease of DJ-1 and Parkin levels, resulting in mitochondrial dysfunction and 
production of reactive oxygen species that lead to a compromised neuron viability [Miñones-Moyano et 
al., 2011]. Recently it was also demonstrated that these two microRNAs repress the expression of α-
synuclein directly targeting its 3’UTR [Kabaria et al., 2015]. Finally, miR-205 was demonstrated to 
represses the expression of LRRK2. The observation that the levels of miR-205 in the frontal cortex 
was significantly lower in PD patients vs healthy controls suggests that this microRNA may play an 
important role in the modulation of LRRK2 expression also in the brains of sporadic PD patients [Cho 
et al., 2013]. 
Despite these interesting results concerning miRNAs that specifically target genes associated with 
familial forms of PD, the predominant role of miRNAs in PD pathogenesis might be their ability to 
regulate other disease-correlated genes. Therefore, it will be particularly important to understand the 
role of microRNAs in the regulation of networks of genes involved in the different pathways 
implicated in the pathogenesis of PD. 
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1.5 Competing endogenous RNAs  
The advent of high-throughput techniques for the study of the transcriptome led to the discovery that 
more than 75% of the genome is transcribed, confirmed the existence of a large number of lncRNAs 
(long non-coding RNAs) and demonstrated that a number of pseudogenes are indeed actively 
transcribed. Recent data also indicate the increasing importance of non-protein coding genes, 
demonstrating the crucial role of lncRNAs in essential regulatory networks frequently dysregulated in 
pathological conditions [Milligan and Lipovich, 2015]. 
Among the many classes of non-coding RNAs with regulatory functions, an interesting new one is 
represented by competing endogenous RNAs (ceRNAs). These transcripts would act by competing 
with protein-coding mRNAs for a small pool of microRNA (miRNAs), thus modulating the miRNA-
mediated expression regulation [Seitz, 2009; Poliseno et al., 2010].  
Good candidates to play the role of ceRNA is the class of pseudogenes, since they have a high-
sequence identity with the ancestral gene and, consequently, they could compete for the binding of the 
same miRNAs. Moreover, many among them are now known to be transcribed, even if they usually 
have lost the ability to generate a functional protein product [Poliseno et al., 2010]. Variations in the 
levels of pseudogene expression may result in changes in the levels of the transcripts regulated by the 
miRNAs targeting the pseudogene. In particular, high levels of ceRNA could bind a great amount of 
miRNA increasing the expression of the corresponding functional gene. By contrast, a low quantity of 
competitor increases the possibility for the shared miRNAs to interact with the protein coding gene, 
leading to the consequent reduction of its expression [Cazalla et al., 2010; Wang et al., 2010; Lee et al., 
2010; Salmena et al., 2011].  
Interestingly, the 5.5-kb-long GBAP1 pseudogene has maintained a 96% of sequence identity with the 
functional gene and shares the same exon-intron organization [Wafaei and Choy, 2005]. GBAP1 is the 
result of a tandem duplication that involves the GBA gene and the MTX1 gene, located immediately 
downstream of GBA (Figure 1.1). This genomic arrangement is evolutionary very recent, considering 
that it is present only in primates [Svobodová et al., 2011]. The main difference between GBA and 
GBAP1 consists in the presence of 3 additional Alu insertions in GBA introns, while a 55-bp deletion 
in exon 9 is a unique hallmark of GBAP1, and can be used to distinguish the two transcripts [Wafaei 
and Choy, 2005]. A large variety of predicted GBAP1 transcripts are annotated in the UCSC genome 
browser, however the majority of them is not experimentally validated (Figure 1.3).  
Since it is known that GBAP1 is an expressed pseudogene, it could represent an endogenous 
competitor of the GBA mRNA, acting as a "sponge" for miRNAs targeting both GBA and GBAP1 
transcripts. 
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Figure 1.3|GBAP1 annotated transcripts. 
GBAP1 locus retrieved from UCSC Genome Browser. In blue the RefSeq genes, in light blue the UCSC Genes and in red 
the Ensembl Gene Predictions.  
 
1.6 Next-generation sequencing and PD 
The recent development of Next-Generation Sequencing (NGS) technologies allows the accurate 
determination of nearly all protein-coding sequence variants in an individual (the so-called whole-
exome sequencing, WES) [Ng et al., 2009] or even the sequencing of the entire genome (whole-genome 
sequencing, WGS) [Foo et al., 2012]. While there has been a considerable debate in the scientific 
community whether to favour WES or WGS, a number of considerations still support the WES 
approach: i) WES costs at least five times less than WGS; ii) the size of WES data per patient are far 
less than WGS data, resulting in reduced processing time and less burden in terms of data storage; iii) 
the functional annotation of coding variations streamlines the prioritization of damaging variants; iv) 
the vast majority (85%) of mutations with large effects on disease-related traits is located within coding 
regions. 
Indeed, the WES approach has been already effectively applied to a number of Mendelian disorders 
[Bamshad et al., 2011], proving that exome sequencing of a small number of related affected individuals 
is a powerful and efficient approach to discover novel disease genes. This strategy was also successfully 
applied to point out novel genes involved in autosomal dominant familial PD (such as VPS35 and 
DNAJC13) [Zimprich et al., 2011; Vilariño-Güell et al., 2011; Vilariño-Güell et al., 2014], whereas 
DNAJC6 and SYNJ1 were shown to cause autosomal recessive juvenile parkinsonism [Edvardson et 
al., 2012; Krebs et al., 2013; Quadri et al., 2013]. 
The identification of genes linked to familial PD has provided crucial insights into the molecular 
mechanisms of PD pathogenesis and identified possible targets for therapeutic intervention. In 
particular, the pathogenic mechanisms highlighted by the genes identified till now place the ubiquitin-
proteasome system dysfunction, lysosomal system dysfunction, oxidative stress, and mitochondrial 
dysfunction at centre stage [Obeso et al., 2010]. Despite these advancements, the majority of the 
expected PD heritability is still missing; indeed, to date, the underlying cause has been identified in only 
~40% of all familial PD cases. Undoubtedly, the discovery of novel PD−causative genes will 
dramatically further our knowledge on the cellular pathways that lead to neurodegeneration and may 
point to novel therapeutics targets for the treatment of PD. 
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Parkinson’s disease is the second most common neurodegenerative disorder, affecting approximately 
0.3% of the general population and 1% of people over the age of 75. Considering its prevalence in the 
population, implications of the costs for treatment (which is only symptomatic), diagnosis, and 
supporting regimens are a heavy burden for Public Health Institutions, making each improvement in 
the field desirable. PD is a complex disorder caused by the combination of so-far largely unidentified 
environmental factors and of predisposing susceptibility genetic components. In recent years, 
considerable progresses have been made in the identification of the genetic components of PD: several 
genes were shown to cause rare monogenic forms of PD, with autosomal-dominant (SNCA, LRRK2, 
VPS35) or autosomal-recessive (parkin, PINK1, DJ1) inheritance. Moreover, a large number of 
“common” predisposing genetic variants, each with a modest effect, have been associated with 
sporadic PD by genome-wide association studies (GWAS); among them, GBA seems to be the main 
genetic risk factor for the disease. These results strongly supported the idea that sporadic and familial 
PD share multiple genetic risks, and also pathogenic pathways. Despite these advancements, the 
majority of the expected PD heritability is still missing. 
In this frame, my PhD project was mainly focused on better understanding disease pathogenesis 
through the identification of novel genetic determinants of PD and the in-depth study of GBA 
expression regulation as a necessary step to gain novel insights on the most important genetic 
component of the disease. I pursued these tasks by following two lines of research: one aimed at 
dissecting GBA gene expression regulation, focusing in particular on the role of GBAP1, a GBA 
pseudogene, in modulating GBA expression through an RNA-based post-transcriptional regulatory 
network, with the view to highlight novel strategies to augment GCase activity in PD patients. The 
second line of research was aimed at identifying novel genes responsible for familial PD, and potentially 
also implicated in sporadic PD. To this aim I have exploited a widespread approach, consisting on the 
whole-exome sequencing of selected PD families, followed by candidate genes prioritization and 
functional validation. The identification of novel genes responsible for rare Mendelian forms of PD 
may have a substantial impact in understanding disease pathogenesis by pointing to novel pathways 
involved in the disease and by identifying novel molecular targets, a crucial step in the design of 
innovative (molecular) mechanism-driven therapies. 
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3.1 Post-transcriptional regulation of GBA 
The pathogenic mechanism underlying the association between mutations in the GBA gene and the 
development of PD remains to be clarified. Starting from the evidence that a widespread deficiency of 
GCase activity was demonstrated not only in PD patient brains with mutations in the GBA gene, but 
also in patients without mutations, we decided to evaluate the possible mechanisms that could alter 
GBA expression levels. In particular, we decided to start from the post-transcriptional regulation of this 
gene, searching for miRNAs targeting GBA. 
3.1.1 MiRNA selection 
We used different software to generate a list of miRNA candidates: we prioritized the ones predicted by 
at least five software and known to have a potential role in neurodegenerative diseases, or that were 
previously implicated in neuronal development. From this analysis were selected as possible candidates 
3 miRNAs: miR-22-3p, miR-132 and, miR-212 (Table 3.1).  
Table 3.1 
miRNA 
(chromosomal position)* 
miRNA:GBA pairing** Brain expression*** 
miR-22-3p 
(chr17:1,617,197-1,617,281) 
3' ugucaagaagUUGACCGUCGAa 5' miR-22 
             || ||||||||  
5' cagccaggaaAAAUGGCAGCUc 3' GBA 
 
Cerebellum (643) 
frontal cortex (219) 
miR-132 
(chr17:1,953,202-1,953,302) 
3' gcuGGUACCGACAUCUGACAAu 5' miR-132 
      |||   ||| ||||||||  
5' ggcCCAAAACUGGAGACUGUUu 3' GBA 
 
Cerebellum (203) 
frontal cortex (818) 
miR-212 
(chr17:1,953,565-1,953,674) 
3' ccGGCACUGACCUCUGACAAu 5' miR-212 
     ||   |||||||||||||  
5' gcCCAAAACUGGAGACUGUUu 3' GBA 
 
Cerebellum (22) 
frontal cortex (70) 
* According to UCSC genome browser (http://genome-euro.ucsc.edu/index.html) on Human Feb. 2009 (GRCh37/hg19) 
Assembly. 
** The RNAhybrid software (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) was used to visualize the miRNA: mRNA 
interactions. 
*** According to deep-sequencing data available through miRBase (http://www.mirbase.org/); numbers in brackets refers 
to read counts per million of RNAseq experiments (annotation confidence: high for miR-22-3p and miR-132; not reported 
for miR-212). 
 
MiR-22-3p is located on chromosome 17 p13.3 in an intron of the non-coding gene MIR22HG (host 
miR-22 gene). Recent studies have associated miR-22-3p with Huntington's disease and Alzheimer's 
disease, highlighting its protective role when over-expressed [Jovicic et al., 2013]. MiRNAs-132 and 212 
belong to the same gene cluster on chromosome 17 p13.3, and they are characterized by seed regions 
with similar sequences; consequently, they may share common targets [Wanet et al., 2012]. Recent 
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studies have highlighted some important processes in which the two miRNAs are involved, especially 
in the brain, confirming their role in synaptic plasticity and neural development [Tognini et al., 2011]. 
Their expression is down-regulated in mouse models of PD; they also appear to be involved in 
psychiatric disorders, like Huntington's disease, Alzheimer's disease, and autism [Cogswell et al., 2008; 
Packer et al., 2008; Talebizadeh et al., 2008; Kim et al., 2007; Wanet et al., 2012].  
The real-time RT-PCR method used for the quantitative analysis of selected miRNAs (based on a 
polyadenylation and a universal reverse transcription approach) did not allow us to reliably quantify 
miR-212 levels, at least in our cellular models (data not shown).  
3.1.2 GBA and GBAP1 are targets of miR-22-3p 
To verify if GBA and GBAP1 are target of miR-22-3p or miR132 we started evaluating the effect of 
microRNA over-expression in HeLa cells. To this end we cloned the precursors of both microRNAs 
into the expression plasmid for eukaryotic cells psiUx (kindly provided by prof. Bozzoni, Università di 
Roma “La Sapienza”) [Denti et al., 2004]. After transfection experiments, the levels of endogenous 
GBA and GBAP1 expression were measured by real-time RT-PCR assays. The obtained results showed 
that miR-22-3p over-expression (50-fold increase) has a significant effect on the levels of GBA an 
GBAP1 transcripts, while the over-expression of miR-132 (180-fold increase) has no detectable effects. 
In particular, concerning miR-22-3p, the levels of GBA and GBAP1 are both reduced after 24 hours of 
transfection, respectively by 72% (p=0.0003) and 64% (p=0.0002) (Figure 3.2 A). 
To confirm these results we set up cotransfection experiments using the vector expressing the miRNAs 
and a vector containing the GBA or GBAP1 3'UTRs cloned in the vector psiCHECK-2 (Promega), 
downstream of the renilla luciferase gene. The recombinant constructs were transfected into HeLa cells 
in the presence of psiUx empty vector (mock) or containing the sequence of pre-miRNAs. The results 
of transfection experiments confirmed that GBA and GBAP1 3’UTRs are responsive to miR-22-3p. 
On the contrary, and in accordance with previous results, no significant reduction was observed in the 
case of miR-132, further confirming that it has no effect on GBA or GBAP1 (Figure 3.2 B). 
In order to validate the results obtained on miR-22-3p, these same experiments were repeated in a 
different cell line; in particular, we chose HEK293 cells for their low amount of endogenous miR-22-3p 
and the well detectable levels of GBA and GBAP1 (Figure 3.1). The obtained results confirmed that 
miR-22-3p over-expression (130-fold increase) leads to an about 50% reduction of both GBA and 
GBAP1 transcripts levels. To check whether modulation by miR-22-3p was detectable also at the 
protein level, the HEK293 cells, transfected for 48 hours with psiUx-miR-22-3p or with the empty 
plasmid, were used to measure the GCase enzymatic activity. All measurements were performed in 
collaboration with the laboratory of Dr. Massimo Aureli (Dipartimento di Biotecnologie Mediche e 
Medicina Traslazionale, Università degli Studi di Milano). The results of these experiments showed a 
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reduction (15% with a p-value of 0.0017) of GCase activity in miR-22-3p overexpressing cells (450-fold 
increase) compared to samples transfected with the empty plasmid (Figure 3.2 C). 
We also replicated the luciferase experiments in HEK293 cells and, to evaluated if the region 
recognized by the miRNA in GBA and GBAP1 3'UTRs (miRNA recognition element, MRE) was the 
one predicted by bioinformatics analysis, we produced mutant constructs lacking the putative miR-22-
3p binding site and then repeated the transfection experiments. The transcripts without the MRE were 
not responsive to miR-22-3p, suggesting that the observed down-regulation of GBA and GBAP1, as a 
result of miR-22-3p over-expression, was due to a direct miRNA-mRNA interaction (Figure 3.2 D).  
 
Figure 3.1|GBA, GBAP1 and miR-22-3p expression levels in 11 cell lines. 
A. GBA and GBAP1 expression levels were measured by real time RT-PCR assays on RNA derived from 11 cell lines. 
HMBS transcripts was used as internal reference. B. MiR-22-3p expression levels were measured by real time RT-PCR 
assays (based on a polyadenylation and a universal reverse transcription approach) using the SYBR Green chemistry on 
RNA derived from 11 cell lines. U6 snRNA was used as internal reference. Results are presented as normalized rescaled 
values, setting as 1 the values of the SH-SY5Y line. Bars represent means + SD of three replicates. 
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Figure 3.2| GBA and GBAP1 are targets of miR-22-3p. 
A. HeLa cells were transfected with 3.5µg psiUX plasmid expressing either miR-22-3p or miR-132 precursors or the empty 
vector. 24h later, RNA was extracted and the GBA and GBAP1 levels were measured by real time RT-PCR. HMBS 
transcripts were used as internal reference. Expression levels are shown as normalized rescaled values, setting as 1 the value 
measured in cell transfected with an empty vector (psiUX, mock). B. The psiCHECK2 vectors, containing either the GBA 
or the GBAP1 3’UTR downstream of the luciferase reporter gene, were independently transfected in HeLa cells together 
with plasmids expressing either the pre-miR-22-3p or the pre-miR-132. After 48h, the luciferase activity was assayed in cell 
extracts. To normalize the renilla luciferase values, the firefly luciferase levels were used. Expression levels are shown as 
normalized rescaled values, setting as 1 the value measured in cell transfected with an empty vector (psiUX, mock). C. 
HEK293 cells were transfected with 875ng of psiUX plasmid expressing miR-22-3p, miR-132 precursors or the empty 
vector. Left panel, 24h later, RNA was extracted and the GBA and GBAP1 levels were measured by real time RT-PCR. 
HMBS transcripts were used as internal reference. Right panel, 48 hours after transfections, cells were collected for 
endogenous GCase activity measurements. In all cases, the results are shown as normalized rescaled values, setting as 1 the 
value measured in cell transfected with an empty vector (psiUX, mock). D. Luciferase reporter assays were repeated in 
HEK293 cells, by transfecting the psiCHECK2 vector coupled to the 3’UTR regions of GBA or GBAP1, with or without 
the putative miRNA recognition element (ΔMRE). Each of the four psiCHECK2 recombinant plasmid was cotransfected 
with the psiUX plasmid expressing miR-22-3p. 48 hours after transfection, cells were collected and lysates prepared to 
perform the reporter assays. To normalize the renilla luciferase values, the firefly luciferase levels were used. Expression 
levels are shown as normalized rescaled values, setting as 1 the value measured in cell transfected with an empty vector 
(psiUX, mock). In all panel, bars represent means + SEM of at least 3 independent experiments each performed at least in 
triplicate. The results were analyzed by unpaired t-test. *: p<0.05, **: p<0.01, ***: p<0.001 
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3.1.3 GBAP1 acts as a GBA ceRNA  
In order to evaluate the possible role of GBAP1 as a GBA ceRNA, we initially analyzed the expression 
levels of GBA, GBAP1 and miR-22-3p in a commercial panel of 20 human tissues and 24 different 
brain areas. The analysis was performed by real-time RT-PCR and the results showed that the 
pseudogene is expressed at well-detectable levels, although always lower than those of GBA (Figure 
3.3), in all analyzed districts; the average ratio between the expression levels of the GBA/GBAP1 was 
equal to 70:1 (given that it oscillates between a minimum of 11:1 in the thymus and a maximum of 
280:1 in the kidney). These results suggest that also the expression levels of the pseudogene may be 
differentially regulated between the different tissues. 
 
Figure 3.3| GBA and GBAP1 expression pattern. 
GBA and GBAP1 expression levels were measured by real time RT-PCR assays using the SYBR Green chemistry on RNA 
derived from a commercial panel of 20 human tissues (upper-case letters) and of 24 brain areas (lower-case letters). HMBS 
transcripts were used as internal reference. Results are presented as normalized rescaled values, setting as 1 the GBA values 
of the SH-SY5Y line. Bars represent means + SD of three replicates. 
After demonstrating that GBAP1 and GBA are targets of miR-22-3p, we focused our attention on the 
pseudogene, in order to assess its possible role as ceRNA in the regulation of GBA. 
We performed transfection experiments over-expressing the 3'UTR of GBAP1 in HepG2 cells, a cell 
line expressing high levels of miR-22-3p and low levels of GBAP1 (Figure 3.1). We used as controls the 
empty vector and the MRE deleted 3’ UTR. The endogenous levels of GBA were measured by real-
time RT-PCR on total RNA extracted from cells 96 hours after transfection. The obtained results 
showed an increase in the expression levels of GBA transcripts (1.68 fold; p=0.0016) when the 
pseudogene full length 3’UTR was over-expressed (Figure 3.4 A). According to the ceRNA hypothesis, 
all transcripts that share the same miRNA response elements should be able to modulate each other 
[Salmena et al., 2011; Karreth and Pandolfi, 2013]. We therefore evaluated the effect of GBAP1 3'UTR 
over-expression on SP1 (Specificity Protein 1) and SIRT1 (Sirtuin1) transcripts, two validated targets of 
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miR-22-3p [Xu et al., 2011]. Moreover, we measured the levels of a transcript not predicted to be 
targeted by miR-22-3p: CELF1 (CUGBP, Elav-Like Family Member 1), a well-detectable ubiquitously-
expressed mRNA, chosen for its long 3’ UTR (6205bp) in order to take into account any nonspecific 
effects. As expected, the over-expression of the full length 3'UTR of GBAP1 induced a significant 
increase of about 1.7 (p<0.015) of SP1 and SIRT1 transcripts, while the expression levels of CELF1 
did not significant change (Figure 3.4 A). These data support the hypothesis of a reciprocal regulation 
among transcripts sharing miR-22-3p as a post-transcriptional regulator. 
We also tested the role of GBAP1 as a ceRNA at the protein level, measuring the enzymatic activity of 
GCase in the same transfection experiments. The enzymatic assay results showed a significant change 
in the GCase activity, which was increased by approximately 1.11 times in cells expressing the full 
length GBAP1 3'UTR compared to controls (p=0.013) (Figure 3.4 B). These results suggest that 
GBAP1 could be able to act as a molecular sponge for miR-22-3p and to modulate the levels of GBA.  
 
Figure 3.4| GBAP1 may act as a ceRNA for GBA and other miR-22-3p-3p targets. 
A. HepG2 cells were transfected with 300ng of the psiCHECK2 plasmid containing the GBAP1 3’UTR with or without the 
MRE. 96h later, RNA was extracted and the levels of GBA, SP1, SIRT1, and CELF1 were measured by real time RT-PCR. 
HMBS transcripts were used as internal reference. Expression levels are shown as normalized rescaled values, setting as 1 
the value measured in cells transfected with an empty vector (psiCHECK2, mock). B. The same overexpression 
experiments were performed to obtain, 96h after transfection, protein extracts for the measurements of the GCase activity. 
In all panels, bars represent means +SEM of three independent experiments, each performed at least in triplicate. The 
results were analyzed by unpaired t-test. *: p<0.05; **: p<0.01. 
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3.1.4 GBAP1 splicing pattern and NMD regulation 
The information currently available in the literature and in databases on GBAP1 transcripts are rather 
fragmentary. However, it is known that some of the existing nucleotide differences between GBA and 
GBAP1 involve splicing sites, and is therefore likely that the mature transcripts of the pseudogene are 
slightly different from the GBA ones. For this reason, we decided to characterize the splicing profile of 
GBAP1 by RT-PCR on RNA extracted from HepG2 cells untreated and treated with cycloheximide, a 
known NMD (nonsense-mediated mRNA decay) pathway inhibitor. The study of GBAP1 splicing 
pattern is complicated by the high sequence identity between the pseudogene and its cognate protein 
coding gene; the main difference within the coding sequence is a region of 55 nucleotides deleted in the 
pseudogene exon 9. We designed RT-PCR assays specific for the GBA and the GBAP1 transcripts 
anchoring one of the two primers to the 55-bp in exon 9 or on the breakpoint of the deletion, 
respectively. The transcripts were initially analyzed using 3 separate assays (A, B, C for GBA and D, E, 
F for GBAP1) (Figure 3.5 A). Agarose gel electrophoresis of the RT-PCR products showed the 
amplification of a single major band for amplicons A, B, C in each condition, demonstrating that GBA 
exons are mainly present in all transcripts. Concerning GBAP1, amplicon F was characterized by a 
single band also when the cells were treated with cycloheximide, indicating the GBAP1 exons 9-11 are 
not subject to alternative splicing. By contrast, some of the exons upstream may be excluded from the 
mature mRNA (exon skipping), as shown by the presence of multiple RT-PCR products on the gel 
(amplicons D and E) (Figure 3.5 A). This remarkable transcript complexity was further characterized by 
nested or semi-nested RT-PCR assays, which led to the identification of the majority of alternative 
splicing events (both in-frame and out-of-frame) involving almost all exons (Figure 3.5 B). Some of 
them are already annotated as predicted transcripts in the UCSC Genome Browser (e.g. the intron 8a 
retention and the exon 4 skipping), while others are novel such as exon 6 skipping or the splicing 
events involving the 5’ UTR. 
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Figure 3.5|GBAP1 splicing profile. 
A. In the upper part of the panel, a schematic representation of GBA and GBAP1 genes is reported. Exons are indicated by 
boxes, introns by line. The fragments amplified by RT-PCRs to analyze the GBA and GBAP1 splicing patterns are indicated 
by dashed lines and a letter. In the lower part of the panel, the electrophoretic analysis (agarose gels 2%) of RT-PCR 
amplicons is shown. RT-PCRs were performed on RNA extracted from HepG2 cells treated or untreated with the NMD 
inhibitor cycloheximide. On the top of each gel, letters indicate the relevant RT-PCR amplicons. B. In the upper part of the 
panel, a schematic representation of the whole gene is presented with broken lines pointing to the major splicing events 
characterizing the 3’ portion of the transcript. Grey boxes indicate the presence of additional exons or extensions of 
annotated exons. In the lower part of the figure, a magnification of the 5’ portion of the gene is reported, with all the 
identified alternative splicing events. Out-of-frame splicings are indicated in all cases by a star. All identified alternative 
splicing events were confirmed by Sanger sequencing of the relevant RT-PCR fragment. 
Considering the high complexity of the GBAP1 splicing and given that the majority of pseudogene 
transcripts are characterized by the presence of premature stop codons (PTCs), we decided to check 
whether the nonsense-mediated mRNA decay could have a role in post-transcriptional regulation of 
GBAP1. Indeed, it is known that also non-coding transcripts containing PTC, as pseudogenes, can be 
subject to the NMD mechanism [Mitrovich and Anderson, 2005]. The possible degradation of GBAP1 
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transcripts due to NMD was investigated by treating HEK293 and HepG2 cells with cycloheximide. 
After 8 hours of treatment, we extracted total RNA and then performed real-time RT-PCR assays to 
measure the levels of GBAP1 and GBA transcripts using as reference the gene coding for connexins. 
The choice of using the connexin transcripts is due to the fact that the coding region of the 
corresponding genes is contained in a single exon, and therefore they are not subject to NMD 
degradation. The levels of two different transcripts of PRKCA gene (encoding for the protein kinase C 
alpha), were used as positive and negative control of the experiment [Paraboschi et al., 2014]. The 
results obtained from these experiments showed that there is an approximately 4-time increase 
(p<0.045) in the levels of GBAP1 following cycloheximide treatment compared to the untreated 
control in both cell lines (Figure 3.6). Even if GBA alternative transcripts were not identified in our 
experiments or reported in literature, it is interesting to observe that, after cycloheximide treatment, 
even the transcript levels of GBA undergo a modest increase (about 2-fold) compared to the untreated 
control (Figure 3.6). These data might indicate that the pseudogene GBAP1 is subject to the NMD 
degradation and suggest a possibly indirect regulation also of the GBA levels by this pathway.  
 
Figure 3.6|GBA and GBAP1 are regulated by the NMD mechanism. 
HEK293 (left) and HepG2 (right) cells were treated with cycloheximide for 8h. After the treatment, RNA was extracted and 
the GBA and GBAP1 levels were measured by real time RT-PCR. Connexin 43 or 32 transcripts were used as internal 
reference. Expression levels are shown as normalized rescaled values, setting as 1 the value measured in untreated (Ctrl) 
cells. RT-PCRs performed on out-of-frame and in-frame PRKCA isoforms, known to be respectively sensitive and 
insensitive to the NMD inhibition were used as positive and negative controls. Bars represent means + SEM of at least 3 
independent experiments, each performed at least in triplicate. The results were analyzed by unpaired t-test. *: p<0.05, **: 
p<0.01. 
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3.1.5 GBA, GBAP1, and miR-22-3p are expressed in iPS-derived neurons 
To evaluate whether the proposed RNA-based regulatory network may be relevant in PD, we measured 
the levels of GBA, GBAP1 and miR-22-3p in a more disease-relevant cellular model. In particular, we 
evaluated their expression levels in iPS and iPS-derived dopaminergic neurons, obtained starting from 
fibroblasts of controls and of PD patients carriers of a GBA mutation (n=2 L444P, n=2 N370S), 
kindly provided by Dr. Michela Deleidi (German Center for Neurodegenerative Diseases, University of 
Tübingen), Dr. Alessio Di Fonzo (Department of Pathophysiology and Transplantation, University of 
Milan), and Prof. Rejko Kruger (Luxembourg Center for Systems Biomedicine, University of 
Luxembourg). 
In order to assess whether GBA, GBAP1 and miR-22-3p are also coexpressed in dopaminergic 
neurons, and how their expression could change during neuronal development, we analyzed their 
transcript levels by real-time RT-PCR, using as internal reference the housekeeping gene HMBS and 
the snoRNA U43. The obtained results showed that the three transcripts are expressed in dopaminergic 
neurons, the diseased cells in PD. We also highlighted that GBA mRNA increases significantly during 
neuronal differentiation (8-fold p=0.0002) and that GBAP1 has a similar trend; by contrast, miR-22-3p 
decreases by almost 2.5 times in neurons (p=0.018) (Figure 3.7). 
Next we compared the expression levels of GBA, GBAP1 and miR-22-3p in dopaminergic neurons of 
PD patients and healthy controls, to study possible differences. Concerning GBA, a clear difference is 
detectable between cases and controls: in PD patients’ neurons the levels of GBA are less than half the 
ones measured in healthy controls (p=0.0094). GBAP1 levels seem to be stable, while miR-22-3p is 
sligthly increased in PD cases (Figure 3.7). 
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Figure 3.7| GBA, GBAP1, and miR-22-3p are expressed in iPS cells and iPSC-derived neurons. 
GBA (panel A), GBAP1 (panel B), and miR-22-3p (panel C) expression levels were measured by real-time RT-PCR assays. 
Boxplots show expression levels according to the disease status; boxes define the interquartile range; the thick line 
represents to the median. Results are shown as normalized rescaled values. Significance level for differences between groups 
was calculated by a t-test, and shown only if significant. *: p<0.05; **: p<0.01; ***: p<0.001; n: number of analyzed subjects. 
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3.2 Transcriptional regulation of GBA and GBAP1 
One of the main determinants that could explain the GBA expression variability is definitely the 
regulation at the transcriptional level. To understand the mechanisms that determine both the 
physiological levels of GBA and the differences described in the literature in the levels of GBA among 
PD patients and controls, it is therefore essential to analyze the two known promoters responsible for 
GBA expression. Furthermore, since GBAP1 might act as a non-coding RNA regulating GBA, also the 
study of the mechanisms that control the pseudogene expression is of great interest. 
GBA is characterized by a promoter (P1), located immediately upstream of exon 1, which is not 
associated with CpG islands and contains a TATA box and different binding sites for transcription 
factors [Horowitz et al., 1989]. 
To date, in the UCSC Genome Browser, five alternative GBA transcripts are described, three of which 
appear to originate from an alternative promoter (P2), located 2.6kb upstream of the translation start 
site. All these transcripts contain an additional exon (exon -1), that does not alter the amino acid 
sequence of the enzyme glucocerebrosidase (Figure 3.8). Only one transcript seems to have an 
alternative start codon in exon 3. The distal promoter P2 has the characteristics of housekeeping 
promoters: it presents a CpG island and multiple binding sites for the Sp1 transcription factor, but no 
TATA or CAAT box [Svobodová et al., 2011]. 
According to the transcripts and the epigenetic markers annotated in the UCSC Genome Browser, even 
the pseudogene GBAP1 could present a proximal and a distal promoter. 
 
Figure 3.8|GBA alternative transcripts annotated in UCSC Genome Browser. 
3.2.1 Characterization of GBA and GBAP1 promoters 
To confirm the existence of the two GBAP1 promoters and to evaluate their functionality compared to 
GBA promoters, we cloned ~1kb of each promoter in the luciferase reporter vector pGL2 upstream of 
the firefly luciferase gene. These four constructs were then used to transfect different cell lines: HeLa, 
SH-SY5Y, HEK293, and HepG2. 
Measurement of the luciferase activity showed, unexpectedly, that the distal promoter P2 is actually 
stronger than the promoter P1, for both GBA and GBAP1, in all transfected cell lines (Figure 3.9). In 
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particular, in HeLa and in HEK293, the GBA P2 promoter is ~12 times stronger than the 
corresponding promoter P1 (in Hela P2/P1=12.8, p=0.00017; in HEK293 P2/P1=11.7, p=0.03); in 
HepG2 P2 is 4.45 times stronger than P1 (p=0.02); while, in the neuronal line SH-SY5Y the difference 
is not significant. Also with regard to GBAP1, the distal promoter is stronger than the proximal one: in 
HeLa P2/P1=5.5 (p=0.00007), in SH-SY5Y P2/P1=2.4 (p=0.007), in HEK293 P2/P1=7 (p=0.002), 
and in HepG2 P2/P1=7.3 (p=0.007). 
 
Figure 3.9| Characterization of the GBA and GBAP1 promoters. 
In each transfection experiment, 1µg of pGL2 vectors containing the 4 different promoters were transfected in HeLa, SH-
SY5Y, HEK293, and HepG2 cells. As controls, also the pGL2 basic, pGL2 promoter and pGL2 control plasmids were 
transfected. After 48h, the luciferase activity was assayed in cell extracts. To normalize luciferase values, each well was also 
transfected with 100ng of the pRL-TK vector, expressing the renilla luciferase gene. The reported normalized results were 
rescaled setting as 1 the values measured in the pGL2 promoter. Bars represent means + SEM of at least 3 independent 
experiments. The results were analyzed by unpaired t-test. *: p<0.05, **: p<0.01, ***: p<0.001. 
3.2.2 Analysis of GBA and GBAP1 promoters by 5’-serial deletions 
In order to better characterize these four promoters, we produced serial 5’-deleted constructs of each 
promoter that were then transfected in SH-SY5Y cells, the most common neuronal cell line, to measure 
the possible differences in the luciferase expression levels. We created 16 plasmids: four starting from 
the full length (FL) P1 promoter of both GBA and GBAP1 (A, A+B, A+B+C, A+B+C+D) and 
three originated from the full-length P2 promoter of the gene and the pseudogene (A, A+B, 
A+B+C) (Figure 3.10, left panels). 
The obtained constructs were co-transfected in SH-SY5Y cells together with the pTK-RL vector, 
containing the renilla luciferase gene, used as reference and after 48h a luciferase reporter assay was 
performed. The strength of the GBA P1 promoter was significantly reduced in the construct 
A+B+C+D, which contains only the last fragment of the P1 promoter: the luciferase activity was 4 
times lower compared to the FL construct (p=0.0004) and 13 times compared to the A+B+C vector 
(p=0.0072). Concerning the P1 promoter of GBAP1, there is a 6.5-fold decrease in luciferase activity as 
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a result of the deletion A+B+C+D (p=0.0002) compared to the full length and a 4.6-fold decrease 
compared to the A+B+C construct (p=0.0048). Conversely, for both the P2 promoters of GBA and 
GBAP1, the deletions did not change significantly the promoter strength (Figure 3.10). 
 
Figure 3.10|5’-serially-deleted constructs to analyze the GBA and GBAP1 promoters. 
Upper panel, P1 promoters. Lower panel P2 promoters. In each transfection experiment, 1µg of pGL2 vectors containing 
the full-length and deleted promoters were transfected in SH-SY5Y cells. As controls, also the pGL2 basic, pGL2 promoter 
and pGL2 control plasmids were transfected. After 48h, the luciferase activity was assayed in cell extracts. To normalized 
luciferase values, each well was also transfected with 100ng of pRL-TK vector expressing the renilla luciferase gene. The 
reported normalized results were rescaled setting as 1 the values measured in the pGL2 promoter. Bars represent means + 
SEM of at least 3 independent experiment. The results were analyzed by unpaired t-test. **: p<0.01, ***: p<0.001. 
3.2.3 P1 promoters of both GBA and GBAP1 are characterized by two CLEAR elements 
The data obtained from transfection experiments of deleted constructs pointed to the last deletion, in 
the proximal promoter of the gene and the pseudogene as the most interesting one. Using the 
prediction software Genomatix Suite, we searched for possible transcription factor binding sites in this 
region. This analysis predicted the presence of particularly interesting sequences located at positions -
118 and -87, i.e. two CLEAR (Coordinated Lysosomal Expression and Regulation) elements. These 
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sequences are recognized by TFEB (Transcription Factor EB), a transcription factor that regulates the 
expression of many lysosomal genes [Palmieri, 2011]. The presence of CLEAR elements in the 
promoter of the GBA gene and the hypothesis that these sequences are involved in TFEB-mediated 
GBA regulation has been previously described by Sardiello et al in 2009. In addition, the 
overexpression of TFEB is able to increase the GBA expression levels and to improve the GCase 
folding and transport to the lysosome [Song et al., 2013]. Interestingly we found that two predicted 
CLEAR elements are present also in the GBAP1 P1 promoter, in the same position.  
To confirm the importance of the two CLEAR elements in the P1 promoters of GBA and GBAP1 we 
produced three additional constructs for each P1 promoters, corresponding to the full length promoter 
lacking one or both CLEAR elements (see Figure 3.11, left panels). These vectors were used to 
transfect the SH-SY5Y cell line. We observed that only the absence of both CLEAR elements 
completely abolishes the promoter activity. 
We confirmed these results cotransfecting a commercial plasmid containing the TFEB cDNA with the 
CLEAR deleted constructs and showing that each CLEAR element is able to respond to TFEB with an 
increase in the luciferase activity comparable to that of the full length one (Figure 3.11). These results 
confirmed that this transcription factor is the main regulatory element of GBA expression and 
surprisingly demonstrated that also GBAP1 could be regulated by TFEB. 
 
Figure 3.11|P1 promoters have two active CLEAR elements 
In each transfection experiment, 1µg of pGL2 vectors containing the full length and deleted promoters were cotransfected 
in SH-SY5Y cells with 400ng of the pEGFP-TFEB plasmid (+TFEB) or the empty vector (-TFEB). As controls also the 
pGL2 basic, pGL2 promoter and pGL2 control plasmids were transfected. After 48h, the luciferase activity was assayed in 
cell extracts. To normalize luciferase values, each well was also transfected with 100ng of pRL-TK vector expressing the 
renilla luciferase gene. The reported normalized results were rescaled setting as 1 the values measured in the pGL2 
promoter. Bars represent means + SEM of at least 3 independent experiment. The results were analyzed by unpaired t-test. 
*: p<0.05, **: p<0.01, ***: p<0.001. 
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3.3 Conclusions and future perspectives  
Parkinson’s disease is a complex disorder with multifactorial etiology, which can result from the 
contribution of different genetic determinants and multiple environmental factors. GWAS and meta-
analyzes have showed the importance of the GBA gene in the development of PD [Sidransky et al., 
2009]. Numerous studies have confirmed that mutations in GBA are more frequent in patients with PD 
compared to healthy controls, showing that carriers of heterozygous mutations in this gene have a 5 
times higher risk to develop PD than the general population [Sidransky et al., 2009; Asselta et al., 2014].  
However, to date, the mechanism underlying the relation between GBA mutations and the 
development of PD remains unclear and it is a cause of debate in the scientific community. In fact, 
there are reports in the literature supporting a gain-of-function effect of the mutated protein, as well as 
publications sustaining a loss-of-function mechanism [Sidransky and Lopez 2012; Swan and Saunders-
Pullman, 2013]. Moreover, a widespread deficiency of GCase activity has been demonstrated not only 
in the brains of PD patients carrying GBA mutations, but also PD patients without GBA mutations 
exhibit a deficiency of GCase in SN [Gegg et al., 2012]. These data suggest that a dysfunction of GCase 
activity or more in general of the lysosomal compartment, may participate in the pathogenesis of the 
disease even in the more frequent sporadic forms of PD. 
This hypothesis stimulated the interests in the development of new therapeutic approaches aimed at 
augmenting the GCase activity [Schapira and Gegg, 2013]. It has already been showed that the 
overexpression of GBA, obtained by adeno-associated virus infection, is able to improve the cognitive 
deficit and to reduce the α-synuclein aggregates in a mouse model of synucleinopathy caused by a 
homozygous mutation in the GBA gene [Sardi et al., 2011; Sardi et al., 2013]. The study of the 
mechanisms that could regulate the levels of GCase is therefore an important prerequisite to better 
understand the involvement of this genetic risk factor in the disease, and to identify new therapeutic 
targets. 
In this thesis, we describe a novel ceRNA-based network with a potential impact on Parkinson’s disease 
involving GBA, its pseudogene GBAP1, and miR-22-3p (Figure 3.12). 
Competing endogenous RNAs are a class of RNA regulators, recently described, that, working as 
molecular "sponges", are able to influence the expression levels of specific mRNAs by competing for a 
limited pool of miRNAs [Seitz, 2009; Poliseno et al., 2010]. In particular, two classes of lncRNAs are 
increasingly recognized as main ceRNA contributors: circular RNAs and pseudogene-derived 
transcripts [Thomson and Dinger, 2016]. Indeed, expressed pseudogenes, are considered ideal ceRNA 
candidates, since they have a high sequence identity with the corresponding ancestral gene and so they 
usually share the same miRNA binding sites [Tay et al., 2014; Thomson and Dinger, 2016]. To date, 
few pseudogenes have been experimentally demonstrated to act as ceRNAs, including: PTENP1 and 
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KRAS1P [Poliseno et al., 2010], OCT4-pg4 [Wang et al., 2013], BRAFP1 [Karreth et al., 2015], and 
CYP4Z2P [Zheng et al., 2015].  
Concerning GBAP1, the GBA pseudogene, literature data are very limited and are primarily focused on 
the origin of this locus and the differences with the functionl protein-coding gene [Horowitz et al., 
1989; Wafaei and Choy, 2005]. For this reason, we evaluated the expression levels of this pseudogene in 
different tissues and brain areas. The results obtained showed that the levels of GBAP1 are always 
lower than the GBA levels but also that this ratio is very variable among the different districts, 
suggesting that GBAP1 expression could be regulated. 
To date there are no miRNAs reported in the literature to directly target GBA; only a miRNA mimic 
screening was described involving 875 miRNAs that evidenced three candidates (miR-127-5p, miR-16-
5p, and miR-195-5p) with important consequences on the GCase activity. However, in all cases, the 
miRNA effect did not seem to be mediated by a direct interaction between the miRNA itself and GBA. 
In fact, the identified miRNAs acted either on the LIMP-2 receptor, which is involved in the trafficking 
of GCase from the endoplasmic reticulum to the lysosome, or on the expression levels of known 
modifiers of the GCase activity [Siebert et al., 2014]. 
In this thesis work, we showed that miR-22-3p is the first miRNA that could modulate GCase activity 
targeting GBA and moreover we suggest that this microRNA could also act on GBAP1, 
downregulating its transcript levels. 
To date, few information on a possible involvement of these non-coding RNAs in Parkinson’s disease 
is overtly present in the literature, with the reported dysregulation of miR-22* in Parkinson’s disease 
patients actually referring to the 5p companion of “our” miR-22-3p [Margis et al., 2011]. Interestingly, a 
very recent paper suggested that miR-22 may exert a neuroprotective effect in Parkinson’s disease, as it 
protects rat pheochromocytoma PC12 cells from 6-hydroxydopamine-induced injury, by modulating 
the levels of its target gene transient receptor potential melastatin 7 (TRPM7) [Yang et al., 2016]. 
However, it should be noted that Yang and colleagues in their paper linked miR-22 down-regulation 
with Parkinson’s disease by mistakenly citing the work of Margis and collaborators [2011], which 
concerned miR-22-5p, as detailed above. Moreover, few studies reported a potential neuroprotective 
effect of miR-22-3p both in rat models of cerebral ischemia-reperfusion injury and in Huntington and 
Alzheimer’s disease through a reduction in inflammation and apoptosis [Jovovic et al., 2013; Yu et al., 
2015]. However, other studies suggested a pro-senescence role of miR-22 in endothelial progenitor 
cells, in cancer, and in the aging heart and brain [Li et al., 2011; Xu et al., 2011; Jazbutyte et al., 2013; 
Zheng and Xu, 2014]. 
The possible existence of a mutual regulation of the GBA and GBAP1 transcripts mediated by miR-22-
3p was then investigated through overexpression experiments designed to increase the levels of the 
pseudogene 3'UTR. This increase is reflected in a significant increase of GBA transcript levels that 
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seems to be dependent on the presence of the identified miR-22-3p target site on GBAP1 3’UTR. The 
positive trend of the GCase activity corroborates our assumption. With this work, we therefore 
hypothesize the existence of a regulatory circuit among transcripts that share miR-22-3p as post-
transcriptional regulator (SP1 and SIRT1) and, in particular, we assess a possible functional role of the 
pseudogene GBAP1 as ceRNA. 
Since GBAP1 seems to act as a non-coding RNA with a regulatory significance for the GBA levels, it 
becomes important to understand the regulation of this transcripts and in particular, if there are 
physiological mechanisms that could increase the pseudogene levels. 
With regard to the post-transcriptional regulation, it was supposed that also the PTC present in non-
coding RNA, such as pseudogenes, can direct those molecules to degradation by the NMD pathway 
[Tay et al., 2014]. In particular, as regards GBAP1, some nucleotide differences between gene and 
pseudogene are located in the consensus sequence of splicing sites, suggesting the possible production 
of alternative transcripts potentially NMD target. We therefore decided to extensively analyze the 
GBAP1 splicing pattern. This analysis allowed the identification of a large variety of alternative 
transcripts, the majority of which cause the introduction of premature stop codons. The qPCR analysis 
of the GBAP1 levels in cells treated with NMD inhibitors suggest that this pathway is an important 
regulator of the GBAP1 expression. In absence of NMD regulation the levels increase up to 4 times 
compared with the basal levels. It is interesting to note that in these experiments it was also possible to 
observe an increase in the GBA transcripts levels. Since there are no literature data and we didn’t 
observe for GBA any alternative splicing product potentially targeting the transcript to NMD, the 
increase of the GBA levels following cycloheximide (a known NMD inhibitor) treatment could 
represent a further confirmation of the reciprocal regulation of GBA and GBAP1 via microRNAs. In 
the future, it will be interesting to confirm this hypothesis blocking the NMD pathway in cells 
knockout for one of the proteins responsible for miRNA maturation, such as DICER. 
Concerning the transcriptional regulation of GBAP1, literature data are essentially related to the GBA 
gene, for which two different promoters are known: a proximal one, placed immediately before the 
exon 1, and a distal one, 2.6kb upstream of the translation start site. Both promoters are characterized 
by the presence of several regulatory elements that may be responsible for a differential gene 
transcription in specific tissues and/or conditions [Svobodová et al., 2011]. According to the 
observation that GBAP1 predicted proximal and distal promoter sequences show a high level of 
identity with those of GBA and that epigenetic marks did not substantially differ between the gene and 
the pseudogene, as inferred from the UCSC Genome Browser ENCODE tracks 
(http://genome.ucsc.edu/; release Feb. 2009, GRCh37/hg19), also GBAP1 gene appears to present a 
proximal and distal promoter.  
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Luciferase experiments confirmed the existence of both GBAP1 predicted promoters and, surprisingly, 
they showed a transactivating activity comparable to the one of GBA promoters. These results are in 
agreement with the high level of sequence identity that GBA and GBAP1 share at the level of the 
promoter elements (described in Svobodová et al., 2011). On the other hand, this observation is in 
contrast with the evidence that the GBAP1 transcript levels are lower that the GBA ones in all the cell 
lines analyzed (Figure 3.1) indicating that epigenetic or post-transcriptional regulation mechanisms 
could have a main role in the pseudogene expression. We also demonstrated by 5’-serial-deletion 
analysis that the gene and the pseudogene share similar regulatory elements. In particular, we found two 
CLEAR elements also in the P1 promoter of GBAP1. We then confirmed that the transcription factor 
TFEB acts on these elements increasing the activity of both GBA and GBAP1 proximal promoters. 
Considering the similar strength of GBA and GBAP1 promoters it will be interesting in the future to 
evaluate the epigenetic regulation of these promoters in order to confirm if the low levels of GBAP1 
transcripts are mainly due to the NMD mechanism or to a modifiable transcriptional regulation. 
In conclusion, considering the results obtained in this thesis, it is possible to hypothesize the existence 
of an RNA-based complex regulatory network that involves GBA, GBAP1 and miR-22-3p (Figure 
3.12). In this network, miR-22-3p (and probably other microRNAs) could modulate the levels of GBA 
transcripts down-regulating GCase activity. Moreover, probably in specific cells or developmental 
stages, upregulation of GBAP1, resulting from post-transcriptional or epigenetic regulatory 
mechanisms, might titrate miRNAs away from the GBA protein-coding transcripts, thus providing a 
physiologic ceRNA effect. This regulatory circuit has several regulatory points that might represent 
potential targets to modulate the GCase level. 
The future goal of this project will be to replicate similar experiments in iPS-derived neurons in which 
we already demonstrated that GBA, GBAP1 and miR-22-3p are expressed, in order to evaluate if the 
modulation of this network could modify the mechanisms of neurodegeneration and for example the 
accumulation of α-synuclein one of the main PD hallmark. 
RESULTS & CONCLUSIONS: GBA REGULATION 
39 
 
Figure 3.12| Schematic representation of the effect of modulating the GBA/GBAP1/miR-22-3p RNA-
based network on endogenous GBAP1 and GBA levels.  
Schematic representation of the ceRNA network involving GBA (blue transcripts) and GBAP1 (orange transcripts), 
harboring the same MRE sites (green and violet ovals). The green MRE sites bind to miR-22-3p (in green), whereas violet 
ones bind to other not-specified miRNAs. The experimental modulation of the proposed ceRNA network impacts on both 
coregulated transcripts. In particular, over-expression of miR-22-3p (left part of the figure) determines the down-regulation 
of both GBA and GBAP1 transcripts. Conversely, over-expression of GBAP1 (e.g., by inhibiting the NMD pathway, as 
experimentally verified in the present study; right part of the figure) will increase the cellular concentrations of miR-22-3p 
MREs, thus resulting in the de-repression of GBA. In the scheme, transcripts destined to degradation are colored in lighter 
shades. 
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A total of 24 Italian families with dominant or recessive PD were selected after the screening for 
frequent PD causing mutations, in collaboration with the Parkinson Center of Milan.  
Among them, 12 were consanguineous and therefore the disease in these families is expected to be the 
result of homozygous recessive mutations. Since only a small percentage (~1%) of potentially-
deleterious homozygous variants within an individual are novel or rare, the number of possible causal 
variants can be substantially reduced. This is the reason why we decided to perform whole-exome 
sequencing (WES) only on the proband of each consanguineous family. 
Concerning dominant families, one of the main difficulties of using exome sequencing approaches to 
identify Mendelian traits is the fact that each individual harbors several hundreds of novel heterozygous 
variants. As a result, the process of identifying the single causal change in a dominant disorder is 
dependent on methods of filtering out non-causal variants. In order to increase the probability of 
successfully identifying a causative gene, we have decided to perform WES on the probands and on the 
available affected cousins or uncles. This approach is currently used to generate shortlists of novel, 
potentially disease-causing variants for disease segregation/transmission studies within each multi-
incident pedigree. This strategy already allowed the identification of a few novel PD genes, among them 
the two most robustly associated with PD are VPS35 and DNAJC13 [Zimprich et al., 2011; Vilariño-
Güell et al., 2011; Vilariño-Güell et al., 2014].  
For a first group of exome-targeted enrichment, library preparation and sequencing were performed at 
the UMass Deep Sequencing Core in collaboration with Prof. Landers (Department of Neurology, 
University of Massachusetts Medical School, USA). Target capture was performed by an 
oligonucleotide-based exome capture solution (SeqCap EZ Human Exome Library v2.0) from 
Nimblegen. The Nimblegen SeqCap EZ Exome Library consists of 2.1 million oligonucleotide probes 
used to capture ~300,000 exons derived from ~30,000 protein coding. The captured exonic DNA were 
then sequenced on an Illumina HiSeq2000 as 100 bp paired-end reads. 
For the second half of samples, I directly performed the genomic capture, using the AmpliSeq Exome 
RDY kit from Thermo Fisher Scientific (a PCR-based target selection) and the sequencing as 200-bp 
single reads with the Ion Proton technology at the Centre of Applied Neurogenetics in Vancouver, 
during my stay in Prof. Farrer’s laboratory. The AmpliSeq Exome RDY kit allows the production of 
~294,000 amplicons starting from 12 pools of primers and spanning ~300,000 exons. 
We obtained an average coverage of ~90x with a percentage of the covered target regions spanning 
from 75% (in the samples prepared with the Nimblegen kit) to 90% (in the samples prepared with the 
AmpliSeq kit). At this level of coverage, the sensitivity of detection of heterozygous variants 
approaches 100% and the estimated false heterozygote discovery rate is 6 per exome [Choi et al., 2009]. 
The resulted reads were aligned to the reference human genome (hg19) with the BWA (Burrows-
Wheeler Aligner) software. The variant detection was accomplished using the GATK software package. 
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The obtained variants were then annotated and filtered at several levels using the Annovar program and 
the Galaxy data analysis web site. Non-synonymous changes were characterized by different software 
(SIFT, Polyphen) to bioinformatically predict whether the change is deleterious to the protein structure 
and/or function. Variants located within 10 base pairs of an exon/intron boundary were also classified 
as potential splicing mutations. Each variant was compared to several annotated SNP databases 
(dbSNP135, HapMap, 1000Genomes Project, Exome Aggregation Consortium-ExAC). Those variants 
that were previously documented to have a population frequency greater than 1% were eliminated 
given that they are unlikely to be the causal variant. We also checked the frequency in an in-house 
cohort of 3538 Italian control exomes to exclude population-specific variants. Of the remaining SNPs, 
45% are predicted to be non-synonymous variants. In the families in which exome was performed on 
two affected individuals, we selected only the shared variants and we also tested the additional available 
family members for proper segregation; while for the consanguineous families, we considered only the 
homozygous variants. 
At the end, we prioritized the filtered variants starting from known genes and then evaluated possible 
candidate genes according to the following criteria: i) interaction with PD causative genes, ii) 
involvement in pathways known to be connected with PD pathogenesis, and finally iii) expression in 
relevant tissues/cells. Finally, Sanger sequencing was used to confirm all selected variants and to study 
their segregation in the relevant families. 
4.1 Identification of mutations in PD-related genes 
The identification of PD patients carrying mutations in known PD genes is a priority to select families 
suitable for the identification of new genes involved in PD pathogenesis. After variant prioritization, we 
identified five families with a dominant inheritance pattern and one proband from a consanguineous 
family (Figure 4.1) bearing mutations in genes already associated with parkinsonism. These cases were 
considered genetically resolved and were then excluded from further analysis.  
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Figure 4.1|Pedigrees of families with mutations in known PD genes (FAM 1-6). 
Filled symbols represent affected patients. Highlighted symbols indicate individuals analyzed by WES (in blue the GBA 
mutated, in violet the LRRK2 mutated, and in red the ATP7B mutated). 
In particular, four families (FAM 1-4) were found to be carriers of heterozygous mutations in the GBA 
gene (Table 4.1), which, as discussed earlier, encode a lysosomal enzyme and is the main genetic risk 
factor for PD (see Introduction, paragraph 1.2). The variants identified in families FAM 1-3 are 
missense mutations predicted to be pathogenic by different software and absent in our in-house cohort 
of Italian controls (n=3538). Only one of them (p.R301C) is reported in dbSNP (with a frequency in 
ExAC lower than the 0.01%). The variant found in FAM 4 is a novel nonsense mutation (p.Q401*). All 
the three missense mutations affect amino acids located in the catalytic domain of the protein, which 
were previously found to be mutated in Gaucher disease patients [LOVD (Leiden Open Variation 
Database) v.2.0 Build 36]. 
Concerning FAM 5, a family with a dominant inheritance pattern, we sequenced the exome of two 
affected brothers (Figure 4.1) and we identified a novel heterozygous missense mutation in the LRRK2 
gene: p.E193K (Table 4.1). This gene, as mentioned in paragraph 1.1, codes for a large multidomain 
protein with a kinase activity that seems to be involved in a number of cellular processes, including 
autophagy and vesicular trafficking, and whose association with PD is well-established [Martin et al., 
2014]. The pathogenic role of this substitution, changing a negatively-charged residue into a positively-
charged one, is suggested by its position within an exposed alpha-helix belonging to an Armadillo 
repeat of the N-terminal domain of the protein. The change of charge on the protein surface could 
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modify LRRK2 interactions with other proteins as well as promote its aggregation into inactive 
oligomers. Expression experiments to characterize the effect of the p.E193K mutation are in progress 
in collaboration with Dr. Piccoli (Center for Integrative Biology, University of Trento). 
Finally, in the proband of consanguineous family FAM 6 (Figure 4.1), we found a homozygous 
missense mutation (p.I116T) in the ATP7B gene (Table 4.1). This gene encode the copper-transporting 
ATPase 2, a member of the P-type ATPase family, a group of proteins that transport metals through 
the plasma membrane. In particular, this protein is predominantly expressed in the liver and at a lower 
level in the kidney and in the brain, and it plays a central role in copper transport, especially in the 
efflux of hepatic copper into the bile. Mutations in this gene are associated to Wilson’s disease, a 
recessive genetic disorder caused by copper accumulation in the liver and in the brain. Symptoms vary 
among and within families and include liver disease in 40% of the patients (recurrent jaundice, acute 
hepatitis or chronic liver disease), neurologic presentation in 40% (parkinsonism or rigid dystonia), and 
psychiatric disturbance in 20% (depression, anxiety disorders, and psychosis) [Patil et al., 2013]. The 
diagnosis is usually established starting for the evidence of one of these symptoms followed by the 
measurement of ceruloplasmin in the serum and copper in the serum and in urine.  
Our patient at the time of the diagnosis (33 years) presented parkinsonism but no liver manifestations; 
the ceruloplasmin and copper evaluation was inconclusive, so he was diagnosed as having 
parkinsonism. 
The identification of a novel mutation in the ATP7B gene in this family allowed us to re-define the 
diagnosis of this patient as an atypical Wilson disease and accordingly modify the therapeutic approach. 
Table 4.1 
    
allelic frequency  
 
pathogenicity 
prediction 
family gene cDNA 
AA 
change 
Italian 
controls 
ExAC SNP_ID Sift Polyphen 
FAM 1 GBA 701G>A G234E / / / D D 
FAM 2 GBA 901C>T R301C / 0.00004 rs374117599 D P 
FAM 3 GBA 1174C>T R392W / / / D D 
FAM 4 GBA 1201C>T Q401* / / / NA NA 
FAM 5 LRRK2 577G>A E193K / / / D D 
FAM 6 ATP7B 347T>C I116T 0.00027 0.00015 rs199773340  D P  
D: damaging, P: probable damaging, NA: not available. 
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4.2 FAM 7: a novel lysosomal gene involved in PD 
We sequenced the exome of the only affected member of a consanguineous family (FAM 7, Figure 4.2 
A). The patient is a 65 year-old man presenting an early onset PD (39 years) characterized by resting 
tremor and bradykinesia with L-DOPA response and no neuropsychiatric symptoms. 
After NGS data analysis, the most promising candidate variant was a homozygous missense mutation 
in the HGSNAT gene (Heparan-Alpha-Glucosaminide N-Acetyltransferase), also known as TMEM76, 
located on chromosome 8. This variant is a transition from C to T at position 1,237 on the cDNA 
(NM_152419) that causes the amino acid substitution p.P413S. This missense variant is present in 
dbSNP138 (rs201346206) with a frequency lower than the 0.1% (frequency reported also in other 
mutation databases, ExAC and 1000genomes) and is predicted to be deleterious by different software 
(SIFT, Polyphen). 
 
Figure 4.2|Identification of a homozygous mutation in the HGSNAT gene in family 7. 
A. Pedigree of the family FAM 7; in black the affected subject. homo=homozygote B. Upper panel, the schematic 
representation of the exon-intron structure of the HGSNAT gene with the genomic localization; the arrow indicates the 
position of the mutation. Middle panel, schematic representation of the HGSNAT protein; the orange arrow specifies the 
position of the mutation in the protein; the circles represent putative Asn-linked oligosaccharide sites; the triangles indicate 
the exon-exon boundaries on the protein. Lower panel, multiple alignment of HGSNAT amino acid sequences from 
different species; proline 413 (in orange) is fully conserved in vertebrates. 
  
The HGSNAT gene spans 62.4kb, is located at position 8p11.21 and it is composed by 18 exons 
(Figure 4.2 B). It encodes a lysosomal acetyltransferase: the heparan-alpha-glucosaminide N-
acetyltransferase or N-acetyltransferase; this protein is involved in the heparan sulfate (HS) degradation. 
In particular, this enzyme catalyses the acetylation of the terminal alpha-glucosamine residues of HS 
converting it into a substrate for the subsequent steps of the degradation process [Fan et al., 2006]. 
The N-acetyltransferase is an integral membrane protein composed by 11 transmembrane domains and 
a large N-terminal lysosomal domain. It is also characterized by a 28 amino acid signal peptide that is 
not cleaved [Durand et al., 2010] and by five predicted sites for Asn-linked glycosylation [Fan et al., 
2006] (Figure 4.2 B). Moreover, the protein is transcribed as a precursor and is then cleaved in the 
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lysosome into a α- and a β- chain, both required for protein activity; this cleavage is necessary for 
protein activation, probably making accessible the active site of the enzyme. It is also known that this 
enzyme works as a homo-oligomer presumably composed by six α- and six β-chains [Durand et al., 
2010]. 
Mutations in the HGSNAT gene were classically associated with the mucopolysaccharidosis (MPS) type 
IIIC, also called Sanfilippo syndrome C (OMIM #252930), a lysosomal storage disorder [Fan et al., 
2006]. It is a severe autosomal recessive disease with an infantile/early childhood onset (3-7 years). 
There are other three subtypes (A, B, D) of Sanfilippo syndrome, caused by mutations in genes coding 
for enzymes involved in the degradation of HS (SGSH, NAGLU, GNS) [Andrade et al., 2015]. 
The prevalence of MPS type III is estimated between 0.3 and 4.1 cases per 100,000 newborns with 
differences among geographical areas; the Sanfilippo syndrome C is the rarest with an incidence of 
1:1,500,000. The four subtypes share the majority of the clinical features and the patients are usually 
classified only by the molecular defect. The main symptoms are progressive cognitive decline, 
behavioral problems, sleeping and speech disorder and, in severe forms, also hearing loss, and visceral 
manifestations, such as mild hepatomegaly, mild musculoskeletal abnormalities and deformities, mild 
coarse facies, and hypertrichosis [Andrade et al., 2015]. 
To date, 66 mutations in the HGSNAT gene were described, including: 37 missense mutations, 14 
splicing variants, 11 small insertions/deletions, and 5 complex alleles [HGMD (Human Gene Mutation 
Database) release 2015.1] These mutations affect different protein domains but all lead to an absent, or 
extremely reduced, enzymatic activity.  
Concerning our patient, the mutated proline is located in the 6th highly hydrophobic transmembrane 
domain and it corresponds to an amino acid residue very conserved during evolution, located in a 
highly conserved portion of the protein (Figure 4.2 B). The substitution of P413 with a serine, a smaller 
polar amino acid, could destabilize the transmembrane helix, leading to an incorrect protein folding. 
This assumption is also corroborated by the existence of another reported mutation in the same α-helix, 
W403C, described to cause protein misfolding, ER retention of the unfolded protein, and eventually 
causing a significant reduction of the protein activity [Feldhammer et al., 2009]. 
Therefore, we measured, in collaboration with the laboratory of Dr. Filocamo (Dipartimento di 
Neuroscienze, IRCCS Istituto G. Gaslini, Genova), the HGSNAT enzymatic activity in the patient’s 
fibroblasts. The activity levels resulted 2.7 nmol/mg/17h, which is significantly lower than the normal 
range (22.1±10.2 nmol/mg/17h), confirming the deleterious effect of the mutation P413S on protein 
activity (Figure 4.3).  
Moreover, we recently identified another PD patient carrying two heterozygous missense mutations in 
the HGSNAT gene (G565R and A615T). This patient presents a late-onset (53 years) PD with rigidity 
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and clumsiness of the right arm at the diagnosis. One year later DaTscan confirmed the diagnosis and 
the patient started the L-DOPA treatment with benefits. He does not present any neuropsychiatric 
symptoms until today. These two mutations are already annotated in dbSNP (rs148632988, 
rs112029032) with a frequency lower than 1% in the main mutation databases. We measured, also for 
this patient, the residual enzymatic activity in fibroblast, which resulted 6.7 nmol/mg/17h (Figure 4.3). 
 
Figure 4.3|Enzymatic activity of HGSNAT mutants measured in vivo. 
Left panel, the N- acetyltransferase enzymatic activity levels measured in patient fibroblasts using a fluorescence assay at the 
laboratory of Dr. Filocamo. Right panel, schematic representation of the residual activity in our patients and Sanfilippo 
syndrome C patients, setting as 100% the average activity of the controls. 
 
The finding of two PD patients who do not present any symptoms characterizing the Sanfilippo C 
syndrome but are carrier of deleterious mutations in the HGSNAT gene, let us hypothesize an 
involvement of N-acetyltransferase deficiency in PD. In particular, the PD patients’ residual enzymatic 
activity (12% and 30%, setting 100% the control average activity) is higher than the activity measured in 
Sanfilippo C patients (2%) but significantly lower compared to controls (Figure 4.3) and to individuals 
heterozygous for mutations causing MPS type III (data not shown). Our hypothesis is that an 
enzymatic activity not enough reduced to cause a lysosomal disorder may predispose to PD, as already 
clearly shown for GBA. 
Supporting our hypothesis there are also literature evidences showing the presence of phosphorylated - 
α-synuclein across different brain regions in 3 cases of MPS IIIB [Hamano et al., 2008] and the 
accumulation of α-synuclein in cortical neurons of 2 cases of MPS IIIA [Winder-Rhodes et al., 2012]. 
Concerning genetic data, a study of 2,308 controls and 926 PD patients showed an association between 
Parkinson’s disease and a common NAGLU haplotype (tag with the SNP rs2071046) with an OR of 
1.3 [Winder-Rhodes et al., 2012]. 
Finally, these evidences and our results corroborate the link between MPS III and Parkinson’s disease 
and more in general further stress the important role of lysosomal dysfunction in neurodegeneration 
and α-synuclein accumulation. 
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4.3 FAM 8: a novel DNAJ gene involved in PD  
We performed exome sequencing on one individual (IV7) from the consanguineous family FAM 8 
affected by early-onset PD (onset at 26 years old) (Figure 4.4). In particular, the patient shows bilateral 
tremor, slow progression and L-DOPA response with cognitive decline and neuropsychiatric 
symptoms. 
The WES data analysis highlighted the presence of a homozygous splicing variant (c.79-2A>G, 
NM_021800) in the DNAJC12 gene. This variant was absent in the main mutation databases and was 
also not present in our cohort of 3538 Italian controls. The segregation in the family was confirmed by 
Sanger sequencing: the affected brother (IV5) resulted homozygous for the mutation while the two 
healthy siblings were one heterozygous (brother, IV2) and the other wild type (IV3). The other family 
members tested resulted carrier of this mutation (III2, III5, III13 and IV8) (Figure 4.4). 
 
Figure 4.4|Pedigree of family FAM 8. 
In black the affected subjects and highlighted by a yellow square the proband who was analysed by WES. The genotype for 
the c.79-2 A>G mutation, confirmed by Sanger sequencing, the age at the diagnosis/present age or age at death are 
reported, if available, under each family member. het=heterozygote, homo=homozygote, wt=wild type.  
4.3.1 DNAJC12 gene and protein 
The DNAJC12 gene spans 27kb, it is located in position 10q21.3 and comprises 5 exons. This gene 
encodes for a J domain-containing protein that belongs to the Hsp40/DNAJ protein family, a 
heterogeneous group of proteins that play the essential role of co-chaperone of the Hsp70 proteins 
[Qiu et al., 2006]. The Hsp40 proteins are characterized by the presence of a highly conserved J-
domain, responsible for the interaction with the ATPase domain of Hsp70s and the stimulation of the 
ATP hydrolysis. The regions outside this domain are usually involved in the interaction with other 
cellular protein. These proteins are homodimeric proteins residing in various subcellular compartments 
as well as in the extracellular milieu [Kampinga and Craig, 2010]. Moreover, some of the DNAJ 
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proteins are present in specific tissues while others are ubiquitously expressed; the variety of expression 
and localization reflects the functional diversity of the Hsp70s [Kampinga and Craig, 2010].  
The DNAJC12 protein is one of the lesser studied among members of the DNAJ family. It is known to 
contain a single J-domain (aa 14-79), mainly encoded by exon 1 and 2, while its specific function is still 
not clear. It was previoulsy reported that DNAJC12 expression is upregulated by the transcription 
factor AIbZIP in a prostate cancer cell line upon ER stress induction [Choi et al., 2014]. DNAJC12 
seems to be localized at the cytoplasm level and to interact mainly with: Hsc70 (a chaperone 
ubiquitously and constitutively expressed), some mitochondrial proteins (such as the pyruvate 
carboxylase), and, under stress conditions, with Bip (which plays a central role in the ER-stress 
response) [Choi et al., 2014]. Moreover, two different DNAJC12 transcripts have been reported: a 
longer one (isoform “a”) coding for a 198 amino acids protein and a shorter transcript (isoform “b”), 
generated by alternative polyadenylation, that encodes for a 109 aa polypeptide (Figure 4.5). Both 
isoforms contain the same J-domain but the functional role is still unknown.  
We evaluated the mRNA expression profile of both isoforms in a commercial panel of 20 human 
tissues and 24 brain areas by real-time RT-PCR, using isoform-specific primers. The levels of isoform a 
are always higher the ones of isoform b. The two isoforms are predominantly expressed in the liver and 
testis among the analyzed tissues and in the cerebellar hemisphere among the brain areas. Isoform a 
also shows high levels in the brain while it is almost absent in the placenta and in the frontal cortex 
(Figure 4.5). 
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Figure 4.5|DNAJC12 isoforms expression pattern. 
A. Schematic representation of the two DNAJC12 isoforms with the position of the primers (represented by arrows) used 
for the transcript levels measurement B, C. Isoform a and b expression levels were measured by real time RT-PCR assays 
using the SYBR Green chemistry on RNA derived from a commercial panel including 20 human tissues (B) and 24 brain 
areas (C). HMBS transcripts were used as internal reference. 
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4.3.2 Characterization of the splicing mutation c.79-2A>G 
We evaluated the possible effect of this mutation c.72-2A>G on splicing in silico, using two different 
software: NNSPLICE 0.9 version and NetGene2. Both algorithms predicted the mutation to 
completely abolish exon 2 acceptor splice site. We confirmed these predictions evaluating by RT-PCR 
the possible aberrant splicing directly on the patient RNA extracted from total blood. In particular, 
agarose gel electrophoresis of the obtained PCR products showed the amplification of a lower 
molecular weight fragment (199bp) compared to the control (278bp). Sanger sequencing confirmed 
that the alternative product is due to complete skipping of exon 2. This aberrant splicing event leads to 
a frame-shift and consequently to the introduction of a premature stop after 13 alternative amino acids 
at the codon 39 of the mutated protein (Figure 4.6 A). Considering that out-of-frame transcripts are 
frequently degraded by the nonsense-mediated mRNA decay mechanism, we measured by real time 
RT-PCR the total levels of DNAJC12 transcripts in the patient and in control RNAs extracted from 
total blood. The results of this experiment showed that the transcript levels are significant reduced in 
the patient (Figure 4.6 B), even if the blood is not the perfect tissue to measure DNAJC12 transcripts 
considering its very low expression in this tissue.  
 
Figure 4.6| Characterization of the c.79-2 A>G mutation effect on splicing. 
A. On the left, the agarose gel showing the results of the RT-PCR assay performed on the RNA extracted from total blood 
of the patient and of a control individual (Ctrl). On the right, the schematic representation of the amplicons obtained from 
the RT-PCR and sequenced by Sanger sequencing with the position of the primers used for the RT-PCR. B. Quantification 
of the total transcript levels of DNAJC12 in 25 controls and in the patient by real time RT-PCR using the HMBS transcripts 
as internal reference. The results were analyzed by unpaired t-test. **: p<0.01. 
4.3.3 Effects of DNAJC12 silencing on α-synuclein 
The possible link between DNAJC12 deficiency and PD was assessed performing silencing 
experiments in SH-SY5Y cells using an antisense oligonucleotide-based approach. In particular, we 
treated the cells with a custom GapmeR, an LNA (Locked Nucleic Acid) oligonucleotide, designed 
using the Exiqon proprietary design software and targeting both DNAJC12 isoforms. We transfected 
the SH-SY5Y cells with two doses (every 24h after cell seeding) of the GapmeR against DNAJC12 or 
the negative control GapmeR and after 24h we evaluated the silencing of DNAJC12 and the 
accumulation of α-synuclein by western blot. We obtained an average DNAJC12 protein 
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downregulation of the 40% compared to the negative control, using the GAPDH protein levels as an 
internal reference. The results of these experiments interestingly showed that the silencing of 
DNAJC12 causes a 2.2-fold increase in the level of monomeric α-synuclein (Figure 4.7). 
 
Figure 4.7| DNAJC12 silencing increases α-synuclein protein levels. 
SH-SY5Y were transfected with two doses (every 24h) of 30nM of a GapmeR designed against DNAJC12 exon 2 or a Ctrl 
GapmeR. After 24h from the second dose, cells were harvested and sonicated for 10 seconds twice in ice. Next, 40µg of the 
total proteins extracted were loaded onto a 13% polyacrylamide gel; for Western Blot, primary antibodies used were: 
monoclonal antbody to α-synuclein (610787, BD Biosciences; diluted 1:1000), monoclonal antbody anti-DNAJC12 
(ab167425, Abcam; diluted 1:5000), and polyclonal antibody to GAPDH (NB300-320, Novus Biologicals, diluted 1:5000); 
secondary peroxidase-conjugated antibodies were used in addition to SuperSignal West Dura Extended Duration Substrate 
revelation kit (Thermo Fisher Scientific). After scanning, the intensity of each band was estimated by densitometric 
quantification using ImageJ software. A. Western Blot representative of six independent experiments. B. Average DNAJC12 
protein levels (B) and average α-synuclein protein levels (C) measured in SH-SY5Y cells treated with the DNAJC12 
GapmeR compared to cells treated with the control GapmeR. GAPDH was used as internal reference. The results were 
analyzed by unpaired t-test. *: p<0.05, **: p<0.01. 
 
4.3.4 Conclusions and future perspectives  
Interestingly, the α-synuclein increase obtained by the silencing of DNAJC12 supports the possible role 
of this gene in the pathogenesis of Parkinson’ disease. Moreover, this protein seems to be involved in 
the ER-stress response and to interact with proteins such as Hsc70 and Bip that play a central role in 
the protein homeostasis especially in the protein folding [Choi et al., 2014]. The ER stress response (or 
Unfolded Protein Response, UPR) is an evolutionary conserved cellular mechanism triggered by 
accumulation of misfolded proteins. Many genes involved in familial PD affect at different point the 
secretory pathway and usually their dysfunction leads to protein accumulation, in particular α-synuclein 
aggregation, and consequently to the activation of the UPR [Mercado et al., 2016]. Moreover, recent 
studies showed that α-synuclein aggregation by nutrient deprivation begins following the ER stress 
response [Jiang et al., 2014] and that silencing x-box binding protein 1 (XBP-1), a UPR transcription 
factor, triggers chronic ER-stress and dopaminergic neuron degeneration [Valdés et al., 2014]. 
Furthermore, the expression of an ER stress marker, glucose regulated protein (GRP78 or Bip), was 
increased in 1-methyl-4-phenylpyridinium (MPP+)-treated neuronal cells. In addition, the expression of 
another ER-stress marker, C/EBP homologous protein (CHOP), was increased in a 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease mouse model [Tsujii S et al., 
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2015]. Moreover, we measured both ER-stress markers (Bip and CHOP) in total blood of 26 PD 
patients and 25 controls using real time RT-PCR assays. We observed a significant increase of both 
markers: concerning Bip, the normalized mean levels in controls are 5.7 and reach 15.17 in PD patients 
(p=0.002), while the average levels of CHOP are 6.05 in controls and achieve 10.00 in cases (p=0.028) 
(Figure 4.8). These data corroborate the link between ER-stress and PD supporting the possible role of 
DNAJC12 in PD pathogenesis. 
 
Figure 4.8|Expression levels of Bip and CHOP transcripts. 
Quantification of the ER-stress markers, Bip (left panel) and CHOP (right panel), by real time RT-PCR on RNA extracted 
from total blood of PD patients and controls using SYBR Green chemistry. HMBS transcripts were used as internal 
reference. The results were analyzed by unpaired t-test. *: p<0.05, **: p<0.01. 
Furthermore, DNAJC12 is not the first Hsp40 protein associated with PD; mutations in two other 
gene coding for DNAJ proteins were described in PD patients. In particular, mutations in the DNAJC6 
gene were associated with autosomal recessive juvenile or early-onset PD [Edvardson et al., 2012] while 
mutations in the DNAJC13 gene were found in patients with late-onset PD [Vilariño-Güell et al., 
2014]. Moreover, other DNAJ protein (DNAJB2, DNAJB6, DNAJC5, DNAJC19, and DNAJC29) 
were reported to be involved in other neurodegenerative disorder, like ataxia or motor neuropathy 
[Koutras and Braun, 2014]. All these proteins have very different functions in the cells but they are 
involved in different proteostasis events. 
As further evidence of the causative role of the DNAJC12 gene, we also found, in collaboration with 
the laboratory of Prof. Farrer (Centre of Applied Neurogenetics, Vancouver, Canada), another early-
onset PD patient presenting a homozygous nonsense mutation (K63*) in this same gene. This proband 
belongs to a Canadian family with no consanguinity reported; he presented a dopa-responsive, 
nonprogressive, juvenile (onset at 13 years) parkinsonism [Rajput et al., 1997]. 
Interestingly, the age of onset of PD fitted the predicted severity of the mutations, being 13 years for 
the nonsense mutation and 26 - 35 years for the splicing mutation, which can be expected to be 
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compatible with trace amounts, although undetectable by RT-PCR, of wild-type splicing. 
We also performed the screening on 100 early-onset Italian PD patients by a PCR-based approach and 
NGS. In particular, we designed 11 amplicons spanning all the coding regions of the gene. We 
performed multiplexed PCR reactions on pools of 10 DNAs each and the obtained amplicons were 
ligated with adapters and unique indexes. The resulted DNA libraries were sequenced on the 
NextSeq500 Illumina sequencer. We didn’t find any additional mutated subject but we are now 
extending this screening to other 100 early-onset and 400 familial PD patients. However, we have to 
consider that mutations in this gene could be very rare and so difficult to identify.  
In conclusion, taking into account the literature data, our finding of two early-onset PD families 
presenting null homozygous mutations in the DNAJC12 gene and our results on α-synuclein 
accumulation upon DNAJC12 silencing, we propose DNAJC12 as a novel gene involved in the 
pathogenesis of Parkinson’s disease. Additional functional analyses will need to be performed to 
establish the function of this protein in the cell and consequently the mechanism linking its deficiency 
to neurodegeneration. In particular, we plan to perform immunofluorescence experiments to assess the 
subcellular localization of DNAJC12 protein at basal state or under ER-stress condition (starvation, 
tunicamycin or DTT treatments) and to confirm its molecular interactors by immunoprecipitation 
experiments. 
In addition, an interesting perspective may be the functional characterization of the role of this gene in 
PD pathogenesis using the patient cells. To this end, we plan to establish dopaminergic neurons 
derived from iPS cells generated starting from immortalized patient fibroblasts obtained from skin 
biopsy. This could be an interesting possibility to evaluate the pathways involved in the 
neurodegeneration process caused by mutations in the DNAJC12 gene in a disease relevant cellular 
model. iPSC-derived neurons have been successfully applied for the functional studies of mutations in 
PD-causing genes, such as SNCA, PINK1, Parkin and GBA [Oliveira et al., 2015, Seibler et al., 2011, 
Rakovic et al., 2015, Schöndorf et al., 2014]. iPS cells and differentiated dopaminergic neurons will be 
established through the already existing collaboration with Prof. Rejko Kruger laboratory (University of 
Luxembourg). 
Finally, we are trying, in collaboration with Dr. Del Giacco (Department of Biosciences, University of 
Milan) to established an animal model to study DNAJC12 and its link to PD. In particular, we are 
planning to use a zebrafish model expressing human α-synuclein in dopaminergic neurons available in 
the laboratory of Dr. Del Giacco and knockdown the DNAJC12 gene by antisense oligonucleotide 
with a synthetic backbone called morpholino. The knockdown morphants will be further characterized 
for the presence of a phenotype or altered behavior. Moreover, cellular features using microscopy and 
altered gene expression by in situ hybridization or biochemical analyses will be performed to evaluate 
cellular phenotypes. 
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BWA software: http://bio-bwa.sourceforge.net/ 
GATK software: http://www.broadinstitute.org/gatk 
Annovar software: http://annovar.openbioinformatics.org/en/latest/ 
Galaxy software: https://usegalaxy.org/ 
SIFT software: http://sift.jcvi.org/ 
Polyphen-2 software: http://genetics.bwh.harvard.edu/pph2/ 
dbSNP database: http://www.ncbi.nlm.nih.gov/SNP 
1000Genomes databases: http://www.internationalgenome.org/1000-genomes-browsers/ 
ExAC databases: http://exac.broadinstitute.org/ 
LOVD database: http://www.lovd.nl/3.0/home 
HGMD database: http://www.hgmd.cf.ac.uk/ac/index.php 
NNSPLICE software: http://www.fruitfly.org/seq_tools/splice.html 
NetGene2: http://www.cbs.dtu.dk/services/NetGene2/ 
UCSC database: https://genome.ucsc.edu/ 
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ABSTRACT 
Parkinson’s disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons of the 
substantia nigra, which causes motor impairment and resting tremor. Currently, mutations in the GBA gene, 
encoding the glucocerebrosidase (GCase) lysosomal enzyme, represent the most frequent cause of 
Parkinson’s disease. GCase deficiency was demonstrated in the brain of Parkinson’s disease patients 
carrying GBA mutations, and, to a lesser extent, also in patients without GBA mutations, suggesting that 
dysregulated GBA expression may have a wider impact in disease pathogenesis. Since the increase of GCase 
activity in the brain has been proposed as a therapy to reduce alpha-synuclein accumulation and to revert 
symptoms, a detailed knowledge on the mechanisms controlling GBA expression might help design novel 
therapeutics. 
Here, we explored the possible existence of a regulatory network involving GBA, microRNAs (miRNAs), 
and competing-endogenous RNAs (ceRNAs). ceRNAs are post-transcriptional regulators that titrate away 
miRNAs from their targets, thus upregulating mRNA expression. The highly-homologous and expressed 
GBA pseudogene (GBAP1) is particularly suited to act as a GBA ceRNA. To verify this hypothesis, we 
bioinformatically selected miRNAs potentially targeting both transcripts, and demonstrated that miR-22-3p 
directly targets both GBA and GBAP1, and significantly decreases their endogenous mRNA levels up to 
70%. Over-expression experiments showed that the GBAP1 3’-untranslated region is able to “sponge” miR-
22-3p, partially releasing GBA from the miR-22-3p control and thus increasing both GBA mRNA and GCase 
levels. The characterization of GBAP1 splicing pattern identified multiple out-of-frame isoforms that are 
down-regulated by the nonsense-mediated mRNA decay (NMD) pathway, suggesting that GBAP1 levels 
and, accordingly, its ceRNA effect, are significantly modulated by NMD. In an attempt to confirm these data 
in a more relevant cell model system, we measured miR-22-3p/GBA/GBAP1 levels in induced pluripotent 
stem (iPS) cells derived from skin fibroblasts of Parkinson’s disease patients with GBA mutations and 
controls. This analysis showed a significant up-regulation of GBA during the dopaminergic differentiation, 
which was nicely paralleled by anticorrelated miR-22-3p levels. Moreover, GBA levels in iPS-derived 
dopaminergic neurons were lower in Parkinson’s disease patients compared to controls. 
Altogether, our results describe the first miRNA controlling GBA levels and suggest that GBAP1 can be 
considered a long non-coding RNA acting as a GBA ceRNA. 
 
Key words: Parkinson’s disease, GBA, pseudogene, competing endogenous RNA, induced pluripotent stem 
cells. 
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INTRODUCTION 
Parkinson’s disease is a neurodegenerative disorder affecting approximately 0.3% of the general population 
and more than 1% of people over 60 (De Lau and Breteler, 2006). It is characterized by depigmentation of 
the substantia nigra (SN) caused by the selective and progressive loss of dopaminergic (DA) neurons, and by 
the presence of intraneuronal inclusions known as Lewy bodies (LB) within the surviving neurons of the SN 
and other brain regions (Spillantini, 1999). Clinical features of Parkinson’s disease include motor 
impairment, encompassing resting tremor, bradykinesia, postural instability, and rigidity, along with non-
motor symptoms, such as autonomic, cognitive, and psychiatric problems (Fahn, 2003). 
Parkinson’s disease is the result of an interaction between multiple environmental factors and inherited 
genetic susceptibility (Klein and Schlossmacher, 2007). Linkage analyses, mainly performed in families with 
a pseudo-Mendelian transmission of the disease, identified at least 14 genes (Lesage and Brice, 2009; Lin 
and Farrer, 2014). The SNCA gene was the first to be discovered thanks to such kind of studies: it codes for 
α-synuclein, the principal component of LB; patients with duplications or triplications of this gene show a 
correlation between the quantity of expressed wild-type protein and the severity of the disease (Eriksen et al., 
2005). More recently, several genome-wide association studies and large-scale meta-analyses have been 
performed to identify risk factors for Parkinson’s disease: these studies strongly stress the pivotal role of 
SNCA, MAPT, and GBA genes in disease susceptibility (Pankratz et al., 2012; Nalls et al., 2014 and 
references therein). 
Until 2004 the GBA gene, coding for the enzyme glucocerebrosidase (GCase), was considered only 
responsible for the Gaucher’s disease, one of the most common lysosomal storage diseases (Sidransky, 
2012). GCase is mainly a lysosomal enzyme and only partly associated with the outer surface of the cell 
membrane (Aureli et al., 2012). GCase catalyzes the hydrolysis of the membrane glucosylceramide (GlcCer) 
to ceramide and glucose, and its deficiency leads to the accumulation of the substrate, responsible for the 
multi-organ clinical manifestations of Gaucher’s disease (De Fost et al., 2003). Importantly, Gaucher’s and 
Parkinson’s diseases have been connected on account of the clinical observation of parkinsonism and LB 
pathology in patients with Gaucher’s disease (Lwin et al., 2004). Compared with the general population, 
patients with the milder form of Gaucher’s disease (type 1) have a 20-fold increased lifetime risk of 
developing parkinsonism (Westbroek et al., 2011), whereas individuals carrying heterozygous GBA 
mutations, have five times greater risk of developing Parkinson’s disease than non-carrier individuals 
(Sidransky et al., 2009). Several studies confirmed that GBA mutations, in particular the two most common 
ones (p.N370S and p.L444P), are more frequent in Parkinson’s disease patients than in healthy controls, 
demonstrating that genetic lesions in this gene are a common risk factor for the disease (International 
Parkinson Disease Genomics Consortium, 2011; Asselta et al., 2014). Recently, we proved the strong effect 
of GBA mutations also in PD progression and survival (Cilia et al., 2016). 
Despite many efforts, the mechanism underlying the relation between GBA mutations and the development 
of Parkinson’s disease remains unclear. There are studies supporting a gain-of-function effect of the mutated 
protein (promoting α-synuclein aggregation), as well as others supporting a loss-of-function mechanism 
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(leading to substrate accumulation, and hence affecting α-synuclein processing and clearance) (Sidransky 
and Lopez, 2012). Importantly, not only a widespread deficiency of GCase activity has been demonstrated in 
the brains of Parkinson’s disease patients carrying GBA mutations, but also Parkinson’s disease patients 
without GBA mutations were shown to exhibit deficiency of GCase in SN as well as in blood (Gegg et al., 
2012; Alcalay et al., 2015). Moreover, neurons and brains of Parkinson’s disease patients showed 
accumulation of GlcCer that directly influences the abnormal lysosomal storage of α-synuclein oligomers, 
thus resulting in a further inhibition of the GCase activity. These findings suggested that the bi-directional 
effect of GlcCer and α-synuclein accumulation forms a positive feedback loop that may lead to a self-
propagating disease (Mazzulli et al., 2011). Recent data also linked GCase impairment to the cell-to-cell 
propagation of α-synuclein aggregates (Bae et al., 2014). Based on the above-mentioned evidence, it is 
plausible that dysregulated GBA levels could represent a common feature in Parkinson’s disease, whereas 
loss-of-function GBA mutations could constitute the specific trigger responsible for Parkinson’s disease 
development in the GBA-associated disease. 
Dysregulation of GBA expression may in theory be due to altered epigenetic, transcriptional, and/or post-
transcriptional regulatory mechanisms. In particular, RNA-based networks, characterized by interactions 
between a specific mRNA, microRNAs (miRNAs), and competing endogenous RNAs (ceRNAs), are 
emerging as post-transcriptional regulators of gene expression (Tay et al., 2014). Moreover, accumulating 
evidence points to deregulation of noncoding RNAs as an important and largely unexplored regulatory layer 
in human neurodegenerative disorders, like Parkinson’s disease (Cooper et al., 2009; Saugstad, 2010). 
MiRNAs are ~20-nucleotide-long regulatory RNAs that act as post-transcriptional regulators of gene 
expression by repressing target mRNAs translation and/or by inducing mRNA degradation. About 2000 
miRNAs have been experimentally validated in humans and many more have been predicted 
bioinformatically, making them a major class of regulators (Kozomara and Griffiths-Jones, 2014). Each 
miRNA might inhibit the expression of multiple target mRNAs, whose recognition is based on imperfect 
complementary binding between miRNAs and their target sites, usually located within the 3’ untranslated 
region (3’UTR) (Lim et al., 2005). Concerning ceRNAs, they were recently described as a novel category of 
regulatory RNAs: these transcripts compete with mRNAs for miRNAs, acting as molecular “sponges” and 
thus influencing mRNA levels (Tay et al., 2014). Pseudogenes are the best ceRNA candidates, since they 
have a high-sequence identity with the ancestral gene (and, consequently, they could be targets of the same 
miRNAs), they can be transcribed, but usually they have lost the ability to generate a functional protein 
product (Poliseno et al., 2010). Interestingly, a highly-homologous (96% sequence identity) expressed GBA 
pseudogene (GBAP1) is located 16 kb downstream of the functional gene (Horowitz et al., 1989). GBAP1 
originated from a recent duplication event, being present only in primates (Martínez-Arias et al., 2001). 
With the aim to better understand GBA expression regulation at the post-transcriptional level, we explored 
the possible existence of a ceRNA-based network involving GBA and GBAP1. Here, we demonstrated that 
GBAP1 may function as a ceRNA to regulate GBA expression by sponging miR-22-3p, thus enlightening a 
novel regulatory circuit that can play a role in the pathogenesis of Parkinson’s disease 
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MATERIALS AND METHODS 
 
Plasmid constructs 
MiR-22-3p and miR-132 precursors were inserted into the psiUX expression vector (kindly provided by 
Prof. I. Bozzoni, Università di Roma La Sapienza, Rome, Italy). GBA and GBAP1 3’UTRs were 
directionally cloned downstream of the renilla luciferase gene in the psiCHECK2 reporter plasmid (Promega, 
Madison, USA). All constructs were produced by PCR amplifying the relevant genomic region from the 
DNA of a healthy subject using an appropriate PCR primer couple (Supplementary Table 1), and 
subsequently by cutting the amplified products with the proper restriction enzyme. Restricted products were 
ligated into the relevant plasmid. 
The constructs carrying the GBA and GBAP1 3’UTR deleted of the miR-22-3p binding site (ΔMRE, miRNA 
recognition element) were obtained by site-directed mutagenesis, by means of the QuikChange kit (Agilent 
Technologies, Santa Clara, USA), following the manufacturer protocol. 
A luciferase construct containing miR-22-3p antisense sequences (miR-22-3p sensor), kindly provided by 
Dr. Da-Zhi Wang (Children's Hospital Boston and Harvard Medical School), was used as a positive control 
(Huang et al., 2013). 
All plasmids were purified using the PureYield™ Plasmid Miniprep System kit (Promega) according to the 
manufacturer’s instructions. All recombinant and mutagenized vectors were verified by conventional Sanger 
sequencing, as described (Asselta et al., 2014). 
 
Prediction of GBA/GBAP1-targeting miRNAs 
Predictions were performed using publicly-available algorithms: microRNA.org (Betel et al., 2008), 
MicroCosm Targets (Griffiths-Jones et al., 2008), PITA (Kertesz et al., 2007), as well as the miRWalk2 suite 
(Dweep and Gretz, 2015). 
 
Cell cultures and transfection experiments 
HEK293 and HeLa cells were cultured according to the standard procedures. 
For miRNA over-expression experiments, cells were cotransfected using 3.5 µg (HeLa) or 875 ng (HEK293) 
of the psiUX plasmid expressing either miR-22-3p or miR-132 precursors. 
For the miRNA-target interaction analysis, HEK293 cells were cotransfected using 300 ng of the psiUX 
plasmid expressing miR-22-3p together with 720 ng of the psiCHECK2 plasmid containing the relevant 
3’UTR. 
For the ceRNA-effect analysis, HEK293 cells were cotransfected using 300 ng of the psiUX plasmid 
expressing miR-22-3p together with 300 ng of the psiCHECK2 plasmid containing the GBAP1 3’UTR, 
whereas HepG2 cells were transfected only with 300 ng of the GBAP1 3’UTR. 
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In each experiment, an equal number of cells (2.5*105 for HeLa, 3*105 for HEK293, 4*105 for HepG2) were 
transfected with the Polyplus jetPRIME (EuroClone, Wetherby, UK) in 6-well plates, as described by the 
manufacturer. Depending on the measurement to be performed at the end of experiment, cells were collected 
24, 48, 72, or 96 hours after transfection (detailed in the relevant figure legend), to obtain either total RNA, 
or cell lysates (see below). 
 
RNA samples 
Expression profiles of GBA, GBAP1, and miR-22-3p were determined using RNA from: a panel of 20 human 
tissues (First Choice total RNA; Ambion, Austin, USA), a panel of 24 human cerebral regions (Clontech 
Laboratories, Palo Alto, USA), 11 cell lines, induced pluripotent stem cells (iPSCs), and DA neurons 
differentiated from iPSCs (see below). 
RNA from cell lines, iPSCs, DA neurons, as well as transfected cells was isolated using the Eurozol kit 
(Euroclone), according to the manufacturer’s protocol. RNA concentration/quality was assessed using the 
Nanodrop ND-1000 (Thermo Fisher Scientific, Waltham, USA). 
 
Semi-quantitative real-time RT-PCR 
For the evaluation of expression levels of specific genes, random hexamers and the Superscript-III Reverse 
Transcriptase (Invitrogen, Carlsbad, USA) were used to perform first-strand cDNA synthesis starting from 1 
µg of RNA extracted from cells, or RNA derived from a panel of human tissues. From a total of 20 µL of the 
reverse-transcription (RT) reaction, 1 µL was used as template for amplifications using the FastStart SYBR 
Green Master Mix (Roche, Basel, Switzerland) on a LightCycler 480 (Roche), following a touchdown 
thermal protocol. Expression levels were normalized using HMBS (hydroxymethylbilane synthase gene) and 
ACTB (β-actin) as housekeeping genes. To discriminate between the quasi-identical GBA and GBAP1 genes, 
we took advantage of the 55-bp deletion in exon 9 characterizing GBAP1 as well as of the few nucleotide 
differences between GBA and GBAP1 spread along the two genes. 
MiR-22-3p and miR-132 levels were measured by real-time RT-PCR by a poly(A) tailing and a universal 
reverse transcription approach, using the miRNA First Strand Synthesis kit (Agilent Technologies) and 
starting from 300 ng of total RNA, according to the manufacturer’s instructions. RT-PCR reactions were 
performed using the universal reverse primer (Agilent Technologies) and miRNA-specific forward primers, 
as described (Soldà et al., 2012). U6 snRNA was used as housekeeping gene. Real-time reactions were 
performed as described above. 
In all cases, real-time RT-PCR assays were performed at least in triplicate on a LightCycler 480, and 
expression levels were analyzed by the GeNorm software (Vandesompele et al., 2002). Correlation between 
GBA/GBAP1/miR-22-3p expression profiles was calculated using the Pearson’s correlation. Pearson’s 
coefficients <-0.5 and >0.5 are considered as anti-correlation and positive correlation, respectively. P values 
<0.05 were considered as statistically significant. 
Primer couples used in RT-PCR assays are listed in Supplementary Table 1. 
 72 
 
Luciferase assays 
For miRNA-target interaction assays, the activities of firefly/renilla luciferase were measured in lysates from 
transfected cells by using the Dual-Luciferase Reporter Assay System (Promega) and the Wallac 1420 
VICTOR3 V reader (PerkinElmer, Waltham, USA). The values of renilla luciferase were normalized against 
the corresponding values of firefly luciferase. 
 
GCase enzymatic activity assays 
Cells to be assayed were washed twice with phosphate buffered saline (PBS), harvested, and then lysed in 
water containing complete protease inhibitor cocktails (Roche). Total cell protein content was measured 
using the Micro BCA assay reagent (Pierce, Rockford, USA). Cells lysates were transferred to a 96-well 
microplate and assays were performed in triplicate. Cell-lysate associated GCase activity was analyzed using 
4-methylumbelliferyl--D-glucopyranoside (MUB-Glc; Glycosynth, Warrington, UK), solubilized at a final 
concentration of 6 mM in McIlvaine Buffer (0.1 M Citrate/0.2 M Phosphate, pH 5.2) containing 0.1% Triton 
X-100. The reaction mixtures were incubated at 37°C under gentle shaking. The fluorescence was recorded 
after transferring 10 L of the mixture in the microplate and adding 190 μL of 0.25 M glycine, pH 10.7. The 
fluorescence was detected by a Wallac 1420 VICTOR3 V reader. Data were expressed as pmoles of 
converted substrate/mg cell proteins × hour. 
 
GBA and GBAP1 splicing pattern and sensitivity to the nonsense-mediated mRNA decay (NMD) 
pathway 
Analysis of GBA/GBAP1 splicing patterns and susceptibility to NMD was undertaken in HepG2 and 
HEK293 cell lines. Cells were plated at a density of 4*105 per 6-well dish and, after 72 hours, treated for 8 
hours with cycloheximide (100 µg/mL; dissolved in dimethyl sulfoxide) or with the vehicle alone. After the 
treatment, cells were washed with PBS and total RNA extracted.  
For the analysis of the splicing pattern, a set of gene-specific or pseudogene-specific RT-PCR assays 
(Supplementary table 1) was designed to catch the vast majority of possible alternative splicing events. RT-
PCRs were performed as described above. The main amplified products, recovered from the agarose gel 
using the Wizard SV Gel and PCR Clean-Up System kit (Promega), were directly sequenced to confirm their 
identity. 
Variations in the expression levels of GBA/GBAP1 upon treatment were quantified by real-time RT-PCR 
assays using as reference an NMD-resistant transcript (i.e., Connexin 43 or Connexin 32 mRNAs, whose 
coding sequences are all contained in a single exon, for HEK293 and HepG2, respectively). The NMD-
sensitive and insensitive PRKCA transcripts were used as controls (Paraboschi et al., 2014). 
 
Fibroblast-derived iPSCs 
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IPSC lines derived from skin fibroblasts of six controls and four Parkinson’s disease patients carrying 
heterozygous GBA mutations (p.L444P, n=2; p.N370S, n=2) were obtained as detailed in (Schondorf et al., 
2014) and following the protocol of Takahashi and colleagues (2007). These iPSCs were subjected to 
neuronal differentiation for 35 days in vitro, according to Kriks and collaborators’ protocol (Kriks et al., 
2011). 
This study has the approval of the local Ethics Committees and was performed according to the Declaration 
of Helsinki. Signed informed consent was obtained from all participants. 
 
RESULTS 
 
MiR-22-3p targets GBA and GBAP1 
Since there is no information on miRNAs modulating GBA expression, we searched bioinformatically for 
miRNAs potentially targeting both GBA and its pseudogene. Predictions were performed using eight 
software; candidate miRNA selection was performed by prioritizing miRNAs: i) predicted by at least five 
algorithms; ii) containing at least 7-nt perfect seed match with GBA and GBAP1 3’UTRs; iii) known to be 
expressed in brain and previously implicated in neurodegenerative diseases. These filtering steps allowed the 
selection of three candidate miRNAs: miR-22-3p, miR-132, and miR-212. For functional validation, we 
prioritized miR-22-3p and miR-132, since they were expressed at higher level in both cerebellum and frontal 
cortex (Supplementary Table 2). 
To verify that GBA/GBAP1 can be targets of miR-22-3p and/or miR-132, we cloned both miRNA precursors 
in a suitable expression vector, and over-expressed them in HeLa cells for 24 hours. We obtained, on 
average, an over-expression of both miRNAs of ~100 fold respect to their endogenous basal levels. The 
results of these experiments showed that miR-22-3p over-expression can significantly reduce GBA and 
GBAP1 endogenous mRNA levels (up to 72%; P<0.0003). Conversely, no GBA modulation was detected 
after miR-132 over-expression (Figure 1A). 
To confirm these results, the 3’UTRs of GBA and GBAP1 were cloned downstream of the luciferase gene in 
the psiCHECK2 vector. These UTRs differ for only 6 nucleotides, none of them mapping in the predicted 
binding sites for miR-22-3p and miR-132. We cotransfected in HeLa cells each of these reporter plasmids 
together with the vector expressing either the miR-22-3p or miR-132 precursor. The results of transfection 
experiments substantially confirmed previous observations, i.e. miR-22-3p was able to target both GBA and 
GBAP1 UTRs (37% and 34% reduction, respectively; P<0.0001). Conversely, miR-132 did not affect the 
expression of the reporter gene (Figure 1B), and was hence not further investigated. 
To better unravel the functional impact of miR-22-3p on the expression of GBA/GBAP1, we decided to study 
miR-22-3p/GBA/GBAP1 expression profiles in 11 cell lines. Real-time RT-PCRs evidenced a ubiquitous 
expression of GBA in the analyzed lines, with highest levels present in HeLa and glioblastoma cells, and 
lowest levels in HepG2 cells. GBAP1 was present in all cell lines, though at lower levels than GBA (from 
186 to 1.8 times less) (Supplementary figure 1A). MiR-22-3p showed a nearly ubiquitous expression profile, 
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with highest levels in HepG2 and glioblastoma cells, and lowest levels in HEK293 (Supplementary figure 
1B). 
Based on these expression profiles, we decided to repeat miR-22-3p over-expression experiments in 
HEK293 cells. Results were comparable to those observed in the HeLa cell line, with GBA and GBAP1 
endogenous mRNA levels significantly decreased, after 24 hours, up to 44% (P<0.05; Figure 1C). We then 
confirmed the effects of miR-22-3p over-expression also at the protein level: measurements of endogenous 
GCase activity demonstrated that the enzyme was down-regulated of 15% after 48 hours of transfection 
(P<0.002; Figure 1C). 
Finally, the specific interaction of miR-22-3p with GBA and GBAP1 3’UTRs was demonstrated by deleting 
the miR-22-3p putative miRNA responsive element (MRE) in the reporter constructs containing the 
relevant UTR, and subsequently cotransfecting each mutagenized plasmid together with the miR-22-3p 
expressing one. In these experiments, a luciferase construct containing miR-22-3p antisense sequences (miR-
22-3p sensor) was used as a positive control (Huang et al., 2013). Our data showed that miR-22-3p 
responsiveness strictly depends on the presence of the predicted responsive element in the 3’UTR, since its 
deletion completely abolishes the miRNA-mediated regulation (Figure 1D). As expected, the level of 
luciferase activity in the miR-22-3p sensor control dramatically dropped (95% reduction). 
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Figure 1: MiR-22-3p targets GBA and GBAP1. 
A) The psiUX vectors, containing either the pre-miR-22-3p or the pre-miR-132 sequence, were independently 
transfected in HeLa cells; 24 hours after transfection, cells were collected and total RNA extracted. Endogenous 
expression levels of GBA and GBAP1 were measured by semi-quantitative real-time RT-PCRs. In all cases, expression 
levels are shown as normalized rescaled values, setting as 1 the value measured in cell transfected with an empty vector 
(psiUX, mock). 
B) The psiCHECK2 vectors, containing either the GBA or the GBAP1 3’UTR downstream of the luciferase reporter 
gene, were independently transfected in HeLa cells together with plasmids expressing either the pre-miR-22-3p or the 
pre-miR-132. 48 hours after transfection, cells were collected and protein lysates prepared to perform the reporter 
assays. The panels show the renilla luciferase activity normalized against the firefly luciferase activity, setting as 1 the 
value measured in cells cotransfected with an empty vector (psiCHECK2, no miRNA overexpression, mock). 
C) Over-expression experiments of the psiUX vector, containing the pre-miR-22-3p sequence, were repeated in 
HEK293 cells. 24 or 48 hours after transfections, cells were collected for extracting total RNA (for endogenous GBA 
and GBAP1 measurements by semi-quantitative real-time RT-PCRs; left) or for preparing protein lysates (for 
endogenous GCase activity measurements; right). In all cases, the value measured in cells cotransfected with an empty 
vector (psiUX, no miRNA over-expression, mock) was set as 1. 
D) Luciferase reporter assays were repeated in HEK293 cells, by transfecting the psiCHECK2 vector coupled to the 
3’UTR regions of GBA or GBAP1, with or without the putative miRNA recognition element (MRE). Each of the four 
psiCHECK2 recombinant plasmid was cotransfected with the psiUX plasmid expressing miR-22-3p. 48 hours after 
transfection, cells were collected and lysates prepared to perform the reporter assays. The panels show the renilla 
luciferase activity normalized against the firefly luciferase activity, setting as 1 the value measured in cells 
cotransfected with an empty vector (psiCHECK2, no miRNA over-expression, mock). As positive control, a luciferase 
construct containing miR-22-3p antisense sequences (miR-22-3p sensor) (Huang et al., 2013) was also transfected. 
In all panels, bars represent means +SEM of three independent experiments, each performed at least in triplicate. 
Significance levels of t-tests are shown. *: P<0.05; **: P<0.01; ***: P<0.005. 
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GBAP1 acts as a ceRNA titrating miR-22-3p and up-regulating GBA 
To assume that GBAP1 can act as a GBA ceRNA by sponging miR-22-3p, we first verified the coexpression 
of the three transcripts in a broad range of samples (20 human tissues as well as 24 different cerebral 
regions). GBA/GBAP1/miR-22-3p were all ubiquitously expressed (Supplementary figure 2). In particular, 
GBA showed minimal expression in the skeletal muscle and the highest level in the medial temporal cortex 
(17 fold the skeletal muscle). GBAP1 expression levels weakly correlated with those of GBA (Pearson’s 
correlation coefficient of 0.53, P<0.0013), in agreement with the possible ceRNA role of GBAP1. 
Interestingly, GBAP1 highest expression levels were registered in the brain, where the disproportion between 
the gene and pseudogene levels is one of the lowest (ratio 1:15). Concerning miR-22-3p, in general we 
observed the lowest levels of expression in brain regions, such as cerebellum, nucleus accumbens, medulla, 
and fetal brain. MiR-22-3p expression levels showed a tendency towards anticorrelation with the levels of 
GBA/GBAP1 (Pearson’s correlation coefficients -0.47 and -0.42, respectively; P<0.0043 and P<0.0094), in 
line with the demonstrated regulatory effect of miR-22-3p on GBA/GBAP1. 
Such encouraging results prompted us to verify if altered levels of GBAP1 could indeed modify the 
expression of GBA. First, as a proof of concept, we over-expressed both the 3’UTR of GBAP1 and the miR-
22-3p hairpin in HEK293 cells. In parallel, the over-expression experiment was conducted using as sponge 
the 3’UTR of GBAP1 without the miR-22-3p responsive element. We showed that GBAP1 3’UTR over-
expression causes a significant increase in the levels of endogenous GBA mRNA only in the presence of the 
miR-22-3p binding site (1.72 fold; P=0.019; Supplementary figure 3A). We also evaluated the ceRNA effect 
at the protein level, by measuring the GCase activity upon miR-22-3p and GBAP1 3’UTR over-expression. 
Our data confirmed that the GBAP1 3’UTR, containing the miR-22-3p binding site, causes a significant 
increase of GCase activity (1.11 fold; P=0.013) (Supplementary figure 3B). 
Second, considering the high levels of miR-22-3p measured in HepG2 cells (16-fold the levels measured in 
HEK293; Supplementary figure 1), we over-expressed in this cell line the 3’UTR of GBAP1 alone (with or 
without the miR-22-3p responsive element) and measured its effect on endogenous GBA. We observed a 
significant increase in the levels of endogenous GBA mRNA once again only in the presence of the miR-22-
3p binding site (1.68 fold; P=0.0016; Figure 2A). The GBAP1 ceRNA effect through miR-22-3p sponging 
was confirmed by measuring the expression levels of known miR-22-3p targets, i.e. the SP1 and SIRT1 genes 
(Xu et al., 2011; Zhang et al., 2016), which both resulted upregulated of ~1.7 fold (P<0.015). Conversely, no 
up-regulation was observed for the CELF1 transcript (Figure 2A), which does not contain any miR-22-3p 
responsive element. These results were corroborated by the measurements of GCase activity in HepG2 cells 
under the same experimental conditions (1.13 fold; P=0.049) (Figure 2B). 
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Figure 2: GBAP1 acts as a ceRNA titrating miR-22-3p and up-regulating GBA. 
A) The psiCHECK2 vectors, containing the GBAP1 3’UTR (with or without the miR-22-3p recognition element, 
MRE) downstream of the luciferase reporter gene, were independently transfected in HepG2 cells. 96 hours after 
transfections, cells were collected for extracting total RNA for measurements by semi-quantitative real-time RT-PCRs 
of endogenous: i) GBA; ii) SP1 (Sp1 Transcription Factor; known miR-22-3p target, positive control) (Xu et al., 2011); 
iii) SIRT1 (Sirtuin 1; known miR-22-3p target, positive control) (Zhang et al., 2016); and iv) CELF1 (CUGBP, Elav-
Like Family Member 1; negative control). The value measured in cells transfected with an empty vector (psiCHECK2, 
mock) was set as 1. 
B) Over-expression experiments of psiCHECK2 vectors, containing the GBAP1 3’UTR (wild type or MRE), were 
repeated to obtain protein lysates for endogenous GCase activity measurements. In this case, the GCase activity was 
measured 96 hours after transfections. 
In all panels, bars represent means +SEM of three independent experiments, each performed at least in triplicate. 
Significance levels of t-tests are shown. *: P<0.05; **: P<0.01. 
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The GBAP1 ceRNA effect could be modulated by the NMD pathway 
To better unravel the reciprocal regulation of the couple GBA/GBAP1, we decided to comprehensively study 
GBA and GBAP1 alternative splicing patterns and the possible regulation of expression of these two genes 
operated by NMD (Popp and Maquat, 2013; Mitrovich and Anderson, 2005). 
To catch the vast majority of all possible splicing events, long-range RT-PCR assays were designed to 
completely cover both genes (Figure 3A). The specific amplification of either GBA or GBAP1 in each assay 
was assured by anchoring one primer to exon 9, in correspondence of the pseudogene-specific 55-bp 
deletion. RT-PCR assays were performed on RNA extracted from HepG2 cells treated or not with the NMD 
inhibitor cycloheximide. This analysis allowed the identification of multiple alternatively-spliced isoforms 
for GBAP1; conversely, GBA did not show any detectable alternative isoform (Figure 3A). Notably, the 
heterogeneity of the splicing pattern of GBAP1 increased after cycloheximide treatment, suggesting that 
multiple pseudogene splicing isoforms may be modulated by NMD. A tentative reconstruction of the main 
splicing variants of GBAP1 was performed by a combination of isoform-specific semi-nested RT-PCRs and 
DNA sequencing, highlighting the presence of multiple transcripts containing a premature termination codon 
(Supplementary Figure 4). 
The global effect of NMD degradation on GBA and GBAP1 levels was also investigated by semi-quantitative 
real-time RT-PCR. This analysis showed a significant increase in the expression level of GBAP1 in treated 
cells (4.18 and 3.92 fold in HEK293 and HepG2 cells, P=0.045 and P=0.0034, respectively), confirming that 
this pseudogene is down-regulated by NMD (Figure 3B). Also GBA transcripts were up-regulated upon 
NMD inhibition (2.28 and 2.35 fold in HEK293 and HepG2 cells), a rather unexpected result given the lack 
of out-of-frame GBA isoforms in our preliminary analysis. However, these results well fit the hypothesis that 
GBAP1 levels may influence GBA expression through a ceRNA effect. As control, in-frame and out-of-
frame PRKCA isoforms, known to be insensitive/sensitive to the NMD blockage (Paraboschi et al., 2014), 
were also analyzed and gave the expected results (Figure 3B). 
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Figure 3: GBAP1 codes for multiple alternatively-spliced isoforms and is modulated by NMD. 
A) Analysis of GBA and GBAP1 splicing patterns. In the upper part of the panel, a schematic representation of GBA 
(reference sequence: NM_001005741.2) and GBAP1 (reference sequence: NR_002188.2) genes is reported. Exons are 
indicated by boxes, introns by line. The 55-bp-long sequence characterizing GBA exon 9 is specified by a grey 
rectangle. The scheme is approximately to scale. The overlapping fragments amplified by RT-PCRs to analyze the GBA 
and GBAP1 splicing patterns are indicated by dashed lines and a letter. In the lower part of the panel, the electrophoretic 
analysis (agarose gels 2%) of RT-PCR amplicons is shown. RT-PCRs were performed on RNA extracted from HepG2 
cells treated (+) or untreated (-) with the NMD inhibitor cycloheximide. On the top of each gel, letters indicate the 
relevant RT-PCR amplicons. 
B) Demonstration of the NMD-mediated degradation of GBAP1 transcripts. The two panel shows expression levels of 
GBAP1 and GBA isoforms in HEK293 and HepG2 cells, untreated or treated for 8 hours with cycloheximide. 
Expression levels of endogenous GBAP1/GBA isoforms were measured by semi-quantitative real-time RT-PCRs 
(results are presented as normalized rescaled values, setting as 1 the value of the untreated samples). The expression 
level of the Connexin 43 or 32 transcripts, known to be insensitive to NMD, were used in the normalization step. RT-
PCRs performed on out-of-frame and in-frame PRKCA isoforms, known to be respectively sensitive and insensitive to 
the NMD blockage (Paraboschi et al., 2014), represent the positive and negative control. In all panels, bars represent 
means +SEM of three independent experiments, each performed at least in triplicate. Significance levels of t-tests are 
shown. *: P<0.05; **: P<0.01. 
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GBA, GBP1, and miR-22-3p are expressed in iPSC-derived neuronal cells 
To be relevant for the molecular pathogenesis of Parkinson’s disease, the GBA/GBAP1/miR-22-3p network 
should work in tissues affected by the disease process, e.g. DA neurons. We hence verified the expression of 
GBA, GBAP1, and miR-22-3p in iPSCs and iPSC-derived neuronal cells (after 35 days of differentiation). 
Semi-quantitative real-time RT-PCR assays were performed on total RNA extracted from iPSCs/neurons 
derived from fibroblasts of six healthy controls and four Parkinson’s disease patients (all carrying GBA 
mutations). 
All the three players of the regulatory circuit were expressed both in iPSCs and iPSC-derived neurons, 
respectively. The process of differentiation towards neurons is accompanied by a significant up-regulation of 
GBA (8 fold in controls, P=0.0002; 3 fold in patients, P=0.0032) and by a parallel increase in expression 
levels of GBAP1 (Figure 4A and B). In addition, we detected a significant down-regulation of the GBA 
transcript in Parkinson’s disease patients respect to controls in DA neurons (0.54 fold, P=0.013). Finally, 
consistently with the observed up-regulation of GBA/GBAP1 during neuronal differentiation, we detected 
lower expression levels of miR-22-3p in DA neurons respect to their precursors (0.39 fold in controls, 
P=0.018; 0.18 fold in patients) (Figure 4C). 
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Figure 4: GBA, GBP1, and miR-22-3p are expressed in iPS cells and iPSC-derived neurons of Parkinson’s 
disease patients and controls. 
GBA (panel A), GBAP1 (panel B), and miR-22-3p (panel C) expression levels were measured by semi-quantitative real-
time RT-PCRs in up to six iPS and iPSC-derived neuronal cells of cases and controls. Boxplots show expression levels 
according to the disease status; boxes define the interquartile range; the thick line refers to the median. Results are 
presented as normalized rescaled values. Significance level for differences between groups was calculated by a t-test, 
and showed only if significant. *: P<0.05; **: P<0.01; ***: P<0.005. 
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DISCUSSION 
Despite the substantial efforts, over the past few years, in understanding the role of long non-coding RNAs 
(lncRNAs) in health and disease, only some of them have been investigated for their biological function 
(Quek et al., 2015). One promising –although debated- idea assigning to lncRNAs a generalized function is 
the “ceRNA hypothesis”, based on the fact that specific RNAs can limit miRNA activity through 
sequestration, thus up-regulating the expression of miRNA target genes (Tay et al., 2014). In particular, two 
classes of lncRNAs are increasingly recognized as main ceRNA contributors, i.e. circular RNAs and 
pseudogene-derived transcripts (Thomson and Dinger, 2016). Specifically concerning pseudogenes, to date 
there are more than 14,500 annotated pseudogenes (Gencode v24, August 2015 freeze, GRCh38; 
http://www.gencodegenes.org/stats/archive.html#a21), but only ~10% are actively transcribed (Sisu et al., 
2014), a pre-requisite for acting as ceRNAs. Indeed, transcribed pseudogenes, mostly deriving from 
duplication events, are considered optimal ceRNA candidates, as they share miRNA-binding sites with the 
ancestral genes (Tay et al., 2014; Thomson and Dinger, 2016). A number of pseudogenes have been so-far 
experimentally demonstrated to act as ceRNAs, including: PTENP1 and KRAS1P (Poliseno et al., 2010), 
OCT4-pg4 (Wang et al., 2013), BRAFP1 (Karreth et al., 2015), and CYP4Z2P (Zheng et al., 2015). In this 
study, we describe a novel ceRNA-based network - with a potential impact on Parkinson’s disease - 
involving GBA, its pseudogene GBAP1, and miR-22-3p (Figure 5). 
The molecular evolution, expression pattern, and mechanisms of transcriptional regulation of GBA have been 
previously investigated (Wafaei and Choy, 2005; Svobodová et al., 2011), mainly because of its direct link 
with the Gaucher’s disease, the most frequently-encountered lipidosis as well as the most common inherited 
disorder in Ashkenazi Jews (Hruska et al., 2008). On the other hand, the few data available on GBA post-
transcriptional regulation principally stem from a miRNA mimic screening aimed to identify miRNAs 
regulating the GCase activity in p.N370S homozygous Gaucher fibroblasts (Siebert et al., 2014). This 
screening involved 875 miRNAs and evidenced at least three candidates (miR-127-5p, miR-16-5p, and miR-
195-5p), exhibiting a Z-score of at least +/- 2, with important consequences on the GCase activity. However, 
in all cases, the miRNA effect did not seem to be mediated by a direct interaction between the miRNA itself 
and GBA; rather, miRNAs acted either on the LIMP-2 receptor, which is involved in the trafficking of GCase 
from the endoplasmic reticulum to the lysosome, or on the expression levels of known modifiers of the 
GCase activity (Siebert et al., 2014). Hence, our work identifies miR-22-3p as the first miRNA directly 
targeting GBA. Interestingly, in the publicly-available dataset of Siebert and coworkers (2014) miR-22-3p 
mimic resulted to down-regulate GCase activity (Z-score=-1.5; suggestive P=0.066), according to our 
results. 
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Figure 5: Schematic representation of the effect of modulating the GBA/GBAP1/miR-22-3p RNA-
based network on endogenous GBAP1 and GBA levels.  
Schematic representation of the ceRNA network involving GBA (blue transcripts) and GBAP1 (orange 
transcripts), harboring the same MRE sites (green and violet ovals). The green MRE sites bind to miR-22-3p 
(in green), whereas violet ones bind to other not-specified miRNAs. The experimental modulation of the 
proposed ceRNA network impacts on both coregulated transcripts. In particular, over-expression of miR-22-
3p (left part of the figure) determines the down-regulation of both GBA and GBAP1 transcripts. Conversely, 
over-expression of GBAP1 (e.g., by inhibiting the NMD pathway, as experimentally verified in the present 
study; right part of the figure) will increase the cellular concentrations of miR-22-3p MREs, thus resulting in 
the de-repression of GBA. In the scheme, transcripts destined to degradation are colored in lighter shades. 
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Concerning GBAP1, sparse information is available to date, and it is primarily focused on the evolution of 
the GBAP1 locus, as an example of a very recently acquired pseudogene (Horowitz et al., 1989; Wafaei and 
Choy, 2005). We hence extensively studied GBAP1 splicing pattern and expression profile, showing that it is 
subjected to multiple physiologic in-frame and out-of-frame splicing events and that it is broadly expressed, 
though often at low levels (Supplementary figure 2). More interestingly, we showed that GBAP1 is targeted 
by NMD, which seems to be the main mechanism regulating its expression level: blocking NMD, the ratio 
between GBA and GBAP1 substantially increased (on average from 1/100 to 1/68 in HepG2 cells, and from 
1/9 to 1/4 in HEK293 cells). Of course, the GBAP1 expression control exerted through NMD raises the 
question about the pseudogene translation, since RNAs should undergo a pioneer round of translation, 
associated with an inspection operated by the NMD machinery, before being degraded (Popp and Maquat, 
2013). Interestingly, it has been recently reported that many lncRNAs, and even 5'UTRs, are translated, and 
GBAP1 was identified among non-canonical human translated open reading frames (Ji et al., 2015). The 
remarkable degradation of GBAP1 operated by NMD not only may cause its low abundance, but also results 
in an increased degradation of bound miRNAs, possibly enhancing GBAP1 efficiency as miRNA sponge, as 
suggested for other pseudogenes (Tay et al., 2014). 
The relevance of post-transcriptional regulation in determining the low GBAP1 expression is also suggested 
by the observation that GBAP1 proximal and distal promoters show high level of sequence identity with 
those of GBA, and are hence predicted to have similar transcriptional strength. For instance, the presence of 
two TATA boxes and two CAAT boxes in the proximal promoter of GBAP1 exactly recapitulates the 
architecture of in-cis regulatory elements characterizing the GBA proximal promoter (Horowitz et al., 1989). 
Moreover, epigenetic marks are not substantially different when comparing the gene and the pseudogene 
promoters, as inferred from the UCSC Genome Browser ENCODE tracks (http://genome.ucsc.edu/; release 
Feb. 2009, GRCh37/hg19). Indeed, our in-house preliminary data, obtained with reporter constructs, show 
that the activity of GBAP1 promoters does reach the transcriptional levels of the corresponding GBA 
promoters (data not shown). 
Our overexpression experiments in different cell lines clearly demonstrated that GBAP1 3’UTR, at 
supraphysiological concentrations, can modulate GBA mRNA levels through a miR-22-3p-mediated 
regulatory circuit. However, these results do not necessarily imply that this ceRNA-based regulation may 
also work in more physiological conditions. To confirm that GBAP1 can act as a GBA ceRNA without 
overexpression, we exploited the predicted differential sensitivity to NMD of the gene and pseudogene 
transcripts (see Figure 3A). Cycloheximide treatment allowed us to increase the relative abundance of the 
endogenous GBAP1 mRNA of around 4 times the basal level and was accompanied by a 2-fold increase in 
GBA transcripts, not directly attributable to NMD, and compatible with a ceRNA effect (Figure 3B). Hence, 
in specific cells or developmental stages, upregulation of GBAP1, resulting from post-transcriptional or 
epigenetic regulatory mechanisms, might titrate miRNAs away from the GBA protein-coding transcripts, 
thus providing a physiologic ceRNA effect. 
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The existence of an RNA-based network controlling GBA expression suggests the intriguing possibility that 
also miR-22-3p or GBAP1 dysregulation could be associated with Parkinson’s disease. To date, few 
information on a possible involvement of these non-coding RNAs in Parkinson’s disease is overtly present in 
the literature, with the reported dysregulation of miR-22* in Parkinson’s disease patients actually referring to 
the 5p companion of “our” miR-22-3p (Margis et al., 2011). Interestingly, a very recent paper suggested that 
miR-22 may exert a neuroprotective effect in Parkinson’s disease, as it protects rat pheochromocytoma PC12 
cells from 6-hydroxydopamine-induced injury, by modulating the levels of its target gene transient receptor 
potential melastatin 7 (TRPM7) (Yang et al., 2016). However, it should be noted that Yang and colleagues in 
their paper linked miR-22 down-regulation with Parkinson’s disease by mistakenly citing the work of Margis 
and collaborators (2011), which concerned miR-22-5p, as detailed above. 
To further explore the involvement of GBA/GBAP1/miR-22-3p in Parkinson’s disease, we investigated their 
expression pattern in disease-relevant tissues using in-silico analyses of microarray datasets publicly 
available through the Gene Expression Omnibus repository (see Supplementary Materials and Methods), as 
well as in-vivo measurements performed on RNA extracted from iPSCs and iPSC-derived neuronal cells of 
Parkinson’s disease cases and controls. In particular, we retrieved three microarray datasets evaluating 
differential gene expression in the SN of post-mortem brains, for a total of 51 cases and 42 controls 
(Supplementary Table 3). In the meta-analysis, we measured a significant down-regulation of both GBA and 
GBAP1 transcripts in Parkinson’s disease patients (P<0.05; Supplementary Figure 5). Notably, we observed 
the same significant down-regulation for GBA transcripts in iPS-derived DA neurons of Parkinson’s disease 
patients; accordingly, miR-22-3p was slightly up-regulated in cases vs. controls (on average 1.96 fold, 
P=0.13; Figure 4). 
A few studies have reported a potential neuroprotective effect of miR-22-3p both in rat models of cerebral 
ischemia-reperfusion injury and in Huntington and Alzheimer’s disease through a reduction in inflammation 
and apoptosis (Jovovic et al., 2013; Yu et al., 2015). However, other studies suggested a pro-senescence role 
of miR-22 in endothelial progenitor cells, in cancer, and in the aging heart and brain (Li et al., 2011; Xu et 
al., 2011; Jazbutyte et al., 2013; Zheng and Xu, 2014). While the neuroprotective effects of miR-22 have 
suggested enhancing its expression as a potential therapeutic strategy for the treatment of neurodegenerative 
conditions, it may well be that miR-22 overexpression represents a pathophysiologic response to protect the 
cell from injury and stress also triggering other non-beneficial effects, like increased aging and reduced 
GCase activity.  
In conclusion, we are aware of the fact that the connection of the here-presented RNA-based network and 
Parkinson’s disease pathogenesis has not been formally proven. However, one can easily imagine a link 
between the down-regulation of the sister transcripts GBA/GBAP1 - or, conversely, the up-regulation of miR-
22-3p - and an aberrant α-synuclein metabolism, as already theorized (Sidransky and Lopez, 2012). A 
confirmed dysregulation of the GBA/GBAP1/miR-22-3p circuit in Parkinson’s disease patients would 
suggest novel possible therapeutic strategies, based either on the direct control of the expression of the 
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miRNA/pseudogene, or on the modulation of the NMD pathway aimed at up-regulating GBAP1 levels (Popp 
and Maquat, 2016). 
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SUPPLEMENTARY MATERIALS AND METHODS 
 
Microarray dataset retrieving and analysis 
Microarray datasets were retrieved from the National Center for Biotechnology Information (NCBI) GEO 
database (http://www.ncbi.nlm.nih.gov/gds/). The database was searched using “Parkinson’s disease”, 
“substantia nigra”, and “human” as keywords (accession date: June 14th, 2016). The manual review of the 
obtained entries allowed the identification of three datasets (GSE7621, GSE8397, and GSE20292), all 
characterized by expression data obtained from RNAs extracted from the substantia nigra of Parkinson’s 
disease cases and healthy controls. Characteristics of selected datasets are listed in Supplementary Table 3. 
The three datasets were analyzed separately by comparing Parkinson’s disease cases vs healthy controls, 
using the GEO2R web application (Barrett et al., 2009; Barrett et al., 2013). GEO2R, available at GEO 
repository, implements Bioconductor R packages (Gentleman et al., 2004; R Core Team, 2013) and provides 
results as a list of genes ordered by significance (P value). We specifically searched this list for probe sets 
corresponding to GBA and GBAP1. The three identified probes (210589_s_at, 209093_s_at, and 216400_at; 
shared by the three datasets) were then individually blatted against the human genome, using the UCSC 
Genome Browser (hg19) to verify if they target correctly the corresponding gene. The 216400_at probe, 
which resulted to recognize intronic sequences, was excluded from further analysis. We hence performed a 
meta-analysis using the expression data associated with the two surviving probe sets and the Integrative 
Meta-analysis of Expression Data (INMEX) program (Xia et al., 2013). Data were uploaded to INMEX, 
processed, annotated, checked, and meta-analyzed by using the “Combining P-values” option, based on the 
Fisher’s method [-2*∑Log(p)] (Xia et al., 2013). The threshold for significance was set to 0.05. 
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Supplementary figure 1: Expression profiles of GBA, GBAP1, and miR-22-3p in cell lines. 
A) Expression levels of GBA and GBAP1 were measured by semi-quantitative real-time RT-PCRs in a panel 
of 11 cell lines. HMBS and ACTB were used as housekeeping genes. 
B) MiR-22-3p expression levels were determined in the same panel of cell lines using a poly(A) tailing and a 
universal reverse transcription approach, followed by real-time RT-PCRs. U6 was used as housekeeping 
gene.In all cases, expression levels are shown as normalized rescaled values, setting as 1 the value measured 
in HepG2 (pane A) and SH-SY5Y (panel B). Bars represent means +SD of three replicates. 
Cell lines: HeLa (epithelial cervical carcinoma); COV434 (granulosa carcinoma); Caco-2 (epithelial 
colorectal adenocarcinoma); HepG2 (liver carcinoma); HEK293 (embryonic kidney); SH-SY5Y 
(neuroblastoma); IMR-32 (neuroblastoma); Glioblastoma; Daoy (medulloblastoma); EAhy296 
(endothelium);- GM06895 (lymphoblastoid line). 
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Supplementary figure 2: Expression profiles of GBA, GBAP1, and miR-22-3p in 20 human 
tissues and 24 human cerebral districts. 
Expression levels of GBA, GBAP1, (panel A) and miR-22-3p (panel B) were measured by real-time 
RT-PCR assays on cDNAs derived from commercial panels of 20 human tissues (listed in upper-case letters) 
and 24 different RNAs from cerebral districts (in lower-case letters; for more details, see legend of 
Supplementary figure 1). 
Each tissue sample consisted in a pool comprising RNA from at least 3 donors. 
Concerning specifications for brain district samples: 
- dura mater, parietal cortex posterior, auditory cortex, putamen, frontal cortex, entorhinal cortex, amygdala, 
hippocampus, orbital frontal cortex, temporal cortex medial, hypothalamus, and pons RNA samples all 
derive from a single person; 
- fetal brain: this sample derives from normal brains of 59 spontaneously aborted male and female Caucasian 
fetuses (20-33 weeks); 
- frontal lobe: pooled from 4 male and female Caucasian individuals (32-61 years old); 
- nucleus accumbens: pooled from 6 male and female Caucasian individuals (23-56 years old); 
- retina: pooled from 25 male and female Caucasian individuals (24-65 years old); 
- insula: pooled from 15 male and female Caucasian individuals (20-68 years old); 
- substantia nigra: pooled from 21 male and female Caucasian individuals (20-62 years old); 
- medulla oblongata: pooled from 29 male and female Caucasian individuals (18-64 years old). 
Results are presented as normalized rescaled values, setting as 1 the values corresponding to skeletal muscle 
(panel A), and thymus (panel B). Bars represent means +SD of three replicates. 
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Supplementary figure 3: GBAP1 acts as a ceRNA titrating miR-22-3p and up-regulating GBA 
in HEK293 cells. 
A) The psiCHECK2 vectors, containing the 3’UTR region of GBAP1 (with or without the miR-22-3p 
recognition element, MRE) downstream of the luciferase reporter gene, were independently transfected in 
HEK293 cells together with the plasmid expressing the pre-miR-22-3p transcript. 24 hours after 
transfections, cells were collected for extracting total RNA for measurements of GBA endogenous levels by 
semi-quantitative real-time RT-PCRs. The value measured in cells transfected with an empty vector 
(psiCHECK2, mock) was set as 1. 
B) Over-expression experiments of psiCHECK2 vectors, containing the two different 3’UTR regions of 
GBAP1, upon miR-22-3p over-expression were repeated for preparing protein lysates for endogenous GCase 
activity measurements. In this case, the GCase activity was measured 48 hours after transfections. 
In all panels, bars represent means +SEM of three independent experiments, each performed at least in 
triplicate. Significance levels of t-tests are shown. *: P<0.05. 
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Supplementary figure 4: GBAP1 is characterized by multiple in-frame and out-of-frame 
splicing isoforms. 
Alternative splicing of the GBAP1 pre-mRNA was analyzed in HepG2 cells, treated with the NMD inhibitor 
cycloheximide, by RT-PCR using primer couples specific for the pseudogene. In the upper part of the figure, 
a schematic representation of the whole gene is presented, with white boxes representing annotated exons, 
lines indicating introns, and broken lines pointing to the major splicing events characterizing the 3’ portion 
of the transcript. Grey boxes indicate the presence of additional exons or extensions of annotated exons. In 
the lower part of the figure, a magnification of the 5’ portion of the gene is reported, with all the identified 
alternative splicing events. Out-of-frame splicings leading to the introduction of a PTC are indicated in all 
cases by a star. The precise mapping of all identified splicing events was confirmed by Sanger sequencing of 
the relevant RT-PCR fragment. 
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Supplementary figure 5: GBA and GBAP1 appear dowregulated in the substantia nigra of 
Parkinson’s disease patients. 
The figure shows box-plots comparing the relative gene expression of GBA/GBAP1 (probe set 209093_s_at, 
hybridizing against both genes; panel A) and GBAP1 (probe set 210589_s_at, specific for GBAP1; panel B) 
in the substantia nigra of Parkinson’s disease patients (case) and healthy controls (control). Both panels 
represent screen shots obtained from the INMEX program (Xia et al., 2013), which rescales all expression 
levels in order to make data immediately comparable at visual inspection. For each box plot, the relevant 
dataset is indicated, together with the number of analyzed individuals. In the case of dataset GSE20292, three 
Parkinson’s disease patients were excluded from the analysis, since they resulted outliers (abnormal low 
levels of both GBA and GBAP1). The meta-analysis P values for the two analyzed probe sets is indicated. 
 
  
 
 
Supplementary table 1: Primers used for cloning, mutagenesis, as well as expression profiling experiments. 
 
Primer Sequence (5’-3’) * Localization ** Application 
GBA_ex9_F 
GBA_ex10_R 
ATTGGGTGCGTAACTTTGTC 
TCCAGGTCGTTCTTCTGACT 
exon 9, chr1:155,205,549-155,205,568 
exon 10, chr1:155,205,040-155,205,059 
real-time RT-PCR assay to evaluate GBA 
expression 
GBAP1_F 
GBAP1_R 
GGACCGACTGGAACCCAT 
TCCAGGTCGTTCTTCTGACTG 
exon 9, chr1:155,184,911-155,184,928 
exon 10, chr1:155,184,413-155,184,433 
real-time RT-PCR assay to evaluate 
GBAP1 expression 
SP1_F 
SP1_R 
AGACAGTGAAGGAAGGGGCT 
GCGTTTCCCACAGTATGACC 
exon 4/5, chr12:53,800,523-53,803,150 
exon 5, chr12:53,803,280-53,803,299 
real-time RT-PCR assay to evaluate SP1 
expression 
SIRT1_F 
SIRT1_R 
TGTTATTGGGTCTTCCCTCAA 
AAATGCAGATGAGGCAAAGG 
exon 7, chr10:69,669,153-69,669,173 
exon 8, chr10:69,672,275-69,672,294 
real-time RT-PCR assay to evaluate SIRT1 
expression 
CELF1_F 
CELF1_R 
GAAGCCAGAAGGAAGGTCCA 
TCCCAAAGGGCATAAACATC 
exon 10/11, chr11:47,494,779-47,496,902 
exon 11, chr11:47,494,697-47,494,716 
real-time RT-PCR assay to evaluate 
CELF1 expression 
HMBS_F 
HMBS_R 
GTTCAGGAGTATTCGGGGAAACC 
TTCCTCAGGGTGCAGGATCTG 
exon 8/9, chr11:118,960,963-118,962,132 
exon 10, chr11:118,962,832-118,962,852 
reference gene for real-time RT-PCR 
assays 
CX32_F 
CX32_R 
GCAGCAGCAGCCAGGTGTGG 
ATACTCGGCCAATGGCAGTA 
exon 1, chrX:70,435,108-70,435,127 
exon 2, chrX:70,443,608-70,443,627 
reference gene for NMD experiments 
CX43_F 
CX43_R 
AAAGTACCAAACAGCAGCGG 
CTCCAGCAGTTGAGTAGGCT 
exon 1, chr6:121,756,846-121,756,865 
exon 2, chr6:121,768,038-121,768,057 
reference gene for NMD experiments 
PRKCA_ex3*_F 
PRKCA_4/5_R 
TCCCCTGTATTGCTAGTCTGC 
CGCAGGTGTCACATTTCATC 
exon 3*, chr17:64,550,643-64,550,663 
exon 4/5, chr17:64,637,571- 64,641,506 
positive control for NMD experiments  
PRKCA_ex3/4F3 
PRKCA_4/5_R 
GGACCCGACACTGATGACC 
CGCAGGTGTCACATTTCATC 
exon3/4 chr17:64,492,387- 64,637,476 
 exon 4/5, chr17:64,637,571- 64,641,506 
negative control for NMD experiments 
miR-22-3p_F1 
Uni_R1 
GCTGCCAGTTGAAGAACT 
CTCAGTCGCATAGCTTGAT 
exon 3, chr17:1,617,210-1,617,227 
real-time RT-PCR assay to evaluate miR-
22-3p expression 
miR-132-3p_F 
Uni_R1 
AGTCTACAGCCATGGTCG 
CTCAGTCGCATAGCTTGAT 
chr17:1,953,223-1,953,240 
real-time RT-PCR assay to evaluate miR-
132-3p expression 
miR-22_KpnI_F 
miR-22_XhoI_R 
AGAGGTACCTTTCCCTTAGGAGCCTGT 
GGCCTCGAGCAGCCCATTTCTGTCACCTT 
chr17:1,617,301-1,617,320 
chr17:1,617,133-1,617,152 
pre-miR-22 molecular cloning 
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miR-132_KpnI_F 
miR-132_XhoI_R 
AGAGGTACCCAGTCCCCGTCCCTCAG 
GGCCTCGAGCACGTGGGATCTTGACTCG 
chr17:1,953,507-1,953,523 
chr17:1,953,123-1,953,141 
pre-miR-132 molecular cloning 
UTR_GBA-GBAP1_SgfI_F 
UTR_GBA-GBAP1_NotI_R 
ACCGGCGATCGCTCACCTGGCTACTCCATTCA 
AAGGAAAAAGCGGCCGCCCACCCAGAATAAAGC
CACT 
exon 11, chr1:155,204,811-155,204,830 
chr1:155,204,214-155,204,233 
GBA and GBAP1 3’UTR molecular 
cloning 
psiUx_F 
psiUx_R 
GATCTTCCCCATCGGTGAT 
CGCTGATCGGAAGTGAGAAT 
psiUx 
psiUx 
recombinant bacterial colony screening 
psiCHECK_2_F 
psiCHECK_2_R 
AGGACGCTCCAGATGAAATG 
AGGACGCTCCAGATGAAATG 
psiCHECK-2 
psiCHECK-2 
recombinant bacterial colony screening 
3’UTR_GBAP1_ΔMRE_F 
3’UTR_GBAP1_ΔMRE_R 
TCCTATGGCACCAGCCAGGAAAAATCTTAAAGGA
GAAAATGTTTGAGCCC 
GGGCTCAAACATTTTCTCCTTTAAGATTTTTCCTG
GCTGGTGCCATAGGA 
 
miR-22 MRE site-directed mutagenesis 
(deletion)  
GBAP1_EX-1_F GGGCTGCTTCTTGACTTCC exon -1, chr1:155,197,281-155,197,299 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX-1/-φ1_F TTCTCTTCGCCGACGGTT exon -1/intron 1, chr1:155,197,168-155,194,848 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_-28-φ1_F TGACAGGGCTTTCCCTATGT intron 1, chr1:155,194,858-155,194,877 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_-φ1_F CTGGGCTCAAAAGATCCTCA intron 1, chr1:155,194,816-155,194,835 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX-1/1_F CTCTTCGCCGACGTGGA exon -1/1, chr1:155,197,168-155,188,730 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX-1/1B_F CTCTTCGCCGACGAGACT exon -1/1, chr1:155,197,168-155,188,711 
RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX-1/1C_F TCTTCGCCGACGTGACC exon -1/1, chr1:155,197,168-155,188,674 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX-1/3_F CTCTTCGCCGACGGTGC exon -1/1, chr1:155,197,168-155,187,837 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX2A_F TCCCAAGCCTTCGGGTAG exon 2, chr1:155,188,248-155,188,265 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX2_F 
TTCGGGTAGGGTAAGCATCA exon 2, chr1:155,188,237-155,188,256 RT-PCR assay to characterize GBAP1 
splicing pattern 
9
9
 
  
 
GBAP1_EX2_R CCACGACACTGCCTGAAGTA exon 2, chr1:155,188,190-155,188,209 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX3_R CCGGTGCAATTAGCCTGTAT exon 3, chr1:155,187,760-155,187,779 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX3/5_F TGCACCGGCACAGGAAT exon 3/5, chr1:155,187,161-155,187,767 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX3/5_R GATGTTATATCCGATTCCTGTGC exon 3/5, chr1:155,187,148-155,187,766 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX4_F TAAGATTTCGCCGCCTATCA exon 4, chr1:155,187,360-155,187,379 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX4_R GAGCCTGAGTCCGTAGCAGT exon 4, chr1:155,187,333-155,187,352 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX5_R ATAGGTGTAGGTGCGGATGG exon 5, chr1:155,187,097-155,187,116 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX7_F TGAGTGGATACCCCTTCCAG exon 7, chr1:155,186,316-155,186,335 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_IVS8A_R GGGAACAGGTGGTGTGTCTC exon 8, chr1:155,185,466-155,185,485 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX8A/8B_R ACCCACACAGGCCTTTAGC exon 8A/8B, chr1:155,185,429-155,185,557 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_F GGACCGACTGGAACCCAT exon 9, chr1:155,184,911-155,184,928 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX9_R ATGTCTACAATGATGGGTTCCAG exon 9, chr1:155,184,899-155,184,921 RT-PCR assay to characterize GBAP1 
splicing pattern 
GBAP1_EX11_R TGAATGGAGTAGCCAGGTGA exon 11, chr1:155,184,184-155,184,203 RT-PCR assay to characterize GBAP1 
splicing pattern 
 
 
* Underlined sequences corresponds to nucleotides added at the primer end to introduce a site for restriction digestion in cloning 
experiments 
** According to UCSC genome browser (http://genome-euro.ucsc.edu/index.html) on Human Feb. 2009 (GRCh37/hg19) Assembly. 
 
 
1
0
0
 
  
Supplementary table 2: MiRNAs predicted as potential targets of GBA and GBAP1. 
 
miRNA 
(chromosomal position)* 
miRNA:GBA pairing** Brain expression*** 
Literature data on 
neurodegenerative diseases 
miR-22-3p 
(chr17:1,617,197-1,617,281) 
3' ugucaagaagUUGACCGUCGAa 5' miR-22 
             || ||||||||  
5' cagccaggaaAAAUGGCAGCUc 3' GBA 
 
Cerebellum (643) 
frontal cortex (219) 
AD: Cheng et al., 2013 
ALS: Parisi et al., 2013 
HD: Jovicic et al., 2013; Lee et 
al., 2011 
PD: Margis et al., 2011 
miR-132 
(chr17:1,953,202-1,953,302) 
3' gcuGGUACCGACAUCUGACAAu 5' miR-132 
      |||   ||| ||||||||  
5' ggcCCAAAACUGGAGACUGUUu 3' GBA 
 
Cerebellum (203) 
frontal cortex (818) 
AD: Smith et al., 2015 
ALS: Freischmidt et al., 2013 
HD: Lee et al., 2011 
PD: Alieva et al., 2015 
miR-212 
(chr17:1,953,565-1,953,674) 
3' ccGGCACUGACCUCUGACAAu 5' miR-212 
     ||   |||||||||||||  
5' gcCCAAAACUGGAGACUGUUu 3' GBA 
 
Cerebellum (22) 
frontal cortex (70) 
AD: Smith et al., 2015 
 
Predictions were performed using microRNA.org, MicroCosm Targets, PITA, as well as the miRWalk2 suite (among the programs implemented in 
miRWalk2, we selected miRWalk2.0, RNA22, miRanda, miRDB, TargetScan, and PICTAR2). In all cases, default parameters were used.). 
* According to UCSC genome browser (http://genome-euro.ucsc.edu/index.html) on Human Feb. 2009 (GRCh37/hg19) Assembly. 
** The RNAhybrid software (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) was used to visualize the miRNA:mRNA interactions. 
*** According to deep-sequencing data available through miRBase (http://www.mirbase.org/); numbers in brackets refers to read counts per million 
of RNA-seq experiments (annotation confidence: high for miR-22 and miR-132; not reported for miR-212). 
ALS: amyotrophic lateral sclerosis; AD: Alzheimer disease; HD: Huntington’s disease; PD: Parkinson’s disease. 
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Supplementary table 3: Characteristics of Parkinson’s disease-related datasets included in the study. 
 
Dataset 
(accession 
number) 
Array type 
PD cases / 
controls 
Origin 
Age at death 
(years ± SD) 
Notes on PD patients  Tissue Reference 
GSE7621 
Affymetrix Human Genome 
U133 Plus 2.0 Array 
16 / 9 Caucasian 
Mean age cases: 77.9 ± 
13.1 
Mean age controls: n.a.  
All PD subjects had advanced 
disease with a mean H&Y 
stage of 4.5 ± 0.7. 
SN tissue from post-
mortem brains 
Lesnick et al., 
2007 
Papapetropoulos 
et al., 2006 
GSE8397 
Affymetrix Human Genome 
U133A Array 
24 / 15 n.a. 
Mean age cases: 80 ± 5.7 
Mean age controls: 70.6 ± 
12.5 
PD patients showed a mean 
disease duration of 13.4 ± 8.3 
SN tissue from post-
mortem brains (NS 
split into medial and 
lateral portions) 
Moran et al., 
2006 
GSE20292 
Affymetrix Human Genome 
U133A Array 
11 / 18 n.a. 
Mean age cases: 76.7  ±  
6.2 
Mean age controls: 71.2  
±  11.1 
- 
SN tissue from post-
mortem brains 
Zhang et al., 2005 
 
Abbreviations: H&Y, Hoehn and Yahr scale; n.a., not available; PD, Parkinson’s disease; SD, standard deviation; SN, substantia nigra. 
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During my PhD, I was also involved in side research projects mainly focused on the molecular 
dissection of mutations responsible for Mendelian disorders (i.e. cystic fibrosis and oculocutaneous 
albinism) and in particular, on the characterization of their effects on RNA metabolism. 
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ORIGINAL ARTICLE
Two novel splicing mutations in the SLC45A2 gene
cause Oculocutaneous Albinism Type IV by unmasking
cryptic splice sites
Letizia Straniero1, Valeria Rimoldi2,3, Giulia Soldà2,3, Lucia Mauri4, Emanuela Manfredini4, Elena Andreucci5,
Sara Bargiacchi6, Silvana Penco4, Giovanni P Gesu4, Alessandra Del Longo7, Elena Piozzi7, Rosanna Asselta2,3
and Paola Primignani4
Oculocutaneous albinism (OCA) is characterized by hypopigmentation of the skin, hair and eye, and by ophthalmologic
abnormalities caused by a deﬁciency in melanin biosynthesis. OCA type IV (OCA4) is one of the four commonly recognized forms
of albinism, and is determined by mutation in the SLC45A2 gene. Here, we investigated the genetic basis of OCA4 in an Italian
child. The mutational screening of the SLC45A2 gene identiﬁed two novel potentially pathogenic splicing mutations: a
synonymous transition (c.888G4A) involving the last nucleotide of exon 3 and a single-nucleotide insertion (c.1156+2dupT)
within the consensus sequence of the donor splice site of intron 5. As computer-assisted analysis for mutant splice-site
prediction was not conclusive, we investigated the effects on pre-mRNA splicing of these two variants by using an in vitro
minigene approach. Production of mutant transcripts in HeLa cells demonstrated that both mutations cause the almost complete
abolishment of the physiologic donor splice site, with the concomitant unmasking of cryptic donor splice sites. To our
knowledge, this work represents the ﬁrst in-depth molecular characterization of splicing defects in a OCA4 patient.
Journal of Human Genetics advance online publication, 28 May 2015; doi:10.1038/jhg.2015.56
INTRODUCTION
Albinism is a heterogeneous group of inherited genetic diseases,
affecting all ethnic backgrounds with an overall prevalence of
approximately 1/17 000 people.1 Oculocutaneous albinism (OCA) is
characterized by a general hypopigmentation of the skin, hair and eye,
and by ophthalmologic abnormalities caused by a deﬁciency in
melanin biosynthesis. Eye and optic system abnormalities include
various degrees of congenital nystagmus, hypopigmentation of iris
leading to iris translucency, reduced pigmentation of the retinal
pigment epithelium, foveal hypoplasia, reduced visual acuity and
refractive errors. Photophobia may be prominent. A characteristic
feature is the misrouting of the optic nerves, consisting in an excessive
crossing of the ﬁbres in the optic chiasma, which can result in
strabismus and reduced stereoscopic vision.2 These clinical signs are
common to all types of albinism and are probably related to melanin
reduction during embryonic development and early postnatal life.3
OCA is an autosomal recessive inherited condition; the four
principal OCA forms (OCA1, OCA2, OCA3 and OCA4) are diagnosed
based on the presence of mutations in the TYR, OCA2, TYRP1 and
SLC45A2 genes, respectively.4–8 Recently, three additional loci involved
in albinism (OCA5–7) have been identiﬁed. In particular, a novel
OCA locus on chromosome 4q24 was found by linkage analysis in a
large consanguineous Pakistani pedigree, but the causal gene (termed
OCA5) has not been identiﬁed yet.9 Conversely, two genes involved in
melanosome maturation and melanocyte differentiation, namely
SLC24A5 and C10orf11,10–12 were identiﬁed as responsible for OCA6
and OCA7.13 However, few data about these recently described OCA
forms are currently available. In addition, an X-linked form of ocular
albinism (OA1), in which the phenotype is mainly restricted to eyes
and optic system, is associated with mutations in the GPR143 gene.14
OCA4 (OMIM *606202, #606574) is worldwide distributed with a
prevalence of 1:100 000 in most populations,7,15–19 but in Japan, it is
the most common form, accounting for about 24% of OCA cases.20
The causative gene is SLC45A2 (solute carrier family 45, member 2;
also known as MATP gene), located on chromosome 5p13.3 and
coding for a membrane-associated transporter protein.7 MATP is
thought to be important for the proper processing and trafﬁcking of
melanosomal proteins Tyr, Tyrp1, Dct (Tyrp2), and seems to act as a
proton-dependent transporter at the melanosomal membrane, show-
ing a possible relationship with the P protein (OCA2).21,22 Moreover,
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recent data based on experiments of heterologous expression of MATP
in Saccharomyces cerevisiae suggested that it also acts as a sucrose
transporter.23
OCA4 clinical phenotype is characterized by a high degree of
heterogeneity, ranging from profound hypopigmentation (similar to
OCA1A) to near normal skin colour. Indeed, some individuals
accumulate pigmentation with age, whereas others remain completely
hypopigmented throughout their life.13,20,24 To date, more than 80
mutations have been identiﬁed in the SLC45A2 gene.25
In this study, we report the identiﬁcation of two hitherto-unknown
splice defects underlying OCA4 in one Italian proband. The functional
consequences of both mutations were elucidated by in vitro expression
experiments.
PATIENTS AND METHODS
Patient
The patient was initially recruited by the Genetic Unit and Ophthalmology
Center of A.O.U. Meyer of Florence, Italy. Subsequently, the patient with his
parents, came to Niguarda Ca’ Granda Hospital to undergo a multidisciplinary
diagnostic workup including ophthalmological, dermatological, ENT (ear, nose
and throat) evaluation and genetic counselling.
This study was conducted according to the Declaration of Helsinki and to the
Italian legislation on sensible data recording. A signed informed consent for the
genetic analysis was obtained from the proband’s parents.
Ophthalmologic evaluation
The patient underwent full ophthalmological and instrumental evaluations,
including motor and sensory status, visual acuity, cycloplegic refraction, iris
transillumination with slitlamp biomicroscope and macular translucency with
indirect ophthalmoscope. The visual acuity assessment for distance and near
was evaluated in monocular and binocular vision with appropriate tests
(Pigassou ﬁgures, E test and Snellen charts).
The following instrumental examinations were performed: optical coherence
tomography, visual evoked potential and electroretinogram. Spectral Domain
OCT (Heildelberg, Germany) was used to evaluate the macular morphological
characteristics, with particular reference to the presence/absence of foveal
depression. Electrophysiological tests (Retimax, CSO, Scandicci, Italy) were
performed to evaluate the optic nerve ﬁber decussation.
Genetic analysis
DNA was extracted from peripheral blood according to standard protocols.
The entire coding region, as well as the adjacent intronic sequences of TYR
(NM_000372.4), OCA2 (NM_000275.2) and SLC45A2 (NM_016180.3) genes
were PCR ampliﬁed from genomic DNA following standard ampliﬁcation
protocols. Ampliﬁed products were sequenced on both strands (primer
sequences and experimental conditions available on request). Sequencing
analysis was performed on an ABI Prism 3730 genetic analyzer (Life
Technologies Corporation, Carlsbad, CA, USA) and the SeqScape software
(Life Technologies Corporation) was used for mutation detection.
To screen for the presence of TYR and OCA2 exons rearrangements
(deletion/duplication), the MLPA (Multiplex Ligation-dependent Probe Ampli-
ﬁcation) kit SALSA P325 (MRC-Holland, Amsterdam, the Netherlands) was
used following the manufacturer’s instructions. The individual peak corre-
sponding to each exon was identiﬁed based on the difference in migration
relative to the size standards 500 LIZ™ (Life Technologies Corporation). The
peak area of each fragment was compared with that of three control samples.
Raw data were analyzed using the Coffalyser software v.9 (MRC-Holland,
Amsterdam, the Netherlands). Each positive result was conﬁrmed by two
independent experiments and on two different DNA extractions.
In vitro analysis of splicing mutations
Computer-assisted analysis for splice-site prediction was accomplished using
the NNSPLICE 0.9 (http://www.fruitﬂy.org/seq_tools/splice.html) and the
Human Splicing Finder (HSF, http://www.umd.be/HSF/) programs.
For the functional characterization of the two newly identiﬁed mutations in
SLC45A2, the relevant genomic DNA region was cloned in the hybrid alpha-
globin-ﬁbronectin minigene plasmid (pBS-KS_modiﬁed), in which the alter-
natively spliced extra-domain-B exon of ﬁbronectin was removed to generate a
site for the insertion of the exon under study.26 In particular, for the analysis of
the c.888G4A substitution, a 746-bp fragment of SLC45A2 (introns 2 to 4) was
PCR ampliﬁed from the patient’s genomic DNA using the following primers:
OCA4_ex3_NdeI_F 5′-ggaattccatatgAGCCCAAGATCACAGCAAGT-3′ and
OCA4_ex3_NdeI_R 5′-ggaattccatatgGGACCAGAGGAAAATGCAGA-3′ and
cloned into the pBS-KS_modiﬁed vector (lowercase letters indicate nucleotides
added to the primers to introduce the NdeI restriction site).
Concerning the c.1156+2dupT variant, a 572-bp region of SLC45A2
(including exon 5 with its ﬂanking intronic sequences) was PCR ampliﬁed
using the following primer pair OCA4_ex5_NdeI_F 5′-ggaattccatatgGAGAT
CTGATGCAGCAAGCA-3′ and OCA4_ex5_NdeI_R 5′-ggaattccatatgGGAACC
CACTGATTCCAAGA-3′, and cloned into the pBS-KS_modiﬁed vector.
The obtained wild-type (pBS-KS-OCA4_ex3_wt and pBS-KS-
OCA4_ex5_wt) and mutant (pBS-KS-OCA4_ex3_mut and pBS-KS-
OCA4_ex5_mut) plasmids were isolated by the PureYield Plasmid Miniprep
System (Promega, Madison, WI, USA). The correct orientation of the two
inserts, as well as the presence/absence of either the c.888G4A or the c.1156
+2dupT variant, were veriﬁed by direct DNA sequencing.
Recombinant plasmids were used for splicing assays, by transiently transfect-
ing 4 μg of each minigene construct in HeLa cells (cultured according standard
procedures). In each experiment, an equal number of cells (2.5× 105) were
transfected with the jetPRIME reagent (Euroclone, Wetherby, UK) in 6-well
plates, as described by the manufacturer. Total RNA was isolated from the cells
24 h after transfection, using the Eurozol kit (Euroclone). Random hexamers
and the ImProm-II Reverse Transcriptase (Promega) were used to perform
ﬁrst-strand cDNA synthesis starting from 500 ng of total RNA, according to the
manufacturer's instructions. Of a total of 20 μl of the reverse-transcription (RT)
reaction, 1 μl was used as template for ampliﬁcations, using primers annealing
to the ﬂanking α-globin/FN1 exonic sequences (α2-3 and Bra2 primers, see
Figure 1a). RT-PCRs were performed under standard conditions using the
GoTaq DNA Polymerase (Promega) on a Mastercycler EPgradient (Eppendorf,
Hamburg, Germany).
Quantitation of splicing isoforms by ﬂuorescent RT-PCR
To obtain a relative quantitation of the different isoforms generated by
minigene assays, competitive ﬂuorescent RT-PCRs were performed on RNA
from transfected cells. To this aim, the same oligonucleotide pair adopted for
splicing assays was used, with the reverse Bra2 primer labelled with the 6-FAM
ﬂuorophore. Ampliﬁed fragments were separated by capillary electrophoresis
on an ABI-3130XL Genetic Analyzer (Life Technologies Corporation) and
quantitated by the GeneMapper v4.0 software (Life Technologies Corporation).
The sum of all ﬂuorescence peak areas in a single run was set equal to 100%,
and the relative quantity of each transcript expressed as a fraction of the total.
RESULTS
Clinical features of the patient
The proband is a 3-year-old male of Italian origin. He has blonde
platinum hair, pale skin and pale grey-blue iris. At 13 months, he had
normal pupillary responses, horizontal nystagmus, astigmatism, no
strabismus, iris transillumination (II-III grade of the Summers scale),
foveal hypoplasia and albinotic fundus. Visual acuity could not be
determined for low collaboration. No other apparent malformation
was found at physical examination.
No consanguineous marriage was claimed by the parents.
The mutational screening of the proband revealed two novel
putative splicing mutations in SLC45A2
The molecular screening of the patient was performed ﬁrst by
analyzing TYR and OCA2 genes, which represent the most
frequently mutated OCA genes in the Italian population.27 Neither
sequencing nor MLPA analysis of both genes revealed any point
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mutation or exon rearrangement. Subsequently, we analyzed the
SLC45A2 gene and identiﬁed two novel putative pathogenic variants.
The ﬁrst one, a c.888G4A transition, is a synonymous change (p.
Q296Q) that involves the last nucleotide of exon 3, suggesting that it
might affect splicing. The second one, a c.1156+2dupT, is a single-
nucleotide insertion within the consensus sequence of the donor splice
site of intron 5 (IVS5+2dupT). The proband’s father was heterozygous
for the c.888G4A variant, while the mother was heterozygous for the
c.1156+2dupT insertion.
These two newly identiﬁed variants were absent in the cohort
of 6503 European American and African American individuals,
whose exome data are freely available through the Exome Variant
Server.28
In vitro characterization of the two novel variants demonstrate their
effect on splicing
The in silico analysis for the c.888G4A transition was performed by
two different computer-assisted software for splice-site prediction:
HSF detected the wild-type donor splice-site of exon 3 with a score of
85.90 and the mutated one with a score of 75.32. The NNSPLICE 0.9
software detected the wild-type donor splice-site with a score of 0.94,
whereas, in the mutant sequence, it was no longer identiﬁed.
Given the unavailability of a suitable biological specimen to extract
RNA, exon 3 of the SLC45A2 gene with the surrounding intronic
sequences was cloned, either in the wild-type or in the mutant version,
into a pBS-KS_modiﬁed hybrid minigene vector (Figure 1a).
The obtained constructs (pBS-KS-OCA4_ex3_wt and pBS-KS-
OCA4_ex3_mut) were transiently transfected into HeLa cells and
SLC45A2 splicing products were analyzed by RT-PCR. All ampliﬁed
fragments were then subjected to direct sequencing to characterize the
aberrant splicing events. Indeed, transfection with the mutant vector
gave rise to multiple aberrant products (Figure 1b). One PCR product
was larger than the expected wild-type one (1222 vs 569 bp).
In addition, four amplicons shorter than the wild type (329, 315,
243, and 179 bp long) were detected: (i) the ﬁrst two caused by the
retention of a shorter exon 3 because of the activation of two
cryptic exonic donor splice sites, 86 and 72 bp downstream of
the wild-type splice acceptor site, respectively; (ii) the third
corresponded to the complete skipping of exon 3; and (iii) the last
one resulted from the skipping of a part of ﬁbronectin exon 24
Figure 1 In vitro analysis of the effect of the c.888G4A (p.Q296Q) mutation on SLC45A2 pre-mRNA splicing. (a) Schematic representation of the hybrid
pBS-KS-OCA4_ex3 minigene: α-globin and ﬁbronectin (FN1) exons are represented by gray boxes, whereas introns are represented by lines (not to scale). The
SLC45A2 exon 3 cloned, with its ﬂanking intronic regions, into the NdeI site of the pBS-KS_modiﬁed vector is reported as a black box. The c.888G4A
mutation, affecting the last nucleotide of exon 3, is indicated by a star. Primers used in RT-PCR experiments are indicated by arrows in correspondence of
their position below the scheme of the minigene construct. (b) Left panel: RT-PCR products, obtained from RNA of HeLa cells transfected with the wild-type
(wt) or the mutant (mut) minigene construct, separated on a 2% agarose gel, are shown. M: molecular weight marker (pUC9-HaeIII). Middle panel: the
GeneMapper window shows ﬂuorescence peaks corresponding to the molecular species ampliﬁed by RT-PCR. Red peaks represent the size standard
(ROX-500 HD); blue peaks (shaded in gray) correspond to the RT-PCR-labeled products, whose abundance is reported on the right of the panel (%). The
x axis indicates ﬂuorescence units. Right panel: schematic representation of the obtained RT-PCR products (veriﬁed by Sanger sequencing). The length of
each fragment is indicated.
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together with the entire SLC45A2 exon 3, due to the activation of an
exonic cryptic donor splice site (Figure 1b). While the skipping of the
entire exon 3 or the inclusion of a shorter 72-bp-long exon 3 are
predicted to cause a frameshift (leading to the introduction of a
premature stop codon after 56 or 80 amino acids, respectively), the
insertion of a 86-bp-long exon 3 is expected to determine the in-frame
deletion of 80 amino acids. The relative quantitation by competitive
ﬂuorescent RT-PCR of all splicing isoforms generated by the minigene
assay evidenced the presence of a residual amount (about 3%) of the
wild-type transcript (Figure 1b).
The effect of the putative splicing mutation c.1156+2dupT was
analyzed with the same approach. Computer-assisted splice-site analysis
using HSF predicted a score reduction of the donor splice site (from
84.38 to 65.26) in the presence of the duplication. Moreover, a stronger
cryptic donor splice site (located 72 bp downstream of the physiologic
acceptor splice site of exon 5) was predicted. Instead, NNSPLICE 0.9
predicted the complete abolishment of the mutant donor splice-site
compared with the wild type (whose score was 0.99).
Subsequently, appropriate minigene constructs were generated
by cloning the relevant PCR-ampliﬁed genomic fragment (from
intron 4 to 5) either in the wild-type or in the mutant version.
Transfection with the mutant vector gave rise to a single splicing
product, shorter than the expected wild-type one (315 vs 367 bp).
Direct DNA sequencing conﬁrmed that this aberrant product is due to
the activation of the exonic cryptic donor splice site identiﬁed by the
HSF in silico analysis. This aberrant splicing event would result in a
frameshift followed by the introduction of a premature stop at codon
380 of the mutant protein, preceded by an abnormal sequence of 11
amino acids (p.V369Tfs*12) (Figure 2).
DISCUSSION
In this study, we analyzed the genetic defects underlying OCA4 in an
Italian albino patient in whom we identiﬁed two novel splicing
mutations, one of which is a synonymous transition (c.888G4A,
p.Q269Q) involving the last nucleotide of exon 3 while the second one
(c.1156+2dupT) lies in the consensus sequence of the donor splice site
of SLC45A2 intron 5 (IVS5+2dupT).
We applied both in silico prediction and in vitro functional
validation to experimentally verify the possible effect of the newly
identiﬁed mutations on SLC45A2 pre-mRNA splicing. For both
mutations, computer-assisted splice-site prediction analysis recognized
a signiﬁcant difference between the wild-type and the mutant
sequences, suggesting that they might impact SLC45A2 splicing. These
predictions were tested by a well-validated in vitro hybrid minigene
approach,26,29,30 which we have recently applied to the study of two
novel splicing mutations in the OCA2 gene.31
Functional analysis demonstrated that both mutations inactivate the
relevant physiologic donor splice site and, at the same time, may lead
to the activation of cryptic sites. In particular, the c.888G4A mutation
seems to induce multiple aberrant splicing events, ranging from intron
retention, complete exon skipping and activation of cryptic donor
splice sites. Noteworthy, this is the second exonic splicing mutation
identiﬁed and characterized in a OCA gene. Instead, the main
functional consequence of the c.1156+2dupT mutation on SLC45A2
splicing is the unmasking of a cryptic exonic donor splice site, leading
to the inclusion of a shorter out-of-frame exon 5. Although the in vitro
characterization of splicing mutations might not completely mirror/
recapitulate the actual splicing events occurring in vivo, it certainly
provides a strong support to the pathogenic role of the identiﬁed
variants. Indeed, minigene experiments have clearly evidenced a nearly
complete loss of the wild-type transcript determined by the presence
of either mutation (Figures 1 and 2). At the same time, most of the
aberrant isoforms that might be produced in vivo as a consequence of
the two identiﬁed mutations are predicted to cause the introduction of
a premature termination codon, which might cause the transcript to
be recognized and degraded by the nonsense-mediated mRNA decay
mechanism.32
The activation of multiple cryptic splice sites within exon 3 observed
in minigene studies prompted us to investigate the recognition of this
exon in physiologic conditions. Interestingly, three SLC45A2 mRNA
isoforms skipping exon 3 are annotated in GenBank (accession
numbers: BC003597 deriving from melanoma; CU678525 and
CU678524 deriving from the ORFeome project) (Supplementary
Figure 1), suggesting that these splicing events could also occur
in vivo. In addition, in silico prediction with the HSF algorithm
identiﬁes a cryptic donor splice site within exon 3 having a score
(80.73) comparable to that of the physiologic one (85.9). The use of
this cryptic splice site would lead to the inclusion of a 86-bp-long in-
Figure 2 In vitro analysis of the effect of the c.1156+2dupT mutation on SLC45A2 pre-mRNA splicing. (a) Schematic representation of the hybrid pBS-KS-
OCA4_ex5 minigene: α-globin and ﬁbronectin (FN1) exons are represented by gray boxes, whereas introns are represented by lines (not to scale). The
SLC45A2 exon 5 cloned, with its ﬂanking intronic regions, into the NdeI site of the pBS-KS_modiﬁed vector is reported as a black box. The c.1156+2dupT
insertion, affecting the donor splice site of exon 5, is indicated by a star. Primers used in RT-PCR experiments are indicated by arrows in correspondence of
their position below the scheme of the minigene construct. (b) Left panel: RT-PCR products, obtained from RNA of HeLa cells transfected with the wild-type
(wt) or the mutant (mut) minigene construct, separated on a 2% agarose gel, are shown. M: molecular weight marker (pUC9-HaeIII). Right panel: schematic
representation of the obtained RT-PCR products (veriﬁed by Sanger sequencing). The length of each fragment is indicated.
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frame exon 3, corresponding to one of the aberrant isoforms detected
in our minigene experiments (Figure 1b and Supplementary Figure 1),
again suggesting its possible occurrence in vivo in physiologic
conditions. Therefore, we attempted to characterize the splicing
events involving exon 3 by RT-PCR assays performed on RNA
extracted from hair follicles of a non-albino control. These
experiments allowed the identiﬁcation, beside the wild-type transcript,
of an additional SLC45A2 isoform. Sequencing revealed that
such aberrant product corresponds to the inclusion of the
86-bp-long in-frame exon 3 (Supplementary Figure 1), conﬁrming
that the predicted cryptic donor splice site can be recognized even in
the absence of the c.888G4A mutation. We cannot exclude that
the skipping of the whole exon 3 could also occur physiologically,
although its detection can be hampered by the concomitant effect of
nonsense-mediated mRNA decay on this out-of-frame isoform.
Indeed, evidence supporting nonsense-mediated mRNA decay as a
mechanism controlling SLC45A2 mRNA levels comes also from
studies on the orthologous gene in birds.33 Taken together, these
observations seem to suggest that exon 3 might be ‘leaky’ in
recognition during mRNA splicing process.
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Whole-gene CFTR sequencing combined with digital
RT-PCR improves genetic diagnosis of cystic ﬁbrosis
Letizia Straniero1,7, Giulia Soldà2,3,7, Lucy Costantino4, Manuela Seia4, Paola Melotti5, Carla Colombo6,
Rosanna Asselta2,3 and Stefano Duga2,3
Despite extensive screening, 1–5% of cystic ﬁbrosis (CF) patients lack a deﬁnite molecular diagnosis. Next-generation
sequencing (NGS) is making affordable genetic testing based on the identiﬁcation of variants in extended genomic regions. In
this frame, we analyzed 23 CF patients and one carrier by whole-gene CFTR resequencing: 4 were previously characterized and
served as controls; 17 were cases lacking a complete diagnosis after a full conventional CFTR screening; 3 were consecutive
subjects referring to our centers, not previously submitted to any screening. We also included in the custom NGS design the
coding portions of the SCNN1A, SCNN1B and SCNN1G genes, encoding the subunits of the sodium channel ENaC, which were
found to be mutated in CF-like patients. Besides 2 novel SCNN1B missense mutations, we identiﬁed 22 previously-known CFTR
mutations, including 2 large deletions (whose breakpoints were precisely mapped), and novel deep-intronic variants, whose role
on splicing was excluded by ex-vivo analyses. Finally, for 2 patients, compound heterozygotes for a CFTR mutation and the
intron-9c.1210-34TG[11–12]T5 allele—known to be associated with decreased CFTR mRNA levels—the molecular diagnosis was
implemented by measuring the residual level of wild-type transcript by digital reverse transcription polymerase chain reaction
performed on RNA extracted from nasal brushing.
Journal of Human Genetics advance online publication, 4 August 2016; doi:10.1038/jhg.2016.101
INTRODUCTION
Cystic ﬁbrosis (CF; OMIM#219700) is one of the most common
autosomal recessive disorders with a median incidence in Europe of 1
in 3500.1 The classical symptoms include chronic obstructive pul-
monary disease, exocrine pancreatic insufﬁciency, and elevation of
sodium and chloride concentrations in the sweat.2 Moreover, most CF
males present with infertility as a result of congenital bilateral absence
of the vas deferens.3 CF is caused by mutations in the CF
transmembrane conductance regulator (CFTR; OMIM*602421)
gene.4,5 It encodes a protein that functions as a Cyclic adenosine
monophosphate-activated chloride channel at the apical membrane of
epithelial cells.6 To date, over 1600 mutations have been described in
the CFTR gene (http://www.genet.sickkids.on.ca/cftr, accessed 22
January, 2016, excluding sequence variations that are possibly poly-
morphisms and variants with an unknown functional meaning).
About 14% of them are classiﬁed as splicing defects, but for ~ 40%
of these, the speciﬁc effect on pre-mRNA splicing is unknown.7
Despite extensive genetic screening, 1–5% of CF patients lack a
deﬁnite molecular diagnosis, even after the sequencing of all exons and
splice junctions.8
The genotype–phenotype relation in CF is very complex: some
phenotypic features are mainly shaped by the CFTR genotype, whereas
others are strongly inﬂuenced by modifying genetic and environmental
factors. A prototypic example is the phenotypic variability associated
with the (TG)m(T)n polymorphic locus at the 3′ end of CFTR intron
9 (formerly known as intron 8). This polymorphism determines the
efﬁciency of exon-10 splicing, with alleles bearing less T repeats and
more TG repeats associated with a lower rate of exon-10 inclusion.9–11
The exon-10 skipped CFTR transcript encodes a misfolded and
nonfunctional protein,12 whose expression, in combination with a
CF-causing mutation in trans, may be associated with monosympto-
matic forms of CF, like congenital bilateral absence of the vas deferens
or chronic airway diseases.13 The T5 allele is also known to modify the
expressivity of the p.Arg117His mutation when in cis.14
To further complicate the CF genotype-phenotype picture, it has
been suggested that mutations in genes coding for the multi-subunit
amiloride-sensitive sodium channel ENaC (SCNN1A, SCNN1B and
SCNN1G) could cause a CF-like phenotype.15 These genes are
expressed primarily on the apical membrane of the epithelial cells of
kidney, lung and colon. Importantly, in the airways, the ENaC channel
activity is inhibited by CFTR. Accordingly, in CF, the ENaC activity is
elevated, thus resulting in a marked increase in sodium intake into
epithelial cells.16 The hypothesis is that an altered ENaC function,
caused by mutations in one of these 3 genes, can ultimately mimic
and/or contribute to the CF phenotype.15
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In recent years, the introduction of massively parallel next-
generation sequencing (NGS) has allowed the simultaneous analysis
of hundred thousand DNA fragments and thus dramatically changed
our approach to the genetic analysis of inherited diseases.17 The major
advantage offered by NGS is the ability to produce an enormous
volume of data in a time- and cost-efﬁcient way. This, combined with
the possibility to multiplex both the capture of target genomic regions
and the sequencing, allows the simultaneous analysis of single genes or
panel of selected genes in a large number of patients at unprecedent-
edly possible speed and costs. At present, commercial kits for
amplicon resequencing of CFTR exons and NGS are available from
different companies or have been in-house developed by research
groups.18 Target capture and sequencing protocols have also been
developed to screen the whole CFTR 190-kb-long genomic region.
However, to our knowledge, whole-gene sequencing was applied only
as a proof-of-principle approach, to search for mutations in an already
characterized cohort of CF patients.19
Here, we developed a whole-gene NGS protocol from one side to
assess the efﬁcacy/sensitivity of targeted resequencing and from the
other to test the method for molecular screening of CF in a panel of
Italian patients with either incomplete or no genetic diagnosis. In 2
cases, absolute mRNA molecule count by digital reverse-transcription
(RT) PCR assays was used to precisely quantify the residual level of the
CFTR wild-type transcript, hence completing the molecular diagnosis.
MATERIALS AND METHODS
This study was approved by local Ethical Committees and was performed
according to the Declaration of Helsinki and to the Italian legislation on
sensible data recording. Signed informed consent was obtained from all
participants and from parents of subjects younger than 18 years.
NGS experiments and data analysis
NGS libraries were prepared starting from 1 μg of genomic DNA from each
patient, using a Nimblegen SeqCap EZ Library custom design capture kit
(Roche/Nimblegen, Madison, WI, USA). Equal amounts of 6 samples were
pooled prior to capture. Libraries were sequenced as 75-bp paired-end reads on
an HiSeq2000 (Illumina, San Diego, CA, USA), according to the manufacturer’s
protocols. Details on DNA extraction, target capture, library preparation,
quality check and sequencing are reported in Supplementary Materials.
Pre-capture pooling, target-enrichment, as well as NGS were performed
through an external service provider (Yale Genome Center; Yale
University, USA).
Data were analyzed between November 2012 and March 2013 using an in-
house developed pipeline (Supplementary Materials). Considering that indel
and structural variant (SV) calling still represent a tricky step, all data were
reanalyzed with the GeneSpring NGS software (Agilent Technologies, Palo Alto,
CA, USA), implementing algorithms speciﬁcally developed for the identiﬁcation
of indels and SV (that is, 'SNP detection' and 'SV detection' options).
Ex-vivo splicing assays of selected deep-intronic variants
To generate hybrid minigene constructs, diverse CFTR regions were PCR
ampliﬁed from the genomic DNA of patients and cloned into the α-globin-
ﬁbronectin hybrid plasmid (modiﬁed pBS-KS),20 as previously described.21
Splicing assays were performed by transiently transfecting 4 μg of each of the 8
recombinant vectors into HeLa cells (cultured according to standard proce-
dures). In each experiment, an equal number of cells (2.5× 105) were
transfected with the FuGENE 6 reagent (Roche) in 6-well plates, as described
by the manufacturer. Total RNA was isolated from cells 24 h after transfection,
using the Eurozol kit (Euroclone, Wetherby, UK). Reverse transcription
polymerase chain reactions (RT-PCRs) were carried out with primers mapping
in the ﬂanking ﬁbronectin exonic regions of the plasmid. All primer sequences
are available on request.
Absolute quantiﬁcation of CFTR transcripts
RNA from nasal brushing was obtained from 2 CF patients and 9 healthy
controls, and reverse transcribed as described in Supplementary Materials.
The level of wild-type CFTR transcripts was evaluated by digital RT-PCR.
Reaction mixtures were prepared by combining 1 μl of cDNA with the
QuantStudio 3D Digital PCR Master Mix and a custom TaqMan assay
(Sigma-Aldrich, Milan, Italy), designed to amplify CFTR transcripts spanning
exons 10-11. For the normalization step, a second TaqMan assay was designed
to co-amplify, in the same tube, the hydroxymethylbilane synthase (HMBS)
mRNA. The sequences of primers and probes used in digital RT-PCR assays are
listed in Supplementary Table 1.
Digital RT-PCRs were performed on a QuantStudio 3D Digital PCR System
(Thermo Fisher Scientiﬁc, Wilmington, DE, USA). Each reaction mixture was
loaded onto a QuantStudio 3D Digital PCR Chip, which contains 20 000 wells,
and cycled under standard conditions for 40 cycles. End-point ﬂuorescence data
were collected and analyzed using the QuantStudio 3D Digital PCR Instrument
and the QuantStudio 3D AnalysisSuite according to the manufacturer’s
instructions. The precision of all copy counts showed with a standard error
of lower than 5%.
RESULTS
Patients
Among individuals referred to the Cystic Fibrosis Centers of Milan
and Verona in the last 5 years, 23 CF patients and one CF carrier
(named CF-1 to CF-24, all of Caucasian origin) were selected for being
submitted to NGS of the entire CFTR gene as well as of the coding
regions and exon/intron boundaries of the SCNN1A, SCNN1B and
SCNN1G genes (Supplementary Table 2).
Among selected patients, 17 had an incomplete genetic diagnosis,
even after screening by conventional copy-number analysis and Sanger
sequencing. In particular, for 5 of them, no mutations were identiﬁed,
whereas 12 were heterozygous for only one genetic defect (2 were
carrier of the F508del mutation). Finally, 3 patients (CF-22, 23 and 24)
were not subjected to any previous molecular screening. In all cases,
the inclusion criterion for entering the study was the availability of the
DNA from both parents.
As controls, we selected 3 patients (CF-15, 17 and 18) showing a
complete genetic diagnosis (all compound heterozygous for substitu-
tions/small deletions), and one heterozygous carrier of a large deletion
(CF-12) (Supplementary Table 3).
NGS sequencing statistics
For NGS analysis, we chose a custom-designed target-enrichment
strategy based on the Nimblegen SeqCap EZ Library capture kit.
Probes were designed on the basis of the genomic coordinates of the
entire 189-kb-long CFTR gene (human genome release GRCh37/hg19,
chr7:117,120,017-117,308,718), and of all exons and splicing junctions
of the ENaC genes (SCNN1A, mapping on chr12p13.31, and SCNN1B
and SCNN1G both located on chr16p12.2). Altogether, the target
regions accounted for a total of 207 508 bp.
A pilot group of DNAs was analyzed by performing the enrichment
step multiplexing six samples, and the sequencing step in a single
HiSeq2000 lane. The overall coverage of the target region was498%,
with only about 3 kb of CFTR intronic repetitive sequences left
uncovered, and a mean coverage of ~ 3500× (in all cases the coverage
was 42600× ) (Supplementary Table 4). As the coverage was
extremely high, we scaled up the number of pooled samples in the
subsequent experiments: multiplexing 6 samples in the capture phase
and 18 in the sequencing step, we obtained a mean depth 41150×
(in all cases the coverage was4800× ), again with a 98% coverage of
the target region (Supplementary Table 4). Unfortunately, one patient
(CF-20) failed the sequencing step.
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On average, each subject resulted carrier of 162 genetic variants, 24 of
which having a minor allele frequencyo1% in the general population.
Identiﬁcation of genetic variants in CFTR
Variants were annotated by ﬁltering them against an in-house
developed database and classiﬁed in one of the following categories:
(1) already known pathogenic mutations (retrieved from: the Cystic
Fibrosis Mutation Database, http://www.genet.sickkids.on.ca/app, the
Human Gene Mutation Database, HGMD, http://www.hgmd.cf.ac.uk/
ac/index.php, and from the CF Centre of Milan database); (2)
potentially pathogenic variants included in dbSNP135; (3) common
(minor allele frequency, MAF41%), likely not pathogenic, variants
annotated in dbSNP135; (4) rare single nucleotide variations (SNVs)
of unknown functional relevance; (5) novel variants. Variants anno-
tated in group 1 were considered of immediate diagnostic relevance,
whereas variations included in groups 2, 4 and 5 were selected for
Sanger sequencing validation. Probably due to the obtained high
coverage, all variants were conﬁrmed (100% concordance rate).
Our pipeline allowed the identiﬁcation of all pathogenic variants
already detected by routine screening (18 alleles for a total of 13
different mutations), including the 21-kb deletion in the CF-12
control individual. In addition, we identiﬁed: (i) 3 point mutations
that were already reported in the literature to be clinically associated
with CF but were not identiﬁed by Sanger sequencing (CF-4, 10 and
11); (ii) one large deletion (CF-16, see further); (iii) 5 known
mutations in the newly-screened CF patients (CF-22, 23 and 24);
and (iv) 22 novel deep-intronic variants of unknown signiﬁcance
(Table 1; Supplementary Table 5). Finally, the poly-thymidine-guanine
and poly-thymidine c.1210–34TG[11–13]T[5–9] tracts were also
inspected. To this aim, the variant caller GeneSpring SNP detection
was used, and it correctly assigned different alleles to all individuals (as
subsequently veriﬁed by Sanger sequencing). In particular, we found 2
patients carrying the T5 pathogenic variant, thus possibly completing
the diagnosis for both of them (see further; Table 1).
Overall, for 6 of the 11 patients with incomplete genetic diagnosis
successfully analyzed, NGS allowed the detection of the second
causative allele, corresponding to a diagnostic yield of 54.6%.
Conversely, no clearly pathogenic mutation was found in the ﬁve
patients negative for CFTR mutations after previous screenings.
Characterization of CFTR large deletions
Using the speciﬁc algorithm 'SV detection' implemented in the
GeneSpring software, we were able to identify 2 large deletions, both
present in the heterozygous state (Table 1).
Table 1 List of mutations identiﬁed by NGS in the CFTR gene
Patient cDNA positiona Proteinb No. of missing CFTR mutations Detectionc TG[11–13]T[5–9] genotype
CF-1 c.220C4T/c.3808G4Ad A74W/D1270N 1 Conﬁrmed TG11T7-TG11T7
CF-2 c.1585-1G4A / 0 Conﬁrmed TG10T7-TG11T5
CF-3 — — 2 — TG11T7-TG11T7
CF-4 c.1650delA G551VfsX18 0 This study TG11T7-TG10T7
c.1585-1G4A / Conﬁrmed
CF-5 c.2657+5G4A / 0 Conﬁrmed TG10T7-TG12T5
CF-6 c.266A4G Y89C 1 Conﬁrmed TG11T7-TG10T7
CF-7 — — 2 — TG11T7-TG10T7
CF-8 c.1521_1523delCTT F508del 1 Conﬁrmed TG10T9-TG10T9
CF-9 c.1521_1523delCTT F508del 1 Conﬁrmed TG10T9-TG11T7
CF-10 c.2657+5G4A / 0 Conﬁrmed TG11T7-TG10T7
c.1210-2A4C / This study
CF-11 c.1040G4C R347P 0 Conﬁrmed TG11T7-TG11T7
c.4250delA E1417EfsX15 This study
CF-12 ex2-3del (21 kb) / 0 Conﬁrmed TG11T7-TG11T7
CF-13 — — 2 — TG10T9-TG11T7
CF-14 — — 2 — TG11T7-TG10T7
CF-15 c.182T4C L61P 0 Conﬁrmed TG11T7-TG10T7
c.1002-1110_1113delTAAG / Conﬁrmed
CF-16 c.1013C4T T338I 0 Conﬁrmed TG11T7-TG10T7
ex25-27del (9.4 kb) / This study
CF-17 c.1624G4T G542X 0 Conﬁrmed TG10T9- TG10T7
c.1002-1110_1113delTAAG / Conﬁrmed
CF-18 c.1624G4T G542X 0 Conﬁrmed TG10T9- TG11T7
c.349C4T R117C Conﬁrmed
CF-19 — — 2 — TG11T7-TG10T7
CF-21 c.1495C4G P499A 1 Conﬁrmed TG11T7-TG10T7
CF-22 c.1521_1523delCTT F508del 1 This study TG10T9- TG10T9
CF-23 c.1624G4T G542X 0 This study TG10T9-TG10T7
c.1002-1110_1113delTAAG / This study
CF-24 c.14C4T P5L 0 This study TG10T9-TG11T7
c.3909C4G N1303K This study
The TG11/12T5 alleles are bolded. /, For splicing mutations, deep intronic mutations and large deletions, the effect at the protein level was not indicated.
aNucleotide position is according to the NM_000492.3 sequence, starting from the ﬁrst nucleotide of the translation start codon.
bWhen possible, mutations are named after their predicted effect at the protein level (according to the sequence deposited in GenBank under accession number NP_000483.3).
c'This study' indicates mutations already reported in the literature but newly detected in the analyzed patients by NGS (highlighted in gray).
dThese 2 mutations are present in cis.
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As expected, the ﬁrst one was identiﬁed in individual CF-12,
from one side conﬁrming the already-available genetic diagnosis,
and from the other underlining the ability of the NGS approach to
detect such genetic lesions. The mutation consisted of a 21-kb-long
deletion encompassing introns 1–3 of the CFTR gene (Figure 1a).
The second structural variant was identiﬁed in patient CF-16: it is a
CFTR
ex2 ex3
21,085bp
IVS1
chr7:117,138,366/370
IVS3
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primer F primer R
ex25 ex26
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9.5-kb-long deletion involving the 3′ end of the CFTR gene
(removing exons 25–27) (Figure 1b).
Inspection of the NGS read alignment also allowed an easy
deﬁnition of the deletion breakpoints for both lesions. Breakpoints
were conﬁrmed by designing couples of primers mapping immediately
upstream and downstream of the breakpoints predicted by the 'SV
detection' software, and PCR amplifying the mutant allele from the
patient’s DNA. Concerning the 21-kb-long deletion (21 085 bp),
Sanger sequence analysis of the PCR product evidenced that, while
the wild-type sequence is characterized by the presence of a 4-bp-long
CTTT sequence at both cleavage sites, in the deleted allele only one
copy is retained. Hence, the precise location of the 5′ and 3′
breakpoints cannot be unambiguously determined, and may
range between positions chr7:117,138,366-117,138,370 and
chr7:117,159,443-117,159,447, respectively (Figure 1a). Concerning
the 9.5-kb-long deletion (9454 bp), sequencing of the deleted allele
evidenced the presence of ﬁve additional nucleotides (TAACT)
between the breakpoints, as already described (Figure 1b).22
Ex-vivo characterization of deep-intronic variants
Among the 22 novel deep-intronic nucleotide substitutions, 4 variants
(named V1–V4) were selected for further characterization because
bioinformatically predicted to potentially interfere with normal
splicing (Supplementary Table 6).
The molecular characterization of the putative V1–V4 mutations
was tackled by using an ex-vivo approach, as RNA to be extracted from
nasal epithelial cells of patients (or their relatives) was not available to
the study. In particular, we generated recombinant minigene con-
structs (4 wild-type, 4 mutant; Supplementary Figure 1A) that were
independently transfected in HeLa cells. Subsequent RT-PCR assays
did not evidence any splicing alteration for transcripts originating
from minigenes carrying the V1, V2 or V3 variants (Supplementary
Figure 1B). Concerning the V4 variant, RT-PCR fragments ampliﬁed
from cells transfected with the wild-type or the mutant construct were
again identical, but in this case an additional band was visible for both
samples. Sequencing analysis revealed that the additional band
originates from the insertion of a pseudoexon of 91 nucleotides,
corresponding to a fragment of CFTR intron 23 lying between
positions IVS23+152 and IVS23+243. However, this unexpected
pseudoexon activation is independent from the presence of the V4
variant, which was no further investigated.
Quantiﬁcation of residual wild-type CFTR transcript by digital RT-
PCR
Since the intron-9c.1210-34TG11-12T5 alleles are known to be
associated with high rates of exon-10 skipping (and hence with low
wild-type CFTR expression levels), we explored the possibility that the
phenotype in patients 2 and 5 could indeed be explained by the
presence of the T5 allele in combination with the corresponding
CF-causing mutation in trans (that is, the splicing mutations
c.1585-1G4A and c.2657+5G4A, determining the out-of-frame
skipping of exons 12 and 16, respectively).23–25 To this aim, we set
up digital RT-PCR assays for the absolute quantiﬁcation of the
wild-type CFTR mRNA, designing PCR primers to speciﬁcally amplify
exon-10-containing transcripts (Figure 2a). Digital PCR26,27 is an
accurate technique allowing the absolute quantiﬁcation of RNA
transcripts by partitioning the PCR reaction mix over a large number
of wells, so that each well contains a single copy or no copies of the
target region. On the basis of the assumption of Poisson distribution
of copies, the number of template copies originally present in the
sample can be recalculated simply counting the number of wells in
which ampliﬁcation has successfully occurred.28
Digital RT-PCRs were performed on RNA extracted from nasal
brushing of the 2 patients and of 9 healthy controls
(none carrying the T5 allele). Digital counts of the wild-type CFTR
transcript resulted 58 and 76 molecules/μl for patient CF-2 and 5,
respectively. These values correspond to 21 and 28% of the mean
wild-type CFTR level measured in controls, in whom the number of
molecules/μl ranged from 128 to 456 (Figure 2b).
Genetic variants in SCNN1B
Sequencing of SCNN1A, SCNN1B and 2SCNN1G genes led to the
identiﬁcation of 2 missense variants in the heterozygous state, both
located in the SCNN1B gene. In particular, in patient CF-3, the
c.1313A4G transition (p.Glu438Gly) was identiﬁed, whereas in
Figure 1 Identiﬁcation of the 21-kb-long and the 9.5-kb-long large deletions. (a, b) The main features characterizing, respectively, the 21-kb-long and the
9.5-kb-long deletions, both identiﬁed in the heterozygous state by NGS. For each deletion, a window of the IGV software showing the alignment of the reads
in the region of the mutation is shown, together with a close-up view at the 5′ deletion breakpoint (highlighting the drop in the number of reads to about
half). Below the IGV window, the relevant CFTR genomic region is displayed, with exons represented by boxes and introns by lines (drawn to scale).
In this scheme, the position of primers used to PCR amplify the region across deletion breakpoints, as well as the breakpoint nucleotide positions along
chromosome 7, are shown. In the lower part of the panel, the sequence electropherogram of the region corresponding to the deletion junction is shown. NGS,
next-generation sequencing; PCR, polymerase chain reaction. A full color version of this ﬁgure is available at the Journal of Human Genetics journal online.
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Figure 2 Evaluation of residual wild-type CFTR transcript using digital
RT-PCR. Absolute expression levels were measured by digital RT-PCRs in
patients CF-2 and CF-5 (that is, subjects carrying a null mutation and the T5
allele in compound heterozygosity), as well as nine healthy controls (none
being carrier of the T5 allele). (a) Schematic representation of the CFTR
gene between exons 10 and 12. Exons and introns are represented by boxes
and lines, and are not drawn to scale. The positions of the primer couple
used for the digital RT-PCR assay are shown by arrows, whereas the TaqMan
probe is indicated by a horizontal line. (b) Histogram representing the results
of digital RT-PCR. The number of copies of the target region is shown,
normalized on the number of copies of the housekeeping HMBS mRNA
(co-ampliﬁed with a second TaqMan assay). Bars represent the mean+the
precision of the assay as calculated by the software.
Targeted NGS applied to CFTR screening
L Straniero et al
5
Journal of Human Genetics
patient CF-11 the c.818A4G substitution (p.Tyr273Cys) was dis-
closed. Both missense variants lead to an amino-acid change affecting
a conserved residue (Supplementary Figure 2), and are found in
European non-Finnish individuals from the Exome Aggregation
Consortium (ExAC) database, both with a global frequency below
1:10 000 (http://exac.broadinstitute.org, last accessed 22 January 2016).
The p.Tyr273Cys variant was classiﬁed as potentially damaging by
seven of nine common programs used to predict the functional impact
of identiﬁed variants (Supplementary Materials), whereas the p.
Glu438Gly variant was predicted to be deleterious by 4 of 9 programs
(Supplementary Table 7).
To understand the possible consequences of the newly-identiﬁed
variants on the SCNN1B protein structure, the molecular model of the
human protein was inspected (Supplementary Figure 2). The SCNN1B
protein is characterized by the presence of 2 transmembrane domains
and a wide extracellular loop (including ~ 70% of the whole amino-
acid sequence). This loop, together with the extracellular domains of
the other 2 subunits, forms a funnel that directs ions from the lumen
into the pore of ENaC.29 The p.Glu438Gly mutation affects the
extracellular domain of the protein, in a region well exposed to the
solvent: the amino-acid substitution is predicted to change a
negatively-charged residue with a small apolar one, thus possibly
modifying the electrostatic signature of this region. Also the
p.Tyr273Cys mutation involves the SCNN1B extracellular domain:
the substitution falls within a beta strand, close to a highly-conserved
Cys residue (Cys272), which is known to participate to the main-
tenance of the overall structure of the channel. Hence, the addition of
a second Cys in this context could perturb the bond network normally
characterizing the region (Supplementary Figure 2).
DISCUSSION
In the era of the P4 medicine ('personalized', 'predictive', 'preventive'
and 'participatory'), the possibility to have a complete genetic
diagnosis is the fundamental prerequisite for directing therapeutic
strategies. CF conforms to this paradigm, especially in the light of the
many efforts made in the last few years to develop new therapies
targeting speciﬁc CFTR mutations.30 At present, commercial kits for
amplicon resequencing of CFTR exons using multiplex ampliﬁcation,
pooling of barcoded samples and NGS are available from different
companies. These solutions promise to completely replace the tradi-
tional multi-step genetic testing of CF, reducing the costs of analysis
and increasing the success rate of the diagnosis. Here, we explored the
application of whole-gene CFTR sequencing to CF genetic testing by
screening a number of 'difﬁcult' cases, that is, patients with an
incomplete diagnosis even after a preliminary extensive molecular
screening. Our approach was successful both in identifying all
mutations (including a large deletion) already detected by routine
screening, and in ameliorating the percentage of genetically-diagnosed
patients (Table 1).
Indeed, our data together with previous literature19 suggest that
whole-gene resequencing can in principle be used as a 'one-step
strategy' to the molecular diagnosis of CF, for a number of reasons.
First, this strategy has the advantage of not suffering from allele-
dropout complications, because the library preparation procedure is
based on probes for the capture step rather than on PCR
ampliﬁcation.31,32 This advantage is worth not only in comparison
with conventional Sanger sequencing, but also with amplicons-based
NGS methods. Second, our strategy should allow the identiﬁcation of
large intragenic deletions, duplications, and rearrangements, which
may go undetected by exon-only resequencing strategies. The inspec-
tion of the NGS read alignment should also allow an immediate
deﬁnition of the deletion breakpoints at the nucleotide level, a process
often laborious and time consuming. Third, thanks to the possibility
to multiplex samples, both at the capture and at the sequencing level,
we observed an increased time efﬁcacy of whole-gene sequencing over
Sanger sequencing. In addition, the foreseeable cost reductions
coupled with the possibility to further multiplex samples (we reached
a mean depth of 41150) promise to make this choice even more
affordable over traditional approaches. Last, even in the unfortunate
event of not being able to complete a genetic diagnosis, the availability
of the sequence of all CFTR intronic regions still represents a great
source of information. For instance, we identiﬁed a total of 22 novel
deep-intronic variants, 18 of which at the moment remain without a
functional meaning (Supplementary Table 5; Supplementary Figure 1).
It is conceivable that in the future the accumulation of data on
intronic sequences and the introduction of high-throughput func-
tional analyses will assign a pathogenic meaning to some of these
genetic variants, further increasing the diagnostic yield.
Even after this extensive sequencing strategy, ﬁve probands did not
show any mutation in CFTR, whereas six were still lacking the second
mutation. Missing mutations could either reside in the few intronic
regions not covered by our NGS experiment, or be one of the already
identiﬁed deep-intronic variants that we did not functionally char-
acterize. Alternatively, considering that indels and structural variants
still represent a problem in the alignment procedures, it is possible
that they were not properly called by the adopted software. Finally, we
cannot rule out the possibility that some patients, despite their CF or
CF-like appearance, are indeed phenocopies with no mutations in
their CFTR gene.33 Accordingly, no mutated allele was identiﬁed in the
ﬁve analyzed patients negative after conventional CFTR genetic
screening. Further studies by whole-exome sequencing might help a
better phenotype classiﬁcation and might potentially reveal novel
gene/s related to the CF phenotype.
Interestingly, it has been reported that patients with a CF-like
disorder, but having mutations in only one copy of their CFTR genes,
were carrier of gain-of-function mutations in the ENaC-encoding
subunits.15,34,35 More recently, Ramos et al.,36 also suggested an
oligogenic nature for CF-like phenotypes, with the description of
patients having no mutations in CFTR but multiple variants in
SCNN1A, SCNN1B SCNN1G, and even in the SERPINA1 gene. The
inclusion of the ENaC subunit genes in our NGS design was aimed at
taking into account also this variable. However, we only found 2
missense variants in the SCNN1B gene, in one case in a patient with a
complete molecular diagnosis of CF (CF-11), in the other in a patient
with no pathogenic mutations in CFTR (CF-3). In both cases, the
functional impact of the relevant variant still remains to be clariﬁed.
RNA analysis, even though not routinely undertaken in diagnostic
laboratories, has proven to be an important step in both the genetic
diagnosis of CF and in the deﬁnition of the pathogenic potential of
point mutations in CFTR. For instance, RT-PCR studies on RNA
extracted from nasal epithelial cells or lymphocytes have been
instrumental to clarify the role of deep-intronic variants affecting
splicing.7,37–39 We used this approach to complete the genetic
diagnosis of a couple of patients resulted compound heterozygotes
for a 'clear' disease-causing mutation and the c.1210-34TG[11-12]T5
alleles (CF-2 and CF-5; Table 1). The use of digital RT-PCR, which is
an extremely accurate and sensitive method for the absolute quanti-
ﬁcation of transcripts, allowed us to verify that both patients have an
overall amount of CFTR mRNA below 30%. This value should indeed
be considered as an overestimate in the case of the CF-5 patient. In
fact, a proper evaluation of the level of wild-type CFTR transcripts
should take into consideration all possible splicing events as well as the
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stability of transcripts bearing premature stop codons. In this frame,
patient CF-5, who carries a splicing mutations affecting exon 16, is
expected to have a lower level of the wild-type CFTR mRNA than that
measured by digital RT-PCR, because the assay was designed for the
speciﬁc ampliﬁcation of the region encompassing exons 10–12. Hence,
our results are in line with previous studies, describing a wide range of
full-length CFTR transcripts (4–20%) associated with mild CF
phenotypes,39–41 and hence reinforce the notion that the T5 allele
can contribute to the CF phenotype in some patients.
In summary, we propose a new diagnostic protocol to be applied to
the genetic diagnosis of CF: a one-shot PCR-based test followed by
full-gene NGS screening (Supplementary Figure 3). The preliminary
PCR-based screening is aimed at the identiﬁcation of the most
common CF mutation, that is, F508del, which can be easily detected
by using either a simple and economic high-resolution melting
analysis or other relatively low-cost genotyping methods (ﬂuorogenic
5′ nuclease PCR assays or ﬂuorescent fragment analysis on a capillary
electrophoresis sequencer). Should this preliminary analysis be nega-
tive, the subsequent NGS step will allow the most comprehensive
search for point mutations and gross alterations. In the light of the
possible improvements in the programs used for mutation detection
and in the hope of further cost drops, this strategy promises to be the
most straightforward, convenient and rapid diagnostic protocol for CF
patients.
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